1 2 3 4 5 6	PHILIP J. KAPLAN (State Bar No. 1 E-mail: philipkaplanlaw@gmail.com LAW OFFICES OF PHILIP J. KAPI 3278 Wilshire Boulevard Suite 106 Los Angeles, California 90010 Telephone: (213) 480-8981 Facsimile: (213) 480-8941 Attorney for Plaintiff PROLUME, LTD.	35735) LAN
7		DISCONCE COLIDE
8		S DISTRICT COURT
9	SUUTHERN DISTR	ICT OF CALIFORNIA
10		
11	PROLUME, LTD., a Delaware Corporation,	Case No. 13CV0130 WQHBLM
12	Plaintiff,	
13		
14	V.	COMPLAINT FOR PATENT INFRINGEMENT
15	GENTARGET, INC., a California	
10	LTD, a Singapore Corporation;	
17	California Corporation; AMSBIO	DEMAND FOR JURY TRIAL
10	Company; GENTAUR	
20	a Belgian Corporation, GENPRICE,	
20	GENTARGET, INC., a California Corporation; BST SCIENTIFIC PTE LTD, a Singapore Corporation; FILGEN BIOSCIENCES, INC., a California Corporation; AMSBIO LLC, a California Limited Liability Company; GENTAUR MOLECULAR PRODUCTS BVBA, a Belgian Corporation, GENPRICE, INC., a California Corporation; DOES 1 through 10, inclusive,	
22	Defendants.	
23		
24		
25		
26		
27		
28		
LAW OFFICES OF PHILIP J. KAPLAN		
	PROLUMECon	mplaintGentarget(1).doc
I	t	

Plaintiff PROLUME, LTD. (hereinafter "PROLUME" or "Plaintiff") hereby
alleges as follows:

PARTIES

On information and belief, Defendant GENTARGET, INC.
 (hereinafter "GENTARGET") is a California corporation with its principal place of
 business at 6640 Lusk Blvd., Suite A107, San Diego, California.

7 2. On information and belief, Defendant BST SCIENTIFIC PTE LTD is
8 a foreign corporation existing under the laws of Singapore, with its principal place
9 of business at 41 Science Park Road, #04-08 The Gemini, Singapore Science Park
10 II, Singapore 117610.

3. On information and belief, Defendant FILGEN BIOSCIENCES, INC.
is a California corporation with its principal place of business at 1313 Elm Street,
El Cerrito, California.

4. On information and belief, Defendant AMSBIO LLC is a California
limited liability company with its principal place of business at 23591 El Toro
Road, #167, Lake Forest, California.

5. On information and belief, Defendant GENTAUR MOLECULAR
PRODUCTS BVBA is a foreign corporation existing under the laws of Belgium,
with its principal place of business at Voortstraat 49, 1910 Kampenhout, Belgium.

6. On information and belief, Defendant GENPRICE, INC. is a
 subsidiary of GENTAUR MOLECULAR PRODUCTS BVBA and is a California
 corporation with its principal place of business at 547 Yurok Circle, San Jose,
 California.

7. Plaintiff is not aware of the true names and capacities of the
defendants sued herein as DOES 1 through 10, inclusive, and therefore sues said
defendants by such fictitious names. When Plaintiff has ascertained the true names
and capacities of said defendants, Plaintiff will seek leave of this court to amend
this complaint accordingly. On information and belief, each of the fictitiously

LAW OFFICES OF PHILIP J. KAPLAN

named defendants is responsible in some manner for the occurrences alleged in this
complaint, and Plaintiff alleges that his damages were proximately and legally
caused by defendants' conduct.

8. At all material times, Plaintiff alleges, each defendant was the agent,
servant and employee of each of the remaining defendants, and was acting within
the purpose, scope and course of said agency, service and employment, with the
express and/or implied knowledge, permission and consent of the remaining
defendants, and each of them, and each of said defendants ratified, approved of,
and/or accepted the benefits of such acts.

10

JURISDICTION/VENUE

9. This is an action for patent infringement arising under the patent laws
of the United States, Title 35, United States Code.

13 10. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§
14 1331 and 1338(a).

On information and belief, Defendants are subject to personal 11. 15 jurisdiction in the Southern District of California (the "District"), consistent with 16 the principles of due process and the California Long Arm Statute, because 17 Defendants maintain offices and facilities in this District, offer their products for 18 sale in this District, have transacted business in this District, have committed 19 and/or induced acts of patent infringement in this District, and/or have placed 20 infringing products into the stream of commerce through established distribution 21 channels with the expectation that such products will be purchased by residents of 22 this District. 23

12. Venue is proper in this District pursuant to 28 U.S.C. § 1391(b),
139(c), 1391(d), and 1400(b). Defendant GENTARGET resides in this judicial
district and, on information and belief, has committed acts of infringement in this
judicial district.

PATENT INFRINGEMENT COUNTS

13. Plaintiff PROLUME is the owner of all right, title, and interest in U.S.
Patent No. 6,232,107 (the "107" patent) and U.S. Patent No. 7,109,315 (the '315)
(collectively, the "PROLUME Patents"), which Defendants are infringing and/or
inducing others to infringe by making, using, offering to sell, and/or selling in the
United States, and/or importing into the United States, products or processes that
practice one or more inventions claimed in the PROLUME Patents.

8 14. Defendants have profited through infringement of the PROLUME
9 Patents. As a result of Defendants' unlawful infringement of the PROLUME
10 Patents, Plaintiff has suffered and will continue to suffer damage. Plaintiff is
11 entitled to recover from Defendants, and from each of them, the damages suffered
12 by Plaintiff as a result of Defendants' unlawful acts.

13 15. Commencing on or about January 11, 2012, Plaintiff gave notice to
14 Defendant GENTARGET of the PROLUME Patents. However, GENTARGET
15 refused, and continues to refuse, to cease its infringement of the PROLUME
16 Patents. Further, on information and belief, Defendant GENTARGET, in addition
17 to its own infringement, has continued its inducement of third-party infringement
18 of the PROLUME Patents, despite Plaintiff's above notice.

19 16. On information and belief, Defendants' infringement, including
20 without limitation the infringement of Defendant GENTARGET was, is, and
21 continues to be willful and deliberate, entitling Plaintiff to enhanced damages and
22 attorneys' fees and costs.

17. On information and belief, Defendants continue their unlawful
infringing activities, and Plaintiff continues to and will continue to suffer
irreparable harm – for which there is no adequate remedy at law – from such
unlawful activity unless Defendants are enjoined by this Court.

28

27

1 2

<u>COUNT I</u>

INFRINGEMENT OF U.S. PATENT NO. 6,232,107

18. Plaintiff hereby adopts, incorporates, and reiterates all of the
preceding allegations of this Complaint.

19. Plaintiff is the owner of all right, title, and interest in the '107 patent,
entitled "Luciferases, Fluorescent Proteins, Nucleic Acids Encoding The
Luciferases And Fluorescent Proteins And The Use Thereof In Diagnostics, High
Throughput Screening And Novelty Items", duly and properly issued by the U.S.
Patent and Trademark Office on May 15, 2001. An excerpt of the '107 patent is
attached as Exhibit "A" and made a part hereof.

20. The '107 patent claims, among other things, proprietary biological
materials ("Gaussia Luciferase" and "Green Fluorescent Proteins") that are used to
directly and easily discover new drug compounds, as well as identifying potential
proteins of therapeutic interest in cells and live animals.

Defendants have been and/or are directly infringing and/or inducing 21. 15 infringement of and/or contributorily infringing the '107 patent by, among other 16 things, making, using, offering to sell or selling in the United States, or importing 17 and/or exporting products and/or services that are covered by at least claims 1 18 through 5 of the 63 claims of the '107 patent, including, by way of example and 19 not limitation, GenTarget Product # LVP366 & LVP366-PBS is described using 20Gaussia Luciferase RNA (infringing at least patent claim nos. 1-22), since a 21 Gaussia nucleotide sequence is combined with a retrovirus which is a vector, 22 which incorporates the Gaussia Luciferase into a cell, cell line, organ, or animal 23 (so that the RNA virus inserts itself into a host cell is converted into DNA), this 24 DNA is integrated into the cell's DNA just like the well known HIV virus, and if 25 combined with it an off/on switch which causes the Gaussia DNA to make and 26 secrete the Gaussia Luciferase (active light emitting protein) from the infected cell, 27 cell line, animal tissue, or animal organ can be visualized optically. Gaussia 28

LAW OFFICES OF PHILIP J. KAPLAN

Luciferase generates light which is clearly detectable, or may stop the generation 1 of light if a drug is applied to kill that cell or block the Gaussia Luciferase from 2 being produced. Gentarget product LVP 362 is a combination product composed 3 of Gaussia Luciferase and a Green Fluorescent Protein (GFP) infringing at least 4 claims 1-22 and additionally claims 43-56 and 58-63. A search of the word 5 "gaussia" at www.gentarget.com reveals 14 products that incorporate Gaussia 6 Luciferase in various combinations including stable cell lines HEK 293 containing 7 Gaussia Luciferase with product sales prices from \$295-650.00/each. Another 8 search of the Gentarget website for the search term "GFP" produced 118 products 9 ranging in price from \$295-800.00 which infringe multiple '107 patent claims. 10

22. Plaintiff has been damaged as a result of Defendants' conduct.
Defendants are, therefore, liable to Plaintiff in an amount that adequately
compensates Plaintiff for Defendants' infringements, which, by law, cannot be less
than a reasonable royalty, together with interest and costs as fixed by this Court
under 35 U.S.C. § 284.

COUNT II

INFRINGEMENT OF U.S. PATENT NO. 7,109,315

23. Plaintiff hereby adopts, incorporates, and reiterates all of the
preceding allegations of this Complaint.

20 24. Plaintiff is the owner of all right, title, and interest in the '315 patent,
21 entitled "Renilla reniformis fluorescent proteins, nucleic acids encoding the
22 fluorescent proteins and the use thereof in diagnostics, high throughput screening and
23 novelty items", duly and properly issued by the U.S. Patent and Trademark Office
24 on September 19, 2006. An excerpt of the '315 patent is attached as Exhibit "B"
25 and made a part hereof.

26 25. The '315 patent claims, among other things, proprietary biological 27 materials ("Renilla reneformis Green Fluorescent Proteins") that are used to

28

16

directly and easily discover new drug compounds, as well as identifying potential
 proteins of therapeutic interest in cells and live animals.

Defendants have been and/or are directly infringing and/or inducing 26. 3 infringement of and/or contributorily infringing the '315 patent by, among other 4 things, making, using, offering to sell or selling in the United States, or importing 5 and/or exporting products and/or services that are covered by claims under the 6 '315 patent. A search of www.gentarget.com using search term "GFP" produced 7 118 products ranging from \$295-800.00. From the Gentarget website it can not be 8 determined which claims are being infringed without an analysis of the DNA 9 sequence used in their products, which is not clearly published on the Gentarget 10 website; however the color of the blue light (as listed in their product literature) 11 that stimulates the Green Fluorescent Protein used in the Gentarget GFP 12 product(s) is 450-490 nm and the color reflected back is Green (525 nm) which 13 matches the spectra of protein covered in claims #1-26 of the '315 patent. 14 Historically, the Renilla Green Fluorescent Protein was the second Green 15 Fluorescent Protein discovered and any subsequent Green Fluorescent Proteins 16 with the same characteristics would be covered by the doctrine of equivalents. 17

27. Plaintiff has been damaged as a result of Defendants' conduct.
Defendants are, therefore, liable to Plaintiff in an amount that adequately
compensates Plaintiff for Defendants' infringements, which, by law, cannot be less
than a reasonable royalty, together with interest and costs as fixed by this Court
under 35 U.S.C. § 284.

23

24 WHEREFORE, Plaintiff prays for judgment against Defendants, and each 25 of them, as follows:

For a judicial determination and declaration that one or more claims
 of the '107 and '715 patents has been infringed, either literally and/or under the
 doctrine of equivalents, by Defendants and/or by others to whose infringement

LAW OFFICES OF PHILIP J. KAPLAN Defendants have contributed and/or by others whose infringement has been
 induced by Defendants;

2. For an order that Defendants account for and pay to Plaintiff all damages to and costs incurred by Plaintiff because of Defendants' infringing activities and other conduct complained of herein;

6 3. For an order that Defendants, their officers, agents, servants, and
7 employees, and those persons in active concert and participation with any of them,
8 be preliminarily and permanently enjoined from infringement of the '107 and '715
9 patents. In the alternative, should the Court find that injunctive relief is not
10 warranted, Plaintiff requests an award of post judgment royalty to compensate for
11 future infringement;

4. For an order that Plaintiff be granted pre-judgment and post-judgment
interest on the damages caused to it by reason of Defendants' infringing activities
and other conduct complained of herein;

5. For a judicial determination and declaration that Defendants'
infringement has been, and continues to be, willful and deliberate;


6. For a judicial determination and declaration that this is an exceptional
case and award Plaintiff its reasonable attorney's fees and costs in accordance with
35 U.S.C. § 285;

7. For an order that Defendants notify all of their customers and users of
infringing products of the Court's judgment, and that Defendants be ordered to
encourage all customers to cease all such infringing actions; and

- 23 ////
- 24 ////
- 25 1///
- 26 ///
- 27 ///
- 28 ////

1	8. For any such other and further relief as the Court may deem just and
2	proper.
3	
4	
5	DATED: Jan. 15, 2013 LAW OFFICES OF PHILIP J. KAPLAN
6	By:
7	PHILIP J. KAPLAN Attorney for Plaintiff
8	PROLUME, LTD. E-mail: philipkaplanlaw@gmail.com
9 10	
10	
12	DEMAND FOR JURY TRIAL
12	Plaintiff hereby demands, pursuant to Rule 38 of the Federal Rules of Civil
14	Procedure, a trial by jury in this matter.
15	
16	DATED: Jan. 15, 2013 LAW OFFICES OF PHILIP J. KAPLAN
17	DATED. Jall. 15, 2015 LAW OFFICES OF TIMEM 5. KAI DAW
18	By:
19	PHILIP L KAPLAN
20	Attorney for Plaintiff PROLUME, LTD. E-mail: philipkaplanlaw@gmail.com
21	
22	
23	
24	
25	
26	
27	
28 LAW OFFICES OF	
PHILIP J. KAPLAN	-8-
	PROLUMEComplaintGentarget[1]

EXHIBIT "A"



United States Patent	6,232,107
Bryan, et al.	May 15, 2001

Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items

Abstract

Isolated and purified nucleic acid molecules that encode a luciferase from Renilla mulleri, Gaussia and Pleuromamma, and the proteins encoded thereby are provided. Isolated and purified nucleic acids encoding green fluorescent proteins from the genus Renilla and Ptilosarcus, and the green fluorescent proteins encoded thereby are also provided. Compositions and combinations comprising the green fluorescent proteins and/or the luciferase are further provided.

Inventors	s: Bryan; Bruce J. (Beverly Hills, PA)	, CA), Szent-Gyorgyi; Christopher (Pittsburgh,
Assignee	: Bryan; Bruce J. (Prolume, LTD (Pittsburgh, PA)	
Appl. No	.: 09/277,716	
Filed:	March 26, 1999	
Current	U.S. Class:	435/189 ; 435/183; 435/252.2; 435/320.1; 435/6.13;

Current International Class:

435/69.1; 435/8 A61K 49/00 (20060101); A61K 47/48 (20060101); C07K 14/435 (20060101); C12N 9/02 (20060101); A61K

38/00 (20060101); C12N 009/02 (); G01N 033/53 (); C12Q 001/66 (); C12P 021/06 () 435/69.1,189,252.3,252.33,320.1,6,8,69.7,183 536/23.2

Field of Search:

References Cited [Referenced By]

U.S. Patent Documents			
<u>2541851</u>	February 1951	Wright	
<u>3384498</u>	May 1968	Ahrabi	
<u>3511612</u>	May 1970	Kennerly et al.	
<u>3565815</u>	February 1971	Christy	
3584211	June 1971	Rauhut	
<u>3634280</u>	January 1972	Dean et al.	
<u>3649029</u>	March 1972	Worrell	
<u>3661790</u>	May 1972	Dean et al.	
<u>3669891</u>	June 1972	Greenwood et al.	
<u>3727236</u>	April 1973	Lloyd et al.	
<u>3873485</u>	March 1975	Fichera	
<u>4021364</u>	May 1977	Speiser	
<u>4175183</u>	November 1979	Ayers	
<u>4177038</u>	December 1979	Biebricher et al.	
<u>4225581</u>	September 1980	Kreuter et al.	
<u>4229790</u>	October 1980	Gilliland et al.	
<u>4269821</u>	May 1981	Kreuter	
<u>4282287</u>	August 1981	Giese	
<u>4313843</u>	February 1982	Bollyky et al.	
<u>4324683</u>	April 1982	Lim et al.	
<u>4478817</u>	October 1984	Campbell et al.	
<u>4528180</u>	July 1985	Schaeffer	
<u>4534317</u>	August 1985	Walsh	
<u>4542102</u>	September 1985	Dattagupta et al.	
<u>4562157</u>	December 1985	Lowe et al.	
<u>4563726</u>	January 1986	Newcomb et al.	

<u>4581335</u>	April 1986	Baldwin
<u>4676406</u>	June 1987	Frischmann et al.
<u>4681870</u>	July 1987	Balint et al.
<u>4714682</u>	December 1987	Schwartz
<u>4717158</u>	January 1988	Pennisi
<u>4735660</u>	April 1988	Cane
<u>4745051</u>	May 1988	Smith et al.
<u>4762881</u>	August 1988	Kauer
<u>4765510</u>	August 1988	Rende
<u>4767206</u>	August 1988	Schwartz
<u>4774189</u>	September 1988	Schwartz
<u>4777128</u>	October 1988	Lippa
<u>4781647</u>	November 1988	Doane, Jr.
<u>4789633</u>	December 1988	Huang
<u>4853327</u>	August 1989	Dattagupta
<u>4861709</u>	August 1989	Ulitzur et al.
<u>4867908</u>	September 1989	Recktenwald et al.
<u>4870009</u>	September 1989	Evans et al.
<u>4882165</u>	November 1989	Hunt et al.
<u>4891043</u>	January 1990	Zeimer et al.
<u>4908405</u>	March 1990	Bayer et al.
<u>4921757</u>	May 1990	Wheatley et al.
<u>4924358</u>	May 1990	Von Heck
<u>4927923</u>	May 1990	Mathis et al.
<u>4950588</u>	August 1990	Dattagupta
<u>4952496</u>	August 1990	Studier et al.
<u>4963117</u>	October 1990	Gualdoni
<u>4968613</u>	November 1990	Masuda et al.
<u>5004565</u>	April 1991	Schaap
<u>5023181</u>	June 1991	Inouye
<u>5093240</u>	March 1992	Inouye et al.
<u>5096807</u>	March 1992	Leaback
<u>5098828</u>	March 1992	Geiger et al.

<u>5139937</u>	August 1992	Inouye et al.
5158349	October 1992	Holland et al.
<u>5162227</u>	November 1992	Cormier
<u>5162508</u>	November 1992	Lehn et al.
<u>5169784</u>	December 1992	Summers et al.
<u>5171081</u>	December 1992	Pita et al.
5182202	January 1993	Kajiyama et al.
<u>5189029</u>	February 1993	Boyer et al.
5196318	March 1993	Baldwin et al.
<u>5196524</u>	March 1993	Gustafson et al.
<u>5219737</u>	June 1993	Kajiyama et al.
<u>5221623</u>	June 1993	Legocki et al.
<u>5222797</u>	June 1993	Holland
<u>5229285</u>	July 1993	Kajiyama et al.
<u>5246834</u>	September 1993	Tsuji et al.
<u>5268463</u>	December 1993	Jefferson
<u>5277913</u>	January 1994	Thompson et al.
<u>5279943</u>	January 1994	Mathis et al.
<u>5292658</u>	March 1994	Cormier et al.
<u>5310421</u>	May 1994	Shapero et al.
<u>5323492</u>	June 1994	DeMars
<u>5330906</u>	July 1994	Kajiyama et al.
<u>5337745</u>	August 1994	Benaron
<u>5352598</u>	October 1994	Kajiyama et al.
<u>5360726</u>	November 1994	Raikhel
<u>5360728</u>	November 1994	Prasher
<u>5362865</u>	November 1994	Austin
<u>5364797</u>	November 1994	Olson et al.
<u>5366881</u>	November 1994	Singh et al.
<u>5374534</u>	December 1994	Zomer et al.
<u>5383100</u>	January 1995	Kikos
<u>5387526</u>	February 1995	Garner et al.
<u>5405905</u>	April 1995	Darr

S412085May 1995Allen et al.S413028May 1995BenaronS413332May 1995MontgomeryS415151May 1995Fusi et al.S418155May 1995Cormier et al.S422075June 1995Saito et al.S422266June 1995Cormier et al.S422266June 1995Nagano et al.S432081July 1995JeffersonS433896July 1995Bell et al.S433896July 1995Bell et al.S43377July 1995Bell et al.S435937July 1995Gossen et al.S435937July 1995Gossen et al.S435937January 1996StultsS44758November 1995Gossen et al.S464758January 1996StultsS491084February 1996Chalfie et al.S605662February 1997Heller et al.S605662February 1997Heller et al.S623257May 1997Heller et al.S623257May 1997Heller et al.S623257May 1997Heller et al.S730321March 1998Ward et al.S730321March 1998Ward et al.S776681July 1998Tsien et al.S777079July 1998Tsien et al.S777079July 1998Tsien et al.S777079July 1998Gormack et al.S777079July 1998Tsien et al.S777079July 1998Tsien et al.S777079July 1998Tsien et	<u>5405958</u>	April 1995	VanGermert
S41332 May 1995 Montgomery S415151 May 1995 Fusi et al. S418155 May 1995 Cormier et al. S422075 June 1995 Saito et al. S422266 June 1995 Cormier et al. S422266 June 1995 Nagano et al. S424216 June 1995 Nagano et al. S433896 July 1995 Kang et al. S433896 July 1995 Bell et al. S433896 July 1995 Bell et al. S433896 July 1995 Stang et al. S435937 July 1995 Bell et al. S435937 July 1995 Stang et al. S44455 January 1995 Gossen et al. S464758 November 1995 Gossen et al. S486455 January 1996 Stults S491084 February 1997 Kazami et al. S605662 February 1997 Kazami et al. S625048 April 1997 Sundberg et al. S625048 April 1997 Collet S71904 February 1998 Shoseyov et al. S7303	<u>5412085</u>	May 1995	Allen et al.
5415151 May 1995 Fusi et al. 5418155 May 1995 Cormier et al. 5422075 June 1995 Saito et al. 5422266 June 1995 Cormier et al. 5422266 June 1995 Nagano et al. 5424216 June 1995 Safto et al. 5433896 July 1995 Kang et al. 5433896 July 1995 Bell et al. 5433897 July 1995 Bell et al. 5435937 July 1995 Saten et al. 5435937 July 1995 Staten et al. 5435937 July 1995 Staten et al. 5435937 July 1995 Gossen et al. 5435937 January 1995 Gossen et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1997 Kazami et al. 560562 February 1997 Kazami et al. 5625048 April 1997 Sundberg et al. 5625048 April 1997 Schert et al. 5719044 February 1998 Shoseyov et al.	<u>5413098</u>	May 1995	Benaron
5418155 May 1995 Cormier et al. 5422075 June 1995 Saito et al. 5422266 June 1995 Cormier et al. 5422266 June 1995 Nagano et al. 5432081 July 1995 Jefferson 5433896 July 1995 Bell et al. 5433896 July 1995 Bell et al. 543397 July 1995 Bell et al. 5435337 July 1995 Bell et al. 543597 August 1995 Gossen et al. 5451347 September 1995 Gossen et al. 546455 January 1996 Stults 5486455 January 1996 Stults 5491084 February 1997 Kazami et al. 5604123 February 1997 Kazami et al. 562562 February 1997 Sundberg et al. 5625048 April 1997 Sundberg et al. 5625048 April 1997 Collet 571998 September 1997 Collet 571908 September 1998 McAllister et al. <	<u>5413332</u>	May 1995	Montgomery
5422075June 1995Saito et al. 5422266 June 1995Cormier et al. 5422266 June 1995Nagano et al. 5422266 July 1995Jefferson 5432081 July 1995Kang et al. 5433896 July 1995Bell et al. 5433897 July 1995Bell et al. 5433977 August 1995Bell et al. 5435937 July 1995Bell et al. 5435937 July 1995Bell et al. 5435937 August 1995Akhavan-Taffi et al. 5446455 January 1995Gossen et al. 5464758 November 1995Gossen et al. 5486455 January 1996Chalfie et al. 5604123 February 1996Chalfie et al. 5604123 February 1997Kazami et al. 5624711 April 1997Sundberg et al. 5625048 April 1997Sundberg et al. 562267 May 1997Heller et al. 5632257 May 1997Heller et al. 5730321 March 1998McAllister et al. 5730321 March 1998Ward et al. 5776681 July 1998Tsien et al. 5777079 July 1998Tsien et al. 5874304 February 1999Zolotukin et al. 5876395 March 1999Bryan 5891646 April 1999Barak et al.	<u>5415151</u>	May 1995	Fusi et al.
5422266 June 1995 Cormier et al. 5424216 June 1995 Nagano et al. 5432081 July 1995 Jefferson 5433896 July 1995 Kang et al. 5433897 July 1995 Bell et al. 5433937 July 1995 Bell et al. 5433937 August 1995 Tsien et al. 5433977 August 1995 Akhavan-Tafti et al. 5451347 September 1995 Akhavan-Tafti et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1997 Kazami et al. 5605662 February 1997 Kazami et al. 5625048 April 1997 Sundberg et al. 5632957 May 1997 Heller et al. 5632057 May 1997 Heller et al. 5632057 May 1997 Utet et al. 5730321 March 1998 Shoseyov et al. 5730321 March 1998 Virta et al. 577079 July 1998 Tsien et al.	5418155	May 1995	Cormier et al.
5424216 June 1995 Nagano et al. 5432081 July 1995 Jefferson 5433896 July 1995 Kang et al. 5433896 July 1995 Bell et al. 5433937 July 1995 Bell et al. 5435937 August 1995 Tsien et al. 5435977 August 1995 Akhavan-Tafti et al. 5451347 September 1995 Akhavan-Tafti et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1996 Chalfie et al. 5605662 February 1997 Kazami et al. 5625048 April 1997 Sundberg et al. 5632957 May 1997 Heller et al. 5632057 May 1997 Heller et al. 5632957 May 1997 Kazami et al. 5730321 March 1998 Shoseyov et al. 5730321 March 1998 Ward et al. 577079 July 1998 Sien et al. 577079 July 1998 Sien et al. <td><u>5422075</u></td> <td>June 1995</td> <td>Saito et al.</td>	<u>5422075</u>	June 1995	Saito et al.
5432081 July 1995 Jefferson 5433896 July 1995 Kang et al. 5433896 July 1995 Bell et al. 5433897 July 1995 Bell et al. 5435937 July 1995 Bell et al. 5439797 August 1995 Tsien et al. 5431347 September 1995 Akhavan-Tafti et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1996 Chalfie et al. 5604123 February 1997 Kazami et al. 5625048 April 1997 Sundberg et al. 5625048 April 1997 Sundberg et al. 5632957 May 1997 Heller et al. 5632957 May 1997 Collet 571998 September 1997 Collet 5730321 March 1998 McAllister et al. 5741668 April 1998 Virta et al. 577079 July 1998 Sien et al. 5874304 February 1999 Zolotukhin et al.	<u>5422266</u>	June 1995	Cormier et al.
5433896 July 1995 Kang et al. 5435937 July 1995 Bell et al. 5435937 August 1995 Tsien et al. 5439797 August 1995 Akhavan-Tafti et al. 5451347 September 1995 Akhavan-Tafti et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1996 Chalfie et al. 5604123 February 1997 Kazami et al. 5605662 February 1997 Kazami et al. 5625048 April 1997 Sundberg et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 Ward et al. 5741668 April 1997 Virta et al. 577079 July 1998 Tsien et al. 5771054 July 1998 Virta et al. 577079 July 1998 Cormack et al. 5874304 February 1999	<u>5424216</u>	June 1995	Nagano et al.
5435937 July 1995 Bell et al. 5439797 August 1995 Tsien et al. 543147 September 1995 Akhavan-Tafti et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1996 Chalfie et al. 5605662 February 1997 Kazami et al. 5624711 April 1997 Sundberg et al. 5625048 April 1997 Sundberg et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoscyov et al. 5730321 March 1998 McAllister et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Tsien et al. 577079 July 1998 Cormack et al. 5777079 July 1998 Tsien et al. 5804387 September 1998 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999	<u>5432081</u>	July 1995	Jefferson
5439797August 1995Tsien et al.5451347September 1995Akhavan-Tafti et al.5464758November 1995Gossen et al.5486455January 1996Stults5491084February 1996Chalfie et al.5604123February 1997Kazami et al.5605662February 1997Heller et al.5625048April 1997Sundberg et al.5632957May 1997Heller et al.5671998September 1997Collet5730321March 1998McAllister et al.5741668April 1998Virta et al.577079July 1998Tsien et al.5804387September 1999Zolotukhin et al.5874304February 1999Barak et al.	<u>5433896</u>	July 1995	Kang et al.
5451347 September 1995 Akhavan-Tafti et al. 5464758 November 1995 Gossen et al. 5486455 January 1996 Stults 5491084 February 1996 Chalfie et al. 5604123 February 1997 Kazami et al. 5605662 February 1997 Kazami et al. 5624711 April 1997 Sundberg et al. 5625048 April 1997 Sundberg et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5730321 March 1998 Shoseyov et al. 5741668 April 1998 Ward et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Tsien et al. 5804387 September 1999 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Bryan 5891646 April 1999 Barak et al.	<u>5435937</u>	July 1995	Bell et al.
5464758November 1995Gossen et al.54864758January 1996Stults5491084February 1996Chalfie et al.5604123February 1997Kazami et al.5605662February 1997Heller et al.5624711April 1997Sundberg et al.5625048April 1997Tsien et al.5632957May 1997Heller et al.5671998September 1997Collet5719044February 1998Shoseyov et al.5730321March 1998Ward et al.5776681July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5439797</u>	August 1995	Tsien et al.
5486455 January 1996 Stults 5491084 February 1996 Chalfie et al. 5604123 February 1997 Kazami et al. 5605662 February 1997 Heller et al. 5624711 April 1997 Sundberg et al. 5625048 April 1997 Tsien et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 McAllister et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Cormack et al. 5804387 September 1997 Zolotukhin et al. 5876995 March 1999 Bryan	<u>5451347</u>	September 1995	Akhavan-Tafti et al.
5491084 February 1996 Chalfie et al. 5604123 February 1997 Kazami et al. 5605662 February 1997 Heller et al. 5624711 April 1997 Sundberg et al. 5625048 April 1997 Tsien et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 McAllister et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Tsien et al. 5804387 September 1999 Coloukhin et al. 5874304 February 1999 Zoloukhin et al. 5876995 March 1999 Bryan	<u>5464758</u>	November 1995	Gossen et al.
5604123 February 1997 Kazami et al. 5605662 February 1997 Heller et al. 5624711 April 1997 Sundberg et al. 5625048 April 1997 Tsien et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 McAllister et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Tsien et al. 5804387 September 1999 Zolotukhin et al. 5874304 February 1999 Barak et al.	<u>5486455</u>	January 1996	Stults
5605662 February 1997 Heller et al. 5624711 April 1997 Sundberg et al. 5625048 April 1997 Tsien et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 McAllister et al. 5741668 April 1998 Ward et al. 57776681 July 1998 Virta et al. 57777079 July 1998 Tsien et al. 5804387 September 1999 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Barak et al.	<u>5491084</u>	February 1996	Chalfie et al.
5624711April 1997Sundberg et al.5625048April 1997Tsien et al.5632957May 1997Heller et al.5671998September 1997Collet5719044February 1998Shoseyov et al.5730321March 1998McAllister et al.5741668April 1998Ward et al.5776681July 1998Virta et al.5777079July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5604123</u>	February 1997	Kazami et al.
5625048 April 1997 Tsien et al. 5632957 May 1997 Heller et al. 5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 McAllister et al. 5741668 April 1998 Ward et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Cormack et al. 5804387 September 1999 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Bryan 5891646 April 1999 Bryan	<u>5605662</u>	February 1997	Heller et al.
5632957May 1997Heller et al.5632957September 1997Collet571998September 1997Collet5719044February 1998Shoseyov et al.5730321March 1998McAllister et al.5741668April 1998Ward et al.5776681July 1998Virta et al.5777079July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5624711</u>	April 1997	Sundberg et al.
5671998 September 1997 Collet 5719044 February 1998 Shoseyov et al. 5730321 March 1998 McAllister et al. 5741668 April 1998 Ward et al. 5776681 July 1998 Virta et al. 5777079 July 1998 Tsien et al. 5804387 September 1998 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Bryan 5891646 April 1999 Barak et al.	<u>5625048</u>	April 1997	Tsien et al.
5719044February 1998Shoseyov et al.5730321March 1998McAllister et al.5741668April 1998Ward et al.5776681July 1998Virta et al.5777079July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5632957</u>	May 1997	Heller et al.
5730321March 1998McAllister et al.5741668April 1998Ward et al.5776681July 1998Virta et al.5777079July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5671998</u>	September 1997	Collet
5741668April 1998Ward et al.5776681July 1998Virta et al.5777079July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5719044</u>	February 1998	Shoseyov et al.
5776681July 1998Virta et al.5777079July 1998Tsien et al.5804387September 1998Cormack et al.5874304February 1999Zolotukhin et al.5876995March 1999Bryan5891646April 1999Barak et al.	<u>5730321</u>	March 1998	McAllister et al.
5777079 July 1998 Tsien et al. 5804387 September 1998 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Bryan 5891646 April 1999 Barak et al.	<u>5741668</u>	April 1998	Ward et al.
5804387 September 1998 Cormack et al. 5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Bryan 5891646 April 1999 Barak et al.	<u>5776681</u>	July 1998	Virta et al.
5874304 February 1999 Zolotukhin et al. 5876995 March 1999 Bryan 5891646 April 1999 Barak et al.	<u>5777079</u>	July 1998	Tsien et al.
5876995 March 1999 Bryan 5891646 April 1999 Barak et al.	<u>5804387</u>	September 1998	Cormack et al.
5891646 April 1999 Barak et al.	<u>5874304</u>	February 1999	Zolotukhin et al.
	<u>5876995</u>	March 1999	Bryan
<u>5912137</u> June 1999 Tsien et al.	<u>5891646</u>	April 1999	Barak et al.
	<u>5912137</u>	June 1999	Tsien et al.

<u>5976796</u>	November 1999	Szalay et al.
	Foreign Patent Documents	
3935974	May., 1991	DE
0025350	Sep., 1980	EP
0194102	Sep., 1986	EP
0226979	Jul., 1987	EP
0245093	Nov., 1987	EP
0246174	Nov., 1987	EP
0387355	Sep., 1990	EP
0386691	Sep., 1990	EP
0194102	Oct., 1991	EP
0540064	May., 1993	EP
0713089	May., 1996	EP
2292595	Jun., 1976	FR
2288232	Oct., 1995	GB
63-317079	Dec., 1988	JP
3030678	Feb., 1991	JP
4258288	Sep., 1992	JP
5064583	Mar., 1993	JP
7222590	Aug., 1995	JP
7241192	Sep., 1995	JP
8603840	Jul., 1986	WO
8703304	Jun., 1987	WO
9001542	Feb., 1990	WO
9201225	Jan., 1992	WO
9204577	Mar., 1992	WO
9215673	Sep., 1992	WO
9313395	Jul., 1993	WO
9418342	Aug., 1994	WO
9425855	Nov., 1994	WO
9507463	Mar., 1995	WO
9518853	Jul., 1995	WO

9521191	Aug., 1995	WO
9525798	Sep., 1995	WO
9607100	Mar., 1996	WO
9607917	Mar., 1996	WO
9623810	Aug., 1996	WO
9627675	Sep., 1996	WO
9711094	Mar., 1997	WO
9726333	Jul., 1997	WO
9729319	Aug., 1997	WO
9728261	Aug., 1997	WO
9741228	Nov., 1997	WO
9814605	Apr., 1998	WO
9826277	Jun., 1998	WO
9949019	Sep., 1999	WO

Other References

Baldwin et al., Cloning of the luciferase structural genes from Vibro harveyi and expression of bioluminescence in Escherichia coli, Biochemistry 23: 3663-3667 (1984).

Belas et al., Bacterial bioluminescence: Isolation and expression of the luciferase genes from Vibrio harveyi, Science 218: 791-793 (1982).

Blinks et al., Multiple forms of the calcium-sensitive bioluminescent protein aequorin, Fed. Proc. 1435: 474 (1975).

Casper et al. Expression of the green fluorescent protein-encoding gene from a tobacco mosaic virus-based vector Gene 173: 69-73 (1996).

Charbonneau et al., "Amino acid sequence of the calcium-dependent photoprotein aequorin," Biochem. 24:6762-6771 (1985).

Chemical Abstract #115(5)43510b (citing, Japanese Patent Application No. JP 3-30678 Osaka).

Cohn et al. "Cloning of the Vibrio harveyi luciferase genes: use of a synthetic oligonucleotide probe", Proc. Natl. Acad. Sci. U.S.A. 80(1):120-123 (1983).

Cohn et al., Nucleotide sequence of the luxa gene of Vibrio harveyi and the complete amino acid sequence of the .alpha. subunit of bacterial luciferase, J. Biol. Chem. 260:6139-6146 (1985).

Database Derwent # 007778737 WPI Acc. No. 89-043849/198906 (citing, Japanese

Patent Application No. JP 63317079, published Dec. 26, 1988). Database Derwent #008196500 (citing WO 9001542, Recombinant luciferase, fragments from it, and gene coding for it -- the luciferase having increased stability and quantum yield). . Database Derwent #008580311 WPI Acc. No. 91-084343/199112 (citing, Japanese Patent Application No. JP 3030678 published Feb. 8, 1991). . Database Derwent #009227258 WPI Acc. No. 92-354680/199243 (citing, Japanese Patent Application No. JP 4258288, published Sep. 14, 1993). . Database Derwent #010423635 WPI Acc. No. 95-324955/199542 (citing, Japanese Patent Application No. JP 7222590, published Aug. 22, 1995). . de Wet et al., "Cloning and expression of the firefly luciferase gene in mammalian cells," Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 368-371, Academic Press (1981). de Wet et al., "Cloning firefly luciferase," Meth. Enzymol. 133:311 (1986). . de Wet et al., "Cloning of firefly luciferase cDNA and the expression of active luciferase in Escherichia coli," Proc. Natl. Acad. Sci. USA 82:7870-7873 (1985). . Engebrecht et al., "Techniques for cloning and analyzing bioluminescence genes from marine bacteria," Meth. Enzymol. 133:83-99, 234 (1986)... Engebrecht et al., Bacterial bioluminescence: Isolation and genetic analysis of functions from Vibrio fischeri, Cell 32: 773-781 (1983). Engebrecht et al., Identification of genes and gene products necessary for bacterial bioluminescence, Proc. Natl. Acad. Sci. USA 81: 4154-4158 (1984)... Frackman et al., "Cloning, organization, and expression of the bioluminescence genes of Xenorhabdus luminescens," J. Bacteriol. 172(10):5767-5773 (1990). . Gast et al., Separation of a blue fluorescence protein from bacterial luciferase. Biochem. Biophys. Res. Commun. 80(1): 14-21 (1978). . Goto et al., Preliminary report on the pink-colored Cypridina luciferase, a natural model of the luciferin-luciferase complex, in Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 203-207, Academic Press (1981). Hastings, Bioluminescence, in Cell Physiol.: Source Book, Sperelakis, ed., pp. 665-681, Academic Press (1995)... Hill et al., Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 396-399, Academic Press (1981). . Hori et al., Structure of native Renilla reniformis luciferin, Proc. Natl. Acad. Sci. USA 74: 4285-4287 (1977). Illarionov et al., Sequence of the cDNA encoding the Ca.sup.2+ -activated photoprotein obelin from the hydroid poly Obelia longissima, Gene 153:273-274

(1995)..

Inouye et al., "Cloning and sequence analysis of cDNA for the luminescent protein aequorin," Proc. Natl. Acad. Sci. USA 82:3154-3158 (1985). .

Inouye et al., "Overexpression and purification of the recombinant Ca.sup.2+ -binding protein, apoaequorin," J. Biochem. 105(3):473-477 (1989).

Inouye et al., "Squid bioluminescence II. Isolation from Watasenia scintillans and synthesis of 2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-3,7-dihydroimidazo[1,2-a]pyrazin-3 -one", Jap. Soc. Chem. Lett. 141-144 (1975).

Johnson et al., "Compartmentalization of algal bioluminescence: autofluorescence of bioluminescent particles in the dinoflagellate Gonyoulax as studied with imageintensified video microscopy and flow cytometry", J. Cell. Biol. 100(5):1435-1446 (1985).

Johnson et al., "Introduction to the Cypridina system," Methods in Enzymology. Bioluminescence and Chemiluminescence. 57:331-349 (1978).

Johnson, Luminescence, Narcosis, and Life in the Deep Sea, pp. 51-56, Vantage Press.

Karatani et al., A blue fluorescent protein from a yellow-emitting luminous bacterium, Photochem. Photobiol. 55(2): 293-299 (1992).

Kohama et al., Molecular weight of the photoprotein aequorin, Biochemistry 10:4149-4152 (1971).

Kurose et al., Bioluminescence of the Ca.sup.2+ -binding photoprotein aequorin after cysteine modification, Proc. Natl. Acad. Sci. USA 86(1): 80-84 (1989).

Lee et al., "Purification of a blue-fluorescent protein from the bioluminescent bacterium photobacterium phosphoreum," Methods Enzymol. (Biolumin. Chemilumin.), 57:226-234 (1978).

Lorenz et al., Isolation and expression of a cDNA encoding Renilla reniformis luciferase, Proc. Natl. Acad. Sci. USA 88: 4438-4442 (1991).

Matthews et al., Purification and properties of Renilla reniformis luciferase, Biochemistry, 16: 85-91 (1977).

McElroy et al., The colors of bioluminescence: Role of enzyme and substrate structure, in Molecular Architecture in Cell Physiology, pp. 63-80, Hayashi et al., eds., Prentice-Hall, Inc., Englewood Cliffs, NJ (1966).

Miyamoto et al., Cloning and expression of the genes from the bioluminescent system of marine bacteria, Meth. Enzymol. 133:70-81 (1986).

Morise et al., Intermolecular Energy Transfer in the Bioluminescent System of Aequorea Biochemistry 13:2656-2662 (1974).

Ormo et al. Crystal Structure of the Aequorea victoria Green Fluorescent Protein Science 273:1392-1395 (1996). Prasher et al., Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 365-367, Academic Press (1981). . Prasher et al., Cloning and expression of the cDNA coding for aequorin, a bioluminescent calcium-binding protein, Biochem. Biophys. Res. Commun. 126(3):1259-1268 (1985). .

Prasher et al., Isolation and expression of a cDNA coding for aequorin, the Ca.sup.2+ - activated photoprotein from Aequorea victoria, Meth. Enzymol. 133:288-297 (1986). . Prasher et al., Primary structure of the Aequorea victoria green-fluorescent protein, Gene 111:229-233 (1992).

Prasher et al., Sequence comparisons of complementary DNAs encoding aequorin isotypes, Biochem. 26:1326-1332 (1987).

Prendergast et al., Chemical and physical properties of aequorin and the green fluorescent protein isolated from Aequorea forsk.ang.lea, Biochemistry 17:3448-53 (1978).

Shimomura et al., Extraction, purification and properties of a aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea, J. Cell. Comp. Physiol. 59:223-238 (1962).

Shimomura et al., Properties and reaction mechanism of the bioluminescence system of the deep-sea shrimp Oplophorus gracilorostris, Biochem 17(6): 994-998 (1978). . Shimomura et al., Properties of the bioluminescent protein aequorin, Biochemistry 8: 3991-3997 (1969).

Shimomura et al. Reactions Involved in Bioluminescence of Limpet (Latia neritoides) and Luminous Bacteria Proc. Natl. Acad. Sci. U.S.A. 69:2086-2089 (1972).

Shimomura et al., Recombinant aequorin and recombinant semi-synthetic aequorins. Cellular Ca.sup.2+ ion indicators, Biochem. J. 270(2): 309-12 (1990).

Shimomura et al., Semi-synthetic aequorin. An improved tool for the measurement of calcium ion concentration, Biochem. J. 251(2): 405-10 (1988).

Shimomura et al. Structure of Light-Emitting Moiety of Aequorin Biochemistry 11:1602-1608 (1972).

Shimomura et al. The Structure of Latia Luciferin Biochemistry 7:1734-1738 (1968). . Shimomura, Structure of the Chromophore of Aequorea Green Fluorescent Protein FEBS Letters 104:220-222 (1979). .

Thompson et al., Cloning and expression of cDNA for the eluciferase from the marine ostracod Vargula hilgendorfi xi, Proc. Natl. Acad. Sci. USA 86: 6567-6571 (1989)...

Tsien, The Green Fluorescent Protein Annu. Rev. Biochem. 67:509-544 (1998). .

Tsuji, Cypridina luciferin and luciferase, Meth. Enzymol. 57:364-372 (1978). .

Tsuji et al., Site-specific mutagenesis of the calcium-binding photoprotein aequorin, Proc. Natl. Acad. Sci. USA 83:8107-8111 (1986).

Tsuji et al., Some properties of luciferase from the bioluminescent crustacean, Cypridina hilgendorfii, Biochem. 13(25):5204-5209 (1974).

Wampler et al. Similarities in the Bioluminescence from the Pennatulacea Biochimicia et Biophysica Acta 314:104-109 (1973).

Ward et al., Extraction of Renilla-type luciferin from the calcium-activated photoproteins aequorin, mnemiopsin, and berovin, Proc. Natl. Acad. Sci. USA 72: 2530-2534 (1975).

"AquaLite.RTM.. A calcium-triggered photoprotein," SeaLite Sciences Technical Report No. 3 (1994).

Amsterdam, et al. The Aequorea victoria Green Fluorescent Protein Can Be Used as a Reporter in Live Zebrafish Embryos Developmental Biology 171:123-129 (1995).

Anctil et al., Mechanism of photoinactivation and re-activatioon in the bioluminescence system of the ctenophore Mnemiopsis, Biochem. J. 22(1): 269-272 (1984).

Badminton et al., nucleoplasmin-targeted aequorin provides evidence for a nuclear calcium barrier, Expt. Cell Research 216(1): 236-243 (1995).

Baldwin et al., "Applications of the cloned bacterial luciferase genes LUXA and LUXB to the study of transcriptional promoters and terminators," Bioluminescence and Chemiluminescence: Basic Chemistry and Analytical Applications, DeLuca and McElroy, Eds., Academic Press (1981).

Becvar et al., A thermodymanic explanation for the kinetic differences observed using different chain length aldehydes in the in vitro bacterial bioluminescent reaction, in Bioluminescence and Chemiluminescence, pp. 147-155, 180-85, Proc. of the IV Int. Bioluminescence and Chemiluminescence Symp., Freiburg, Sep. 1986.

Button et al., Aequorin-expressing mammalian cell lines used to report Ca.sup.2+ mobilization, Cell Calcium 14(9):663-671 (1993).

Chalfie et al. Green Fluorescent Protein as a marker for Gene Expression Science 263:802-805 (1994).

Charbonneau et al. Ca.sup.2 +-induced Bioluminescence in Renilla reniformis Purification and Characterization of a Calcium-Triggered Luciferin-Binding Protein J. Biol. Chem. 254:769-780 (1979).

Cody et al. Chemical structure of the Hexapeptide Chromophore of the Aequorea Green-Fluorescent Protein Biochemistry 32:1212-1218 (1993).

Cormack et al. Yeast-enhanced green fluorescent protein (yEGFP): a reporter of gene expression in Candida albicans Microbiology 143:303-311 (1997).

Cormier "Renilla and Aequorea bioluminescence" pp 225-233 in Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications. DeLuca et al eds, Academic Press 1981. . Cormier et al., Evidence for similar biochemical requirements for bioluminescence among the coelenterates, J. Cell Physiol. 81:291-298 (1972).

Dabiri et al. Myofibrillogenesis visualized in living embryonic cardiomyocytes Pro. Natl. Acad. Sci. USA 94:9493-9498 (1997).

Database Derwent #009443237 WPI Acc. No. 93-136754/199317 (citing Japanese Patent Application No. JP 5064583, published Mar. 19, 1993).

Fey et al. Green Fluorescent protein production in the cellular slime molds Polysphondylium pallidum and Dictyostelium discoideum Gene 165:127-130 (1995). . Giuliano et al. Fluorescent-protein biosensors: new tools for drug discovery TiBech 16: 135-140 (1998). .

Hart et al. "Renilla reniformis bioluminescence: Luciferase-catalyzed production of nonradiating excited states from luciferin analogues and elucidation of the excited state species involved in energy transfer to Renilla green fluorescent protein", (1979) Biochemistry 18:2204-2210 (1979).

Heinlein et al. Interaction of Tobamovirus Movement Proteins with the Plant Cytoskeleton Science 270:1983-1985 (1995).

Hori et al., Renilla luciferin as the substrate for calcium induced photoprotein bioluminescence. Assignment of luciferin plutomers in aequorin and mnemiopsin, Biochemistry 14: 2371-2376, (1975).

Ikawa et al. A rapid and non -invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP) FEBS Letters 375:125-128 (1995).

Inouye et al., "Expression of apoaequorin complementary DNA in Escherichia coli," Biochem. 25:8425-8429 (1986).

Inouye et al., "Imaging of luciferase secretion from transformed Chinese hamster ovary cells," Proc. Natl. Acad. Sci. USA 89:9584-9587 (1992).

Inouye et al., Electroporation as a new technique for producing transgenic fish, Cell Differ. Devel. 29:123-128 (1990).

Inouye et al., Monitoring gene expression in Chinese hamster ovary cells using secreted apoaequorin, Analyt. Biochem. 201(1): 114-118 (1992).

Kain et al., Green Fluorescent Protein as a reporter of Gene Expression and Protein Localization BioTechniques 19:650-655 (1995).

Karp et al., Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 360-363, Academic Press (1981). . Kendall et al., Changes in free calcium in the endoplasmic reticulum of living cells detected using targeted aequorin, Anal. Biochem. 22(1):173-81 (1994). . Knight et al., Imaging calcium dynamics in living plants using semi-synthetic recombinant aequorins, J. Cell Biol. 121(1):83-90 (1993). . Knight et al., Transgenic plant aequorin reports the effects of touch and cold-shock and elicitors on cytoplasmic calcium, Nature 352(6335): 524-526 (1991). . Leach et al., Commercially available firefly luciferase reagents, in Methods in Enzymology. Bioluminescence and Chemiluminescence Part B 133:51-69, Academic Press (1986). .

Legocki et al., Bioluminescence in soybean root nodules: Demonstration of a general approach to assay gene expression in vivo by using bacterial luciferase, Proc. Natl. Acad. Sci. USA 81:9080-9084 (1986).

McElroy, et al., The Chemistry and Applications of Firefly Luminescence,

Bioluminescence and Chemiluminescence, 179-185, Academic Press, Inc. (1981). . Miller et al. An improved GFP cloning cassette designed for prokaryotic transcriptional fusions Gene 191:149-153 (1997). .

Miyawaki et al. Fluorescent indicators for CA.sup.2+ based on green fluorescent proteins and calmodulin Nature 388:882-887 (1997).

Morin, Energy in a Bioluminescent System, J. Cell Physiol., 77:313-318 (Need Year).

Nakajima-Shimada et al., Monitoring of intracellular calcium in Saccharomyces cerevisiae with an apoaequorin cDNA expression system, Proc. Natl. Acad. Sci. USA 88(15): 6878-6882 (1991).

Plautz et al., Green Fluorescent protein and its derivatives as versatile markers for gene expression in living Drosophila melanogaster, plant and mamalian cells Gene 173:83-87 (1996).

Rivera et al., AquaLite.RTM. Streptavidin for supersentive TSH assays in microtiter plates and coated tubes, SeaLite Sciences Technical Report No. 6.

Rizuto et al., Rapid changes of mitochondrial Ca.sup.2+ revealed by specifically targeted recombinant aequorin, Nature 358(6384): 325-327 (1992).

Rutter et al., Involvement of MAP kinase in insulin signalling revealed by noninvasive imaging of luciferase gene expression in single living cells, Current Biology 5(8): 890-9 (1995).

Saran et al., Intracellular free calcium level and its response to cAMP stimulation in developing Dictyostelium cells transformed with jellyfish apoaequorin cDNA, FEBS Lett. 337(1): 43-7 (1994).

Sedlak et al., Bioluminescent Technology for Reagents, Diagnostics and Toxicology, Genetic Engineering News, Sep. 15, 1995.

Sgoutas et al., AquaLite.RTM. bioluminescence assay of thyrotropin in serum evaluated, Clin. Chem. 41(11):1637-1643 (1995).

Sheu et al., Measurement of intracellular calcium using bioluminescent aequorin exposed in human cells, Analyt. Biochem. 209(2): 343-347 (1993).

Straight et al. GFP tagging of budding yeast chromosomes reveals that protein--protein interations can mediate sister chromatid cohesion Current Biology 12:1599-1608 (1996).

Stults et al. Use of Recombinant Biotinylated Apoaequorin in Microtiter and Membrane-Based Assays: Purification of Recombinant Apoaequorin from Escherichia coli Biochemistry 31:1433-1442 (1992).

Terry et al. Molecular characterisation of recombinant green fluorescent protein by fluoresence corrrelation microscopy Biochemical and Biophysical Research Communication 217:21-27 (1995).

Thompson et al., Vargula hilgendorfii luciferase: a secreted reporter enzyme for monitoring gene expression in mammalian cells, Gene 96:257-262 (1990).

Travis, J. Following the Inner Light, Glow Genes provide revealing pictures of infections Science News 150:220-221 (1996).

Xu et al. A bioluminescence resonance energy transfer (BRET) system: Application to interacting circadian clock proteins Proc. Natl. Acad. Sci. USA 96:151-156 (1999). . Amato, Race quickens for non-stick blood monitoring technology, Science 258:892-893 (1992). .

Apt et al., Evolution of phycobiliproteins, J. Mol. Biol. 248: 79-96 (1995). . Bondar et al., Cadmium-induced luminescence of recombinant photoprotein obelin,

Biochim Biophys. Acta 1231: 29-32 (1995). .

Campbell et al., Formation of the Ca.sup.2+ -activated photoprotein obelin from apoobelin and mRNA inside human neutrophils, Biochem. J. 252(1):143-9 (1988).

Cardullo et al. Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer Pro.Natl. Acad. Sci. USA 85:8790-9794 (1988).

Crescitelli, Adaptations of visual pigments to the photic environment of the deep sea, J. Exptl. Zool. Supp. 5: 66-75 (1991).

Database Derwent #008987167 (citing WO 9204577, Chemiluminescence prodn. in liq.-contg. vesssel--by placing reagent envelope in liq. or vessel base).

Gautier et al., Alternate determination of ATP and NADH with a single bioluminescence-based fiber-optic sensor, Fifth International Conference on Solid State Sensors and Actuators and Eurosensors III, Montreux, Switzerland, Jun. 25-30, 1989.

Gilbert et al., Expression of genes involved in phycocyanin biosynthesis following recoivery of Synechococcus PCC 6301 from nitrogen starvation, and the effect of gabaculine on cpcBa transcript levels, FEMS Microbiol. Lett. 140: 93-98 (1996). . Glazer, Phycogbilisomes: structure and dynamics, Ann. Rev. Microbiol. 36:173-98 (1982). .

Houmard et al., Genes encoding core components of the phycobilisome in

cyanobacterium Calothrix sp. srain PCC 7601: occurrence of a multigene family, J. Bacteriol. 170(12): 5512-5521 (1988).

Kronick, The use of phycobiliproteins as flkuorescent labels in immunoassay, J. Immunolog. Meth. 92: 1-13 (1986).

Liu et al., A cyanidium caldarium Allophycocyanin .beta. subunit gene, Plant Physiol. 103:293-294 (1993).

Lucas et al., Coelenterazine is a superoxide anion-sensitive chemiluminescent probe: its usefulness in the assay of respiratory burst in neutrophils, Analyt. Biochem. 206(2):273-277 (1992).

Muller and Campbell, "The chromophore of pholasin: A highly luminescent protein", J. Biolumin. Chemilum. 5:25-30 (1990).

Nicoli et al., Bacterial luciferase: The hydrophobic environment of the reactive sulfhydryl, J. Biol. Chem. 249: 2393-2396 (1974).

O'Day et al., Aristostomias scintillans (Malacostiedae): a deep sea fish with visual pigments apparently adapted to its own bioluminescence, Vision Res. 14:545-550 (1974).

Peerce et al. Distance between substrate sites on the Na-glucose cotransporter by fluoresence energy transfer Proc. Natl. Acad. Sci. USA 83:8092-8096 (1986).

Pilot et al., Cloning and sequencing of the genes encoding the .alpha. and .beta. subunits of C-phycocyanin from the cyanobacterium Agmenellum quadruplicatum, Proc. Natl. Acad. Sci. USA 81: 6983-6987 (1984).

Shimomura, "Cause of spectral variation in the luminescence of semisynthetic aequorins", Biochem J. 306:537-543 (1995).

Shimomura, Bioluminescence in the sea: photoprotein systems [Review], Symposia of the Society of Experimental Biology 39: 351-372 (1985).

Shimomura et al., Peroxidized coelenterazine, the active group in the photoprotein aequorin, Proc. Natl. Acad. Sci. USA 75(6): 2611-5 (1978).

Shimomura et al., Regeneration of the photoprotein aequorin, Nature 256: 236-238 (1975).

Shimomura et al., Resistivity to denaturation of the apoprotein of aequorin and reconstitution of the luminescent photoprotein from the partially denatured apoprotein, Biochem J. 199:825-828 (1981).

Shimomura et al., The relative rate of aequorin regeneration from apoaequorin and coelenterazine analogues, Biochem. J. 296(Pt. 3): 549-551 (1993).

Smalley et al., "Localization of fluorescent compounds in the firefly light organ", J. Histochem. Cytochem. 28(4):323-329 (1980).

Smith et al., Bioluminescent immunoassays using streptavidin and biotin conjugates of recombinant aequorin, reprinted from American Biotechnology Laboratory, Apr.

1995..

Stability of AquaLite.RTM.: lyophilized and in solution, SeaLite Sciences Technical Report No. 8 (1994).

Stephenson et al. Studies on the Luminescent Response of the Ca.sup.2+ -Activated Photoprotein, Obelin Biochimica et Biophysica Acta 678:65-75 (1981).

Tsuji et al., Mechanism of the enzyme-catalyzed oxidation of Cypridina and firefly luciferins studied by means of .sup.17 O.sub.2 and H.sub.2.sup.18 O.sup.1, Biochem. Biophys.Res. Commun. 74(2):606-613 (1977).

Vysotski et al., Luminescence of Ca.sup.2+ -activated photoprotein obelin initiated by NaOCl and MnCl.sub.2, J. Biolumin. Chemilumin. 8:301-305 (1993).

Vysotski et al., Mn.sup.2+ -activated luminescence of the photoprotein obelin, Arch. Bioch. Biophys. 316:92-99 (1995).

Ward, Energy Transfer Processes in Bioluminescence Photochem. Photobiol. Rev. 4:1-57.

Ward et al., An energy transfer protein in coelenterate bioluminescence, J. Biol. Chem. 254: 781-788 (1979).

Ward et al. Energy Transfer Via Protein--Protein Interation in Renilla Bioluminescence Photochemistry and Photobiology 27:389-396 (1978).

Ward et al. In Vitro Energy Transfer in Renilla Bioluminescence The Journal of Physical Chemistry 8:2289-2291 (1976).

Ward et al. Reversible Denaturation of the Aequorea Green-Fluorescent Protein: Physicial Separation and Characterization of the Renatured Protein Biochemistry 21:4535-4550 (1982).

Ward, General Aspects of Bioluminescence, in Chemi- and Bioluminescence, Burr, ed., Marcel Dekker, Inc., New York.

Ward, Properties of the Coelenterate Green-Fluorescent Proteins Bioluminescence and Chemiluminescence 235-242 (1981).

Watanabe et al., Bunding of murine monoclonal antibodies to the active and inactive configurations of aequorin, FEBS Lett. 246(1-2): 73-77 (1989).

Watkins et al., Requirement of the C-terminal proline residue for stability of the Ca.sup.(2+) -activated photoprotein aequorin, Biochem. J. 293(Pt.1): 181-185 (1993). . Welches et al., Active center studies on bacterial luciferase: Modification of the enzyme with 2,4-dinitrofluorobenzene, Biochemistry 20:512-517 (1981).

Widder et al., "Far red bioluminescence from two deep-sea fishes", Science 225:512-514 (1984).

Wienhausen et al., Luciferases from different species of fireflies are antigenically similar, Photochem. Photobiol. 42:609-611 (1985).

Ziegler et al., Active center studies on bacterial luciferase: Locations of the protease

labile regions and the reactive cysteinyl residue in the primary structure of the .alpha. subunit, Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 376-377, Academic Press (1981). .

Anderson, Radiolaria, Springer-Verlag, New York (1983). .

Bayer and Wichek (1980) The Use of Avidin/Biotin Complex as a Tool in Molecular Biology. Meth. Biochem. Anal. 26, 1-45.

Berg et al., Long-chain polystyrene-grafted polyethylene film matrix: a new support for solid-phase peptide synthesis, J. Am. Chem. Soc. 111:8026-8027 (1989).

Berg et al., Peptide synthesis on polystyrene-grafted polyethylene sheets, Pept., Proc. Eur. Pept. Symp., 20th, Jung et al. (Eds.), pp. 196-198 (1989).

Berg et al., Polystyrene-grafted polyethylene: Design of film and felt matrices for solid-phase peptide synthesis, Innovation Perspect. Solid Phase Synth. Collect. Pap., Int. Symp., 1st, Epton (ed.), pp. 453-459 (1990).

Bodanszky and Bodanszky, The Practice of Peptide Synthesis, Springer-Verlag, New York, (1984).

Bunnin et al. The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library, Proc. Natl. Acad. Sci. USA, 91:4708-4712 (1994).

Carlsson et al. Protein Thiolation and Reversible Protein--Protein Conjugation Biochem. J. 173: 723-737 (1978).

Childress, "Oxygen minimum layer: Vertical distribution and respiration of the mysid gnathophausia ingens", Science 160:1242-1423 (1968).

DeWitt et al., Diversomers: an approach to nonpeptide, nonoligomeric chemical diversity, Proc. Natl. Acad. Sci. USA 90: 6909-6913 (1993).

DeWitt et al., DIVERSOMER.TM. Technology: solid phase synthesis, automation, and integration for the generation of chemical diversity, Drug Dev Res 33:116-124 (1994).

Dialog Abstract 002042687, citing: JP 7241192. .

Duzgunes et al., Fusion of phospholipid vesicles induced by divalent cations and protons; modulation by phase trasitions, free fatty acids, monovalent cations, and polyamines, Cell Fusion, Ch. 11 Divalent Cations and Protons, Sowers, A.E. (ed.) pp. 241-267 (1984).

Goodchild, "Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties", Perspectives on Bioconjugate Chemistry, Mears, ed., American Chemical Society, Washington, D.C., Ch 6, pp. 77-99 (1993).

Gordon et al. Topographical localization of the C-terminal region of the voltagedependent sodium channel from Electrophorus electricus using antibodies raised against a synthetic peptide Proc. Natl. Acad Sci. 84:308-312 (1987).

Guyomard et al., Integration and germ line transmission of foreign genes

microinjected into fertilized trout eggs, Biochimie 71:857-863 (1989).

Hazum et al., A photocleavable protecting group for the thiol function of cysteine,

Pept., Proc. Eur. Pept. Symp., 16th, Brunfeldt, K (Ed), pp. 105-110 (1981). .

Hermanson et al., Immobilized Affinity Ligand Techniques, Chaps. 1 and 2, Academic Press, Inc. (1992).

Immobilized Biochemicals and Affinity Chromatography, Advances in Experimental Medicine and Biology, vol. 42, ed. R. Dunlap, Plenum Press, N.Y. (1974) Table of Contents.

Immobilized Enzyme, Antigens, Antibodies and Peptides. Preparation and

Characterization, Marcel Dekker, Inc., N.Y., Howard H. Weetall (ed.) (1975).

Kennedy and Cabral, Immobilized Enzymes, in Solid Phase Biochemistry, Analytical and Synthetic Aspects, Scouten, Ed., 7:253-391 (1983).

Kent et al., Preparation and properties of tert-butyloxcarbonylaminocayl-4-

(oxymethyl) phenylacetamidomethyl-(Kel F-g-styrene) resin, an insoluble,

noncrosslinked support for solid phase peptide synthesis, Israel J. Chem. 17: 243-247 (1978).

Kozak, Structural Features in Eukaryotic mRNAs that Modulate the Initiation of Translation The Journal of Biological Chemistry 266: 19867-19870 (1991).

Kroger et al., "A new calcium binding glycoprotein family constitutes a major diatom cell wall component", EMBO 13:4676-4683 (1996).

Kroger et al., "Frustulins: domain consevation in a protein family associated with diatom cell walls", Eur. J. Biochem. 239:259-264 (1996).

Liposome Technology, Targeted Drug Delivery and Biological Interaction, vol. III, G. Gregoriadis (ed.), CRC Press, Inc. (1984) Table of Contents.

Mengeling et al., A microplate assay for analysis of solution-phase glycosyltransferase reactions: Determination of kinetic constants, Anal. Biochem. 199:286-292 (1991).

Millon et al., "Synthesis of a new reagent, ethyl 4-azidobenzoylaminoacetimidate, and its use for RNA-protein cross-linking within Escherichia coli ribosomal 30-S subunits", Eur. J. Biochem. 110:485-492 (1980).

Molecular Biology of the Gene, 4th Edition, 1987, ed. Watson et al. The Benjamin/Cummings Pub. co. Pg 224.

Mosbach, AMP and NAD as `general ligands`, Affinity Techniques. Enzyme Purification: Part B. Methods in Enzymology, vol. 34, W. B. Jakoby, et al. (eds.), Acad. Press, N.Y. (1974).

Mosbach et al. Immobilization of enzymes to various acrylic copolymers. Methods in Enzymology 44:53-65 (1976).

Mosbach et al. Immobilized coenzymes. Methods in Enzymology 44:859-887 (1976). . Mosbach, K and Mattiasson, B. Multistep enzyme systems. Methods in Enzymology 44:453-478 (1976)...

Mosbach, K. Immobilized Enzymes. Methods in Enzymology 44:3-7 (1976). . Ozato et al., Production of transgeniuc fish: introduction and expression of chicken .gamma.-crystalline gene in medaka embryos, Cell Differ. Devel. 19:237-244 (1986). .

Peffer et al., "Strand-invasion of duplex DNA by peptide nucleic acid oligomers",

Proc. Natl. Acad. Sci. U.S.A. 90:10648-10652 (1993). .

Pierce Catalog, pp. T123-T154, 1994. .

Pierce Catalog & Handbook, pp. 090-0110, T155-T200 (1994). .

Pierce Catalog, ImmunoTechnology Catalog & Handbook (1992-1993). .

Sambrook et al., Molecular Cloning, 2nd ed., Cold Springs Harbor Laboratory press, New York (1989).

Stewart and Young, Laboratory techniques in solid phase peptide synthesis, Solid Phase Peptide Synthesis, 2d Ed., Pierce Chemical Co., pp. 53-73 (1984).

Studier et al. Use of T7 RNA Polymerase to Direct Expression of Cloned Genes Methods in Enzymology 185: 60-89 (1990).

Travis, J., X-rays speed healing of rat spinal cords, Science News 150:214, (1996). . Wang et al. Implications for bcd mRNA localization from spatial distribution of exu protein in Drosophila oogenesis Nature 369:400-403 (1994).

Wu et al. Rseonance Energy Transfer: Methods and Application Analytical Biochemistry 218:1-13 (1994).

Database EMBL Nucleotide and Protein Sequences, AC=U19278, "Green fluorescent protein; cloning vector pGFP-C3", artificial sequence, abstract, (1995).

Latz, et al., "Recovery and stimulation of copepod bioluminescence", J. Exp. Mar. Biol. Ecol. 136:1-22 (1990).

Shimomura and Johnson, "Comparison of the amounts of key components in the bioluminescence systems of various coelenerates", Comp. Biochem. Physiol. 64B:105-107 (1979).

Chalfie, Green fluorescent protein, Photochemistry and Photobiology, 62(4):651-656 (1995).

Database EMBL Nucleotide and Protein Sequences, AC=AF025844, Co-reporter vector pRL-Null, complete sequence, abstract, (1997).

Delagrave et al., Red-shifted excitation mutants of the green fluorescent protein, Bio/Technology 13(2):151-154 (1995).

Ehrig et al., Green-fluorescent protein mutants with altered fluorence

excitationspectra, FEBS Letters 367:163-166 (1995). .

Fratamico et al., Construction and characterization of Escherichia coli 0157:H7 strains expressing firefly luciferase and green fluorescent protein and their use in survival studies, J of Food Protection 60(10):1167-1173 (1997).

Grentzmann et al., A dual-luciferase system for studying recoding signals, RNA 479-486 (1998). .

Heim et al., Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer, Current Biology 6(2):178-182 (1996).

Mitra et al., Fluorescence resonance energy tranfer between blue-emitting and redshifted excitation derivatives of the green fluorescent protein, Gene 73(1):13-17 (1996).

Romoser et al., Detection in living cells of Ca2+-dependent changes in the fluorescence emission of an indicator composed of two green fluorescent protein variants liked by a calmodulin-binding sequence, J. of Biolog. Chem. 272(20):13270-13274 (1997).

Sandalova, Some notions about structure of bacterial luciferase, obtained by analysis of amino acid sequence, and study of monoclonal antibodies binding, In Biological Luminescence, Proceedings of International School, 1st, ed., Jezowska-Trzebiatowska et al., World Science (1990).

Sherf et al., Dual-luciferase reporter assay: an advanced co-reporter technology integrating firefly and Renilla luciferase assays, Promega Notes 57:2-5 (1996). . Spurlok et al., A fine structure study of the anthocodium in Renilla mulleri, J. of Cell Biology 64:15-28 (1975)..

Primary Examiner: Achutamurthy; Ponnathapu Assistant Examiner: Rao; Manjunath N. Attorney, Agent or Firm: Seidman; Stephanie Heller, Ehrman, White & Mculiffe LLP

Parent Case Text

RELATED APPLICATIONS

This application claims priority to U.S. provisional application Ser. No. 60/102,939, filed Oct. 1, 1998, to Bruce Bryan and Christopher Szent-Gyorgyi, entitled "LUCIFERASES, FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THE LUCIFERASES AND FLUORESCENT PROTEINS AND THE USE THEREOF IN DIAGNOSTICS, HIGH THROUGHPUT SCREENING AND NOVELTY ITEMS". Priority is also claimed to U.S. provisional application Ser. No.60/089,367, filed Jun. 15, 1998, to Bruce Bryan and Christopher Szent-Gyorgyi, entitled "GAUSSIA LUCIFERASE, NUCLEIC ACIDS ENCODING THE LUCIFERASE AND METHODS USING THE LUCIFERASE", and to U.S. provisional

application Ser. No.60/079,624, filed Mar. 27, 1998, to Bruce Bryan and Christopher Szent-Gyorgyi, entitled "RENILLA GREEN FLUORESCENT PROTEIN COMPOSITIONS AND METHODS." For U.S. purposes, benefit of priority to each of these applications is claimed under 35 U.S.C. .sctn.119(e).

This application is also related to subject matter in U.S. application Ser. No. 08/757,046, filed Nov. 25, 1996, to Bruce Bryan entitled "BIOLUMINESCENT NOVELTY ITEMS", now U.S. Pat. No. 5,876,995, issued Mar. 2, 1999, and in U.S. application Ser. No. 08/597,274, filed Feb. 6, 1996, to Bruce Bryan, entitled "BIOLUMINESCENT NOVELTY ITEMS". This application is also related to U.S. application Ser. No. 08/908,909, filed Aug. 8, 1997, to Bruce Bryan entitled "DETECTION AND VISUALIZATION OF NEOPLASTIC TISSUE AND OTHER TISSUES". The application is also related to U.S. application Ser. No. 08/990,103, filed Dec. 12, 1997, to Bruce Bryan entitled "APPARATUS AND METHODS FOR DETECTING AND IDENTIFYING INFECTIOUS AGENTS".

The subject matter of each of the above noted U.S. applications and provisional applications is herein incorporated by reference in its entirety.

Claims

What is claimed is:

1. An isolated nucleic acid fragment, comprising a sequence of nucleotides encoding a Renilla mulleri luciferase, a Gaussia luciferase or a Pleuromamma luciferase, wherein the sequence of nucleotides is selected from the group consisting of

a sequence of nucleotides set forth in SEQ ID No. 17, SEQ ID No. 19, or SEQ ID No. 28;

a sequence of nucleotides encoding the amino acid sequence set forth in SEQ ID No. 18, SEQ ID No. 20 or SEQ ID No. 29; or

a sequence of nucleotides that hybridizes under high stringency to the sequence of nucleotides set forth in SEQ ID No. 17, SEQ ID No.19 or SEQ ID No. 28.

2. A nucleic acid probe or primer, comprising at least 14 contiguous nucleotides selected from the sequence of nucleotides set forth in the coding portion of SEQ ID Nos. 19 or 28.

3. The nucleic acid probe or primer of claim 2, comprising at least 16 contiguous nucleotides selected from the sequence of nucleotides set forth in the coding portion of SEQ ID Nos. 19 or 28.

4. The nucleic acid probe or primer of claim 2, comprising at least 30 contiguous nucleotides selected from the sequence of nucleotides set forth in the coding portion of SEQ ID Nos. 17, 19 or 28.

5. A plasmid, comprising the nucleic acid fragment of claim 1.

6. The plasmid of claim 5 that is an expression vector.

7. The plasmid of claim 6, comprising a sequence of nucleotides encoding:

a promoter region;

a Gaussia, Pleuromamma or Renilla mulleri luciferase; and

a selectable marker;

wherein the sequence of nucleotides encoding the luciferase is operatively linked to the promoter, whereby the luciferase is expressed.

8. The plasmid of claim 6, further comprising a sequence of nucleotides encoding a green fluorescent protein (GFP).

9. A recombinant host cell, comprising the plasmid of claim 6.

10. The cell of claim 9, wherein the cell is selected from the group consisting of a bacterial cell, a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

11. A method for producing a Gaussia, Renilla mulleri or Pleuromamma luciferase protein, comprising growing the recombinant host cell of claim 9, wherein the luciferase protein is expressed by the cell, and recovering the expressed luciferase protein.

12. An isolated nucleic acid fragment encoding a green fluorescent protein (GFP), comprising the sequence of nucleotides selected from the group consisting of

a sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30 or SEQ ID No. 31;

a sequence of nucleotides encoding the amino acid sequence set forth in SEQ ID No. 16 or SEQ ID No. 32; or

a sequence of nucleotides that hybridizes under high stringency to the sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30 or SEQ ID No. 31.

13. A nucleic acid probe or primer, comprising at least 14 contiguous nucleotides selected from the sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30.

14. The probe or primer of claim 13, comprising at least 16 contiguous nucleotides selected from the sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30.

15. The probe or primer of claim 13, comprising at least 30 contiguous nucleotides selected from the sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30.

16. A plasmid, comprising the sequence of nucleotides of claim 12.

17. An expression vector, comprising:

the plasmid of claim 16,

a promoter element;

a multiple cloning site for the introduction of nucleic acid; and

a selectable marker;

wherein the nucleic acid encoding the multiple cloning site is positioned between nucleic acids encoding the promoter element and the green fluorescent protein and wherein the nucleic acid encoding the green fluorescent protein is operatively linked to the promoter element.

18. The plasmid of claim 16, further comprising a sequence of nucleotides encoding:

a promoter element;

a selectable marker;

wherein, the sequence of nucleotides encoding the green fluorescent protein is operatively linked to the promoter element, whereby the green fluorescent protein is expressed.

19. The plasmid of claim 18, further comprising a sequence of nucleotides encoding a luciferase.

20. A recombinant host cell, comprising the plasmid of claim 16.

21. The cell of claim 20, wherein the cell is selected from the group consisting of a bacterial cell, a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

22. A nucleic acid construct, comprising a sequence of nucleoides encoding a luciferase and a sequence of nucleotides encoding a green fluorescent protein (GFP), wherein the luciferase is encoded by:

a sequence of nucleotides set forth in SEQ ID No. 17, SEQ ID No. 19, or SEQ ID No. 28;

a sequence of nucleotides encoding the amino acid sequence set forth in SEQ ID No. 18, SEQ ID No. 20 or SEQ ID No. 29; and

a sequence of nucleotides that hybridizes under high stringency to the sequence of nucleotides set forth in SEQ ID No. 17, SEQ ID No. 19 or SEQ ID No. 28.

23. The nucleic acid construct of claim 22, wherein the GFP is a Renilla green fluorescent protein (GFP) or a Ptilosarcus GFP.

24. The nucleic acid construct of claim 23, wherein the Renilla GFP is a Renilla reniformis, Renilla kollokeri or Renilla mulleri GFP.

25. The nucleic acid construct of claim 22, wherein the GFP is encoded by:

a sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30 or SEQ ID No. 31;

a sequence of nucleotides encoding the amino acid sequence set forth in SEQ ID No. 16 or SEQ ID No. 32; and

a sequence of nucleotides that hybridizes under high stringency to the sequence of nucleotides set forth in SEQ ID No. 15, SEQ ID No. 30 or SEQ ID No. 31.

26. The nucleic acid construct of claim 25, wherein the luciferase and GFP are from Renilla.

27. The nucleic acid construct of claim 26, wherein the Renilla luciferase and GFP are from Renilla mulleri.

28. The nucleic acid construct of claim 22, wherein the nucleotide sequence encoding the luciferase and GFP are linked contiguously.

29. The nucleic acid construct of claim 22 that is DNA.

30. The nucleic acid construct of claim 22 that is RNA.

31. A plasmid, comprising the nucleic acid construct of claim 22.

32. The plasmid of claim 31, further comprising a sequence of nucleotides encoding:

a promoter element;

a selectable marker;

wherein, the sequence of nucleotides encoding the luciferase and GFP is operatively linked to the promoter element, whereby a fusion protein of the luciferase and GFP is expressed.

33. A recombinant host cell, comprising the plasmid of claim 31.

34. The cell of claim 33, wherein the cell is selected from the group consisting of a bacterial cell, a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

35. The nucleic acid construct of claim 22, wherein the nucleotide sequence encoding the luciferase and GFP are not contiguous.

36. The nucleic acid construct of claim 35, further comprising a sequence of nucleotides that encodes a ligand binding domain of a protein.

37. A nucleic acid probe or primer, comprising at least 14 nucleotides that encode amino acids 51 to 68, 82 to 98 or 198 to 208 set forth in SEQ ID No. 16, amino acid sequence set forth in SEQ ID No. 24, amino acids 9-20 set forth in SEQ ID No. 25 or amino acids 39-53 set forth in SEQ

ID No. 27.

38. The probe or primer of claim 37, comprising a sequence of nucleic acids in SEQ ID No.15 that that encode amino acids 51 to 68, 82 to 98 and 198 to 208 set forth in SEQ ID No. 16.

39. A method of isolating nucleic acid that encodes a Renilla green fluorescent protein (GFP), comprising:

screening a Renilla nucleic acid library with a probe or plurality of probes of claim 37; and

identifying and isolating nucleic acid that encodes a GFP.

40. A method of isolating nucleic acid that encodes a Renilla green fluorescent protein (GFP), comprising:

amplifying nucleic acid in a Renilla nucleic acid library with a primer or plurality of primers of claim 37; and

isolating the amplified nucleic acids, whereby nucleic acid encoding a GFP is identified and isolated.

41. The isolated nucleic acid fragment of claim 1, wherein the a sequence of nucleotides encodes a Renilla mulleri luciferase.

42. The isolated nucleic acid fragment of claim 1, wherein the a sequence of nucleotides encodes a Gaussia luciferase.

43. The isolated nucleic acid fragment of claim 1, wherein the a sequence of nucleotides encodes a Pleuromamma luciferase.

44. The isolated nucleic acid fragment of claim 42, wherein the Gaussia is a member of the species of princeps.

45. The isolated nucleic acid fragment of claim 1, wherein the nucleic acid is DNA.

46. The isolated nucleic acid fragment of claim 1, wherein the nucleic acid is RNA.

47. A host cell, comprising a plasmid of claim 5.

48. The isolated nucleic acid fragment of claim 12, wherein the nucleic acid is DNA.

49. The isolated nucleic acid fragment of claim 12, wherein the nucleic acid is RNA.

50. The isolated nucleic acid fragment of claim 12, wherein the sequence of nucleotides encodes a Renilla green fluorescent protein (GFP).

51. The isolated nucleic acid fragment of claim 12, wherein the sequence of nucleotides encodes a Ptilocarpus green fluorescent protein.

52. The isolated nucleic acid fragment of claim 50, wherein the Renilla species is selected from the group consisting of Renilla reniformis, Renilla kollokeri and Renilla mulleri.

53. The construct of claim 23, wherein the GFP is a Renilla green fluorescent protein (GFP).

54. The construct of claim 23, wherein the GFP is a Ptilosarcus GFP.

55. The nucleic acid construct of claim 22, wherein the luciferase is a Renilla mulleri luciferase.

56. The nucleic acid construct of claim 22, wherein the luciferase is a Gaussia luciferase.

57. The nucleic acid construct of claim 22, wherein the luciferase is a Pleuromamma luciferase.

58. The nucleic acid construct of claim 56, wherein the Gaussia luciferase is a Gaussia princepes luciferase.

59. A plasmid, comprising the nucleic acid construct of claim 25.

60. The nucleic acid construct of claim 25, wherein the nucleotide sequence encoding the luciferase and GFP are contiguous.

61. The nucleic acid construct of claim 25, wherein the nucleotide sequence encoding the luciferase and GFP are not contiguous.

62. A nucleic acid probe or primer, comprising at least 16 contiguous nucleotides that encode on amino acids 51 to 68, 82 to 98 and 198 to 208 set forth in SEQ ID No. 16, amino acid sequence set forth in SEQ ID No. 24, amino acids 9-20 set forth in SEQ ID No. 25 or amino acids 39-53

set forth in SEQ ID No. 27.

63. A nucleic acid probe or primer, comprising at least 30 contiguous nucleotides that encode on amino acids 51 to 68, 82 to 98 and 198 to 208 set forth in SEQ ID No. 16, amino acid sequence set forth in SEQ ID No. 24, amino acids 9-20 set forth in SEQ ID No. 25 or amino acids 39-53 set forth in SEQ ID No. 27.

Description

FIELD OF INVENTION

The present invention relates to isolated and purified nucleic acids and encoded proteins from the genera Renilla, Gaussia, Philocarpus and Pleuromamma. More particularly, nucleic acids encoding luciferase and fluorescent proteins from species of these genera are provided.

BACKGROUND OF THE INVENTION

Luminescence is a phenomenon in which energy is specifically channeled to a molecule to produce an excited state. Return to a lower energy state is accompanied by release of a photon (hy). Luminescence includes fluorescence, phosphorescence, chemiluminescence and bioluminescence. Bioluminescence is the process by which living organisms emit light that is visible to other organisms. Luminescence may be represented as follows:

where X^* is an electronically excited molecule and hy represents light emission upon return of X^* to a lower energy state. Where the luminescence is bioluminescence, creation of the excited state derives from an enzyme catalyzed reaction. The color of the emitted light in a bioluminescent (or chemiluminescent or other luminescent) reaction is characteristic of the excited molecule, and is independent from its source of excitation and temperature.

An essential condition for bioluminescence is the use of molecular oxygen, either bound or free in the presence of a luciferase. Luciferases, are oxygenases, that act on a substrate, luciferin, in the presence of molecular oxygen and transform the substrate to an excited state. Upon return to a lower energy level, energy is released in the form of light [for reviews see, e.g., McElroy et al. (1966) in Molecular Architecture in Cell Physiology, Hayashi et al., eds., Prentice-Hall, Inc., Englewood Cliffs, N.J., pp. 63-80; Ward et al., Chapter 7 in Chemi-and Bioluminescence, Burr, ed., Marcel Dekker, Inc. NY, pp.321-358; Hastings, J. W. in (1995) Cell Physiology:Source Book, N. Sperelakis (ed.), Academic Press, pp 665-681; Luminescence, Narcosis and Life in the United States Patent: 6232107

Deep Sea, Johnson, Vantage Press, NY, see, esp. pp. 50-56].

Though rare overall, bioluminescence is more common in marine organisms than in terrestrial organisms. Bioluminescence has developed from as many as thirty evolutionarily distinct origins and, thus, is manifested in a variety of ways so that the biochemical and physiological mechanisms responsible for bioluminescence in different organisms are distinct. Bioluminescent species span many genera and include microscopic organisms, such as bacteria [primarily marine bacteria including Vibrio species], fungi, algae and dinoflagellates, to marine organisms, including arthropods, mollusks, echinoderms, and chordates, and terrestrial organism including annelid worms and insects.

Assays employing bioluminescence

During the past twenty years, high-sensitivity biochemical assays used in research and in medicine have increasingly employed luminescence and fluorescence rather than radioisotopes. This change has been driven partly by the increasing expense of radioisotope disposal and partly by the need to find more rapid and convenient assay methods. More recently, the need to perform biochemical assays in situ in living cells and whole animals has driven researchers toward protein-based luminescence and fluorescence. The uses of firefly luciferase for ATP assays, aequorin and obelin as calcium reporters, Vargula luciferase as a neurophysiological indicator, and the Aequorea green fluorescent protein as a protein tracer and pH indicator show the potential of bioluminescence-based methods in research laboratories.

Bioluminescence is also beginning to directly impact medicine and biotechnology; for example, Aequorea GFP is employed to mark cells in murine model systems and as a reporter in high throughput drug screening. Renilla luciferase is under development for use in diagnostic platforms.

Bioluminescence generating systems

Bioluminescence, as well as other types of chemiluminescence, is used for quantitative determinations of specific substances in biology and medicine. For example, luciferase genes have been cloned and exploited as reporter genes in numerous assays, for many purposes. Since the different luciferase systems have different specific requirements, they may be used to detect and quantify a variety of substances. The majority of commercial bioluminescence applications are based on firefly [Photinus pyralis] luciferase. One of the first and still widely used assays involves the use of firefly luciferase to detect the presence of ATP. It is also used to detect and quantify other substrates or co-factors in the reaction. Any reaction that produces or utilizes

NAD(H), NADP(H) or long chain aldehyde, either directly or indirectly, can be coupled to the light-emitting reaction of bacterial luciferase.

Another luciferase system that has been used commercially for analytical purposes is the Aequorin system. The purified jellyfish photoprotein, aequorin, is used to detect and quantify intracellular Ca.sup.2+ and its changes under various experimental conditions. The Aequorin photoprotein is relatively small [.about.20 kDa], nontoxic, and can be injected into cells in quantities adequate to detect calcium over a large concentration range [3.times.10.sup.-7 to 10.sup.-4 M].

Because of their analytical utility, luciferases and substrates have been studied and wellcharacterized and are commercially available [eq., firefly luciferase is available from Sigma, St. Louis, Mo., and Boehringer Mannheim Biochemicals, Indianapolis, Ind.; recombinantly produced firefly luciferase and other reagents based on this gene or for use with this protein are available from Promega Corporation, Madison, Wis.; the aequorin photoprotein luciferase from jellyfish and luciferase from Renilla are commercially available from Sealite Sciences, Bogart, Ga.; coelenterazine, the naturally-occurring substrate for these luciferases, is available from Molecular Probes, Eugene, Oreg.]. These luciferases and related reagents are used as reagents for diagnostics, quality control, environmental testing and other such analyses.

Because of the utility of luciferases as reagents in analytical systems and the potential for use in high throughput screening systems, there is a need to identify and isolated a variety of luciferases that have improved or different spectral properties compared to those presently available. For all these reasons, it would be advantageous to have luciferases from a variety of species, such as Gaussia and various Renilla species available.

Fluorescent Proteins

Reporter genes, when co-transfected into recipient cells with a gene of interest, provide a means to detect transfection and other events. Among reporter genes are those that encode fluorescent proteins. The bioluminescence generating systems described herein are among those used as reporter genes. To increase the sensitivity bioluminescence generating systems have been combined with fluorescent compounds and proteins, such as naturally fluorescent phycobiliproteins. Also of interest are the fluorescent proteins that are present in a variety of marine invertebrates, such as the green and blue fluorescent proteins, particularly the green fluorescent protein (GFP) of Aequorea victoria.

The green fluorescent proteins (GFP) constitute a class of chromoproteins found only among

certain bioluminescent coelenterates. These accessory proteins are fluorescent and function as the ultimate bioluminescence emitter in these organisms by accepting energy from enzyme-bound, excited-state oxyluciferin (e.g., see Ward et al. (1979) J. Biol. Chem. 254:781-788; Ward et al. (1978) Photochem. Photobiol. 27:389-396; Ward et al. (1982) Biochemistry 21:4535-4540).

The best characterized GFPs are those isolated from the jellyfish species Aequorea, particularly Aequorea victoria (A. victoria) and Aequorea forskalea (Ward et al. (1982) Biochemistry 21:4535-4540; Prendergast et al. (1978) Biochemistry 17:3448-3453). Purified A. victoria GFP is a monomeric protein of about 27 Kda that absorbs blue light with excitation wavelength maximum of 395 nm, with a minor peak at 470 nm, and emits green fluorescence with an emission wavelength of about 510 nm and a minor peak near 540 nm (Ward et al. (1979) Photochem. Photobiol. Rev 4:1-57). This GFP has certain limitations. The excitation maximum of the wildtype GFP is not within the range of wavelengths of standard fluorescein detection optics.

The detection of green fluorescence does not require any exogenous substrates or co-factors. Instead, the high level of fluorescence results from the intrinsic chromophore of the protein. The chromophore includes modified amino acid residues within the polypeptide chain. For example, the fluorescent chromophore of A. victoria GFP is encoded by the hexapeptide sequence, FSYGVQ, encompassing amino acid residues 64-69. The chromophore is formed by the intramolecular cyclization of the polypeptide backbone at residues Ser65 and Gly67 and the oxidation of the .alpha.-.beta. bond of residue Tyr66 (e.g., see Cody et al. (1993) Biochemistry 32:1212-1218; Shimomura (1978) FEBS Letters 104:220-222; Ward et al. (1989) Photochem. Photobiol. 49:62S). The emission spectrum of the isolated chromophore and the denatured protein at neutral Ph do not match the spectrum of the native protein, suggesting that chromophore formation occurs post-translationally (e.g., see Cody et al. (1993) Biochemistry 32:1212-1218).

In addition, the crystal structure of purified A. victoria GFP has been determined (e.g., see Ormo (1996) Science 273:1392-1395). The predominant structural features of the protein are an 11-stranded .beta. barrel that forms a nearly perfect cylinder wrapping around a single central .alpha.-helix, which contains the modified p-hydroxybenzylideneimadaxolidinone chromophore. The chromophore is centrally located within the barrel structure and is completely shielded from exposure to bulk solvent.

DNA encoding an isotype of A. victoria GFP has been isolated and its nucleotide sequence has been determined (e.g., see Prasher (1992) Gene 111:229-233). The A. victoria CDNA contains a 714 nucleotide open reading frame that encodes a 238 amino acid polypeptide of a calculated

M.sub.r of 26,888 Da. Recombinantly expressed A. victoria GFPs retain their ability to fluoresce in vivo in a wide variety organisms, including bacteria (e.g., see Chalfie et al. (1994) Science 263:802-805; Miller et al. (1997) Gene 191:149-153), yeast and fungi (Fey et al. (1995) Gene 165:127-130; Straight et al. (1996) Curr. Biol. 6:1599-1608; Cormack et al. (1997) Microbiology 143:303-311), Drosophila (e.g., see Wang et al. (1994) Nature 369:400-403; Plautz (1996) Gene 173:83-87), plants (Heinlein et al. (1995); Casper et al. (1996) Gene 173:69-73), fish (Amsterdam et al. (1995)), and mammals (Ikawa et al. (1995). Aequorea GFP vectors and isolated Aequorea GFP proteins have been used as markers for measuring gene expression, cell migration and localization, microtubule formation and assembly of functional ion channels (e.g., see Terry et al. (1995) Biochem. Biophys. Res. Commun. 217:21-27; Kain et al. (1995) Biotechniques 19:650-655).The A. victoria GFP, however, is not ideal for use in analytical and diagnostic processes. Consequently GFP mutants have been selected with the hope of identifying mutants that have single excitation spectral peaks shifted to the red.

In fact a stated purpose in constructing such mutants has been to attempt to make the A. victoria GFP more like the GFP from Renilla, which has thus far not been cloned, but which has properties that make it far more ideal for use as an analytical tool. For many practical applications, the spectrum of Renilla GFP would be preferable to that of the Aequorea GFP, because wavelength discrimination between different fluorophores and detection of resonance energy transfer are easier if the component spectra are tall and narrow rather than low and broad [see, U.S. Pat. No. 5,625,048]. Furthermore, the longer wavelength excitation peak (475 nm) of Renilla GFP is almost ideal for fluorescein filter sets and is resistant to photobleaching, but has lower amplitude than the shorter wavelength peak at 395 nm, which is more susceptible to photobleaching [Chalfie et al. (1994) Science 263:802-805].

There exists a phylogenetically diverse and largely unexplored repertoire of bioluminescent proteins that are a reservoir for future development. Many of these, such as nucleic acid encoding Renilla GFPs have not, despite concentrated efforts to do so.

For these reasons, it would be desirable to have a variety of new luciferases and fluorescent proteins, particularly, Renilla GFP available rather than use muteins of A. victoria GFP. It has, not, however, been possible to clone the gene encoding any Renilla GFPs. It would also be desirable to have a variety of GFPs and luciferases available in order to optimize systems for particular applications and to improve upon existing methods. Therefore, it is an object herein to provide isolated nucleic acids encoding heretofore unavailable luciferases and the protein encoded thereby. It is also an object herein to provide isolated nucleic acids encoding Renilla GFPs, GFPs from other species, and luciferases from a variety of species, and the proteins encoded thereby. It is also an object herein to provide bioluminescence generating systems that

include the luciferases, luciferins, and also include GFPs.

SUMMARY OF THE INVENTION

Isolated nucleic acids that encode fluorescent proteins and nucleic acids that encode luciferases are provided. Nucleic acid molecules encoding GFPs from Renilla and from Ptilosarcus are provided. Nucleic acid molecules that encode the Renilla mulleri luciferase, a Gaussia species luciferase and a Pleuromamma species luciferase are provided. Nucleic acid probes derived therefrom are also provided. Functionally equivalent nucleic acids, such as those that hybridize under conditions of high stringency to the disclosed molecules, are also contemplated.

Host cells, including bacterial, yeast and mammalian host cells, and plasmids for expression of the nucleic acids encoding each luciferase and GFP and combinations of luciferases and GFPs are also provided in these hosts are also provided. The genes can be modified by substitution of codons optimized for expression in selected host cells or hosts, such as humans and other mammals, or can be mutagenized to alter the emission properties.

Luciferases

Recombinant host cells, including bacterial, yeast and mammalian cells, containing heterologous nucleic acid encoding a Renilla mulleri luciferase and the nucleic acid are provided. In preferred embodiments, the heterologous nucleic acid encodes the sequence of amino acids set forth in SEQ ID No. 18. In more preferred embodiments, the heterologous nucleic acid encodes the sequence of nucleotides set forth in SEQ ID No. 17. Also provided are functionally equivalent nucleic acids, such as nucleic acid molecules that hybridize under moderate or high stringency to the sequence of nucleotides set forth in SEQ ID No. 17, particularly when using the probes provided herein.

Isolated nucleic acids that encode luciferases from Gaussia are provided herein. In particular, nucleic acid fragments that encode Gaussia princeps luciferase, and nucleic acid probes derived therefrom are provided. In a particular embodiment, the luciferase is encoded by the sequence of nucleotides set forth in SEQ ID No. 19. Also provided are nucleic acid molecules that hybridize under moderate or high stringency to the sequence of nucleotides set forth in SEQ ID No. 19, particularly when using probes provided herein. Probes derived from this nucleic acid that can be used in methods provided herein to isolate luciferases from any Gaussia species are provided. In an exemplary embodiment, nucleic acid encoding Gaussia princeps luciferase is provided. This nucleic acid encodes the sequence of amino acids set forth in SEQ ID No. 20.

Nucleic acids that encode Pleuromamma luciferase are provided. In particular, a nucleic acid molecule that encodes a Pleuromamma luciferase and the encoded luciferase are set forth in SEQ ID Nos. 28 and 29, respectively. Nucleic acid encoding a Pleuromamma luciferase has also been isolated.

Expression vectors that contain DNA encoding a Renilla mulleri, Gaussia or Pleuromamma luciferase linked in operational association with a promoter element that allows for the constitutive or inducible expression of the luciferase are provided. In preferred embodiments, the vectors are capable of expressing the Renilla mulleri luciferase in a wide variety of host cells. Vectors for producing chimeric Renilla mulleri luciferase fusion proteins, preferably chimeric antibody-luciferase or acetylcholine esterase fusion proteins, containing a promoter element and a multiple cloning site located upstream or downstream of DNA encoding Renilla mulleri luciferase are also provided.

Recombinant cells containing heterologous nucleic acid encoding a Gaussia luciferase are also provided. Purified Gaussia luciferases and compositions containing a Gaussia luciferase alone or in combination with at other components of a bioluminescence-generating system, such as a Renilla green fluorescent protein, are provided. The Gaussia luciferase can be used, for example, to provide fluorescent illumination of novelty items or used in methods of detecting and visualizing neoplastic tissue and other tissues, detecting infectious agents using immunoassays, such homogenous immunoassays and in vitro fluorescent-based screening assays using multiwell assay devices, or provided in kits for carrying out any of the above-described methods. In particular, the Gaussia luciferase may be used in conjunction with suitable fluorescent proteins in assays provided herein.

Methods using the probes for the isolation and cloning of luciferase-encoding DNA in Gaussia, Pleuromamma and other species are also provided. In preferred embodiments, the nucleic acid probes are degenerate probes of at least 14 nucleotides, preferably 16 to 30 nucleotides, that are based on amino acids set forth in SEQ ID No. 19 and or the sequence of nucleotides set forth in SEQ ID No. 29.

Vectors containing DNA encoding a Gaussia luciferase or Pleuromamma luciferase are provided. In particular, expression vectors that contain DNA encoding the luciferase linked in operational association with a promoter element that allows for the constitutive or inducible expression of luciferase are provided. In preferred embodiments, the vectors are capable of expressing the luciferase in a wide variety of host cells. Vectors for producing chimeric luciferase fusion proteins (see, e.g., U.S. Pat. No. 5,464,745, which describes the use of protein binding domains; see SEQ ID Nos. 21 and 22, which set forth the sequences of a cellulose binding domainluciferase fusion protein; and which are depicted in FIGS. 1 and 2) containing a promoter element and a multiple cloning site located upstream or downstream from DNA encoding Gaussia or Pleuromamma luciferase are also provided. In a particular embodiment, DNA encoding the luciferase is linked to DNA encoding the N-terminal portion of the cellulose binding domain (CBD.sub.clos; see, SEQ ID Nos. 21 and 22) in a PET vector (Novagen; see, U.S. Pat. Nos. 5,719,044 and 5,738,984, 5,670,623 and 5,496,934 and the Novagen catalog; complete sequences of each PET vector are provided with purchase of the vector).

Fusions of the nucleic acid, particularly DNA, encoding a Gaussia or Pleuromamma luciferase with DNA encoding a GFP or phycobiliprotein are also provided herein. Also provided are fusions of Renilla luciferase and a Renilla GFP. In these fusions the luciferase and GFP encoding DNA can be contiguous or separated by a spacer peptide. The fusions are used to produce fusion proteins, which by virtue of the interaction between the luciferase and GFP pair have a variety of unique analytical applications. The interaction is assessed by the emission spectrum of the luciferase-GFP protein pair in the presence of a luciferin and appropriate binding factors.

Recombinant host cells containing heterologous nucleic acid encoding a Gaussia or Pleuromamma luciferase are provided. In certain embodiments, the recombinant cells that contain the heterologous DNA encoding the luciferase are produced by transfection with DNA encoding a luciferase or by introduction of RNA transcripts of DNA encoding the protein. The DNA may be introduced as a linear DNA fragment or may be included in an expression vector for stable or transient expression of the encoding DNA.

The cells that express functional luciferase may be used alone or in conjunction with a bioluminescence-generating system, in cell-based assays and screening methods, such as those described herein. Presently preferred host cells for expressing the luciferase are bacteria, yeasts, fungi, plant cells, insect cells and animal cells.

Purified Gaussia, Pleuromamma and Renilla mulleri luciferases are provided. These luciferases are preferably obtained by expression of the nucleic acid provided herein in prokaryotic or eukaryotic cells that contain the nucleic acid that encodes the luciferase protein; and isolation of the expressed protein.

Compositions containing the luciferases are provided. The compositions can take any of a number of forms, depending on the intended method of use therefor. In certain embodiments, for example, the compositions contain a Gaussia luciferase, Gaussia luciferase peptide or Gaussia luciferase fusion protein, formulated for use in luminescent novelty items, immunoassays, donors in FET [fluorescent energy transfer] assays, FRET [fluorescent resonance energy transfer]

express a luciferase; plant food containing a luciferin or luciferase, preferably a luciferin for use with transgenic plants that express luciferase; and beverages, such as beer, wine, champagne, soft drinks, and ice cubes and ice in other configurations; fountains, including liquid "fireworks" and other such jets or sprays or aerosols of compositions that are solutions, mixtures, suspensions, powders, pastes, particles or other suitable form.

soaps, body paints, and bubble bath; items such as inks, paper; foods, such as gelatins, icings and

frostings; fish food containing luciferins and transgenic fish, particularly transgenic fish that

Any article of manufacture that can be combined with a bioluminescence-generating system as provided herein and thereby provide entertainment, recreation and/or amusement, including use of the items for recreation or to attract attention, such as for advertising goods and/or services that are associated with a logo or trademark is contemplated herein. Such uses may be in addition to or in conjunction with or in place of the ordinary or normal use of such items. As a result of the combination, the items glow or produce, such as in the case of squirt guns and fountains, a glowing fluid or spray of liquid or particles. The novelty in the novelty item derives from its bioluminescence.

GFPS

Isolated nucleic acids that encode GFPs from Renilla are provided herein. Also provided are isolated and purified nucleic acids that encode a component of the bioluminescence generating

assays, HTRF [homogeneous time-resolved fluorescence] assays or used in conjunction with multi-well assay devices containing integrated photodetectors, such as those described herein.

In more preferred embodiments, the bioluminescence-generating system includes, in addition to the luciferase a Renilla mulleri or Ptilosarcus GFP. These compositions can be used in a variety of methods and systems, such as included in conjunction with diagnostic systems for the in vivo detection of neoplastic tissues and other tissues, such as those methods described herein.

Combinations containing a first composition containing a luciferase and a second composition containing one or more additional components of a bioluminescence-generating system for use with articles of manufacture to produce novelty items are provided. These novelty items are

designed for entertainment, recreation and amusement, and include, but are not limited to: toys, particularly squirt guns, toy cigarettes, toy "Halloween" eggs, footbags and board/card games; finger paints and other paints, slimy play material; textiles, particularly clothing, such as shirts, hats and sports gear suits, threads and yarns; bubbles in bubble making toys and other toys that produce bubbles; balloons; figurines; personal items, such as cosmetics, bath powders, body lotions, gels, powders and creams, nail polishes, make-up, toothpastes and other dentifrices,

system and a green fluorescent protein (GFP) of a member of the genus Renilla, and the proteins encoded thereby are provided. In particular, nucleic acid fragments that encode Renilla green fluorescent protein (GFPs) and the Renilla mulleri luciferase, and nucleic acid probes derived therefrom are provided.

Nucleic acid molecules encoding Renilla GFP are provided. In particular, nucleic acid molecules encoding a Renilla GFP that includes the coding portion of the sequence of nucleotides set forth in SEQ ID No. 15 or that hybridizes under moderate or high stringency to the sequence of nucleotides set forth in SEQ ID No. 15, particularly when using probes provided herein, are provided. Probes derived from this nucleic acid that can be used in methods provided herein to isolated GFPs from any Renilla species. In an exemplary embodiment, nucleic acid encoding Renilla mulleri GFP is provided. This nucleic acid encodes the sequence of amino acids set forth in SEQ ID No. 16.

Nucleic acid probes can be labeled, which if needed, for detection, containing at least about 14, preferably at least about 16, or, if desired, 20 or 30 or more, contiguous nucleotides of sequence of nucleotides encoding a Renilla GFP, particularly Renilla mulleri. In preferred embodiments, the nucleic acid probes for the Renilla GFP are selected from the sequence of nucleotides set forth in SEQ ID No. 15.

Methods using the probes for the isolation and cloning of GFP-encoding DNA in Renilla and other species are also provided. In preferred embodiments, the nucleic acid probes are degenerate probes based upon the conserved regions between the Renilla species of GFP as set forth in FIG. 3. Such degenerate probes contain at least 14 nucleotides, preferably 16 to 30 nucleotides, that are based on amino acids 51 to 68, 82 to 98 and 198 to 208 set forth in SEQ ID No. 16, amino acid sequence set forth in SEQ ID No. 24, amino acids 9-20 set forth in SEQ ID No. 25 and amino acids 39-53 set forth in SEQ ID No. 27. In other preferred embodiments, the nucleic acid probes encoding the above-described preferred amino acid regions are selected among the sequence of nucleotides encoding these regions as set forth in SEQ ID NO. 15 . Alternatively, nucleic acids, particularly those set forth in SEQ ID No. 15 that encode the noted regions may be used as primers for PCR amplification of libraries of a selected Renilla species, whereby DNA comprising that encodes a Renilla GFP is isolated.

Nucleic acids that encode a Ptilosarcus GFP are set forth in SEQ ID Nos. 30 and 31; the encoded GFP is set forth in SEQ ID No. 32. Also provided are nucleic acid molecules that hybridize under moderate or high stringency to the sequence of nucleotides set forth in SEQ ID Nos. 28, 30 and 31.

Vectors containing DNA encoding a Renilla or Ptilosarcus GFP are provided. In particular, expression vectors that contain DNA encoding a Renilla or Ptilosarcus GFP linked in operational association with a promoter element that allows for the constitutive or inducible expression of Renilla or Ptilosarcus GFP are provided. Native Renilla GFP has been expressed.

The vectors are capable of expressing the Renilla GFP in a wide variety of host cells. Vectors for producing chimeric Renilla GFP fusion proteins containing a promoter element and a multiple cloning site located upstream or downstream of DNA encoding Renilla GFP are also provided.

Recombinant cells containing heterologous nucleic acid encoding a Ptilosarcus GFP, Renilla GFP, Renilla mulleri luciferase, Gaussia luciferase, and Pleuromamma luciferase are also provided. Purified Renilla mulleri GFP, Renilla reniformis GFP peptides and compositions containing a Renilla GFPs and GFP peptides alone or in combination with at least one component of a bioluminescence-generating system, such as a Renilla mulleri luciferase, are provided. The Renilla GFP and GFP peptide compositions can be used, for example, to provide fluorescent illumination of novelty items or used in methods of detecting and visualizing neoplastic tissue and other tissues, detecting infectious agents using immunoassays, such homogenous immunoassays and In vitro fluorescent-based screening assays using multi-well assay devices, or provided in kits for carrying out any of the above-described methods. In particular, these proteins may be used in FP [fluorescence polarization] assays, FET [fluorescent energy transfer] assays, FRET [fluorescent resonance energy transfer] assays and HTRF [homogeneous time-resolved fluorescence] assays and also in the BRET assays and sensors provided herein.

Non-radioactive energy transfer reactions, such as FET or FRET, FP and HTRF assays, are homogeneous luminescence assays based on energy transfer are carried out between a donor luminescent label and an acceptor label [see, e.g., Cardullo et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85:8790-8794; Peerce et al. (1986) Proc. Natl. Acad. Sci. U.S.A. 83:8092-8096; U.S. Pat. No. 4,777,128; U.S. Pat. No. 5,162,508; U.S. Pat. No. 4,927,923; U.S. Pat. No. 5,279,943; and International PCT Application No. WO 92/01225]. Non-radioactive energy transfer reactions using GFPs have been developed [see, International PCT application Nos. WO 98/02571 and WO 97/28261]. Non-radioactive energy transfer reactions using GFPs and luciferases, such as a luciferase and its cognate GFP (or multimers thereof), such as in a fusion protein, are contemplated herein.

Nucleic acids that exhibit substantial sequence identity with the nucleic acids provided herein are also contemplated. These are nucleic acids that can be produced by substituting codons that encode conservative amino acids and also nucleic acids that exhibit at least about 80%,

preferably 90 or 95% sequence identity. Sequence identity refers to identity as determined using standard programs with default gap penalties and other defaults as provided by the manufacturer thereof.

The nucleic acids provide an opportunity to produce luciferases and GFPs, which have advantageous application in all areas in which luciferase/luciferins and GFPs have application. The nucleic acids can be used to obtain and produce GFPs and GFPs from other, particularly Renilla species using the probes described herein that correspond to conserved regions (see, e.g., FIG. 3). These GFPs have advantageous application in all areas in which GFPs and/or luciferase/luciferins have application. For example, The GFP's provide a means to amplify the output signal of bioluminescence generating systems. Renilla GFP has a single excitation absorbance peak in blue light (and around 498 nm) and a predominantly single emission peak around 510 nm (with a small shoulder near 540). This spectra provides a means for it to absorb blue light and efficiently convert it to green light. This results in an amplification of the output. When used in conjunction with a bioluminescence generating system that yields blue light, such as Aequorea or Renilla or Vargula (Cypridina), the output signal for any application, including diagnostic applications, is amplified. In addition, this green light can serve as an energy donor in fluorescence-based assays, such as fluorescence polarization assays, FET [fluorescent energy transfer] assays, FRET [fluorescent resonance energy transfer] assays and HTRF [homogeneous time-resolved fluorescence] assays. Particular assays, herein referred to as BRET [bioluminescence resonance energy transfer assays in which energy is transferred from a bioluminescence reaction of a luciferase to a fluorescent protein], are provided.

Non-radioactive energy transfer reactions, such as FET or FRET, FP and HTRF assays, are homogeneous luminescence assays based on energy transfer that are carried out between a donor luminescent label and an acceptor label [see, e.g., Cardullo et a. (1988) Proc. Natl. Acad. Sci. U.S.A. 85:8790-8794; Peerce et al. (1986) Proc. Natl. Acad. Sci. U.S.A. 83:8092-8096; U.S. Pat. Nos. 4,777,128; 5,162,508; 4,927,923; 5,279,943; and International PCT Application No. WO 92/01225]. Non-radioactive energy transfer reactions using GFPs have been developed [see, International PCT application Nos. WO 98/02571 and WO 97/28261].

Mutagenesis of the GFPs is contemplated herein, particularly mutagenesis that results in modified GFPs that have red-shifted excitation and emission spectra. The resulting systems have higher output compared to the unmutagenized forms. These GFPs may be selected by random mutagenesis and selection for GFPs with altered spectra or by selected mutagenesis of the chromophore region of the GFP.

Recombinant host cells containing heterologous nucleic acid encoding a Renilla or Ptilosarcus

GFP are also provided. In certain embodiments, the recombinant cells that contain the heterologous DNA encoding the Renilla or Ptilosarcus GFP are produced by transfection with DNA encoding a Renilla or Ptilosarcus GFP or by introduction of RNA transcripts of DNA encoding a Renilla or Ptilosarcus protein. The DNA may be introduced as a linear DNA fragment or may be included in an expression vector for stable or transient expression of the encoding DNA.

In certain embodiments, the cells contain DNA or RNA encoding a Renilla mulleri GFP or a Ptilosarcus GFP (particularly from a species other than P. gurneyi) also express the recombinant Renilla mulleri GFP or Ptilosarcus polypeptide. It is preferred that the cells are selected to express functional GFPs that retain the ability to fluorescence and that are not toxic to the host cell. In some embodiments, cells may also include heterologous nucleic acid encoding a component of a bioluminescence-generating system, preferably a photoprotein or luciferase. In preferred embodiments, the nucleic acid encoding the bioluminescence-generating system component is isolated from the species Aequorea, Vargula, Pleuromamma, Ptilosarcus or Renilla. In more preferred embodiments, the bioluminescence-generating system component is a Renilla mulleri luciferase including the amino acid sequence set forth in SEQ ID No. 18 or the Pleuromamma luciferase set forth in SEQ ID No. 28, or the Gaussia luciferase set forth in SEQ ID No. 19.

The GFPs provided herein may be used in combination with any suitable bioluminescence generating system, but is preferably used in combination with a Renilla or Aequorea, Pleuromamma or Gaussia luciferase.

Purified Renilla GFPs, particularly Renilla mulleri GFP, and purified Renilla reniformis GFP peptides are provided. Presently preferred Renilla GFP for use in the compositions herein is Renilla mulleri GFP including the sequence of amino acids set forth in SEQ ID No. 16. Presently preferred Renilla reniformis GFP peptides are those containing the GFP peptides selected from the amino acid sequences set forth in SEQ ID Nos 19-23.

The Renilla GFP, GFP peptides and luciferase can be isolated from natural sources or isolated from a prokaryotic or eukaryotic cell transfected with nucleic acid that encodes the Renilla GFP and/or luciferase protein.

Fusions of the nucleic acid, particularly DNA, encoding Renilla or Ptilosarcus GFP with DNA encoding a luciferase are also provided herein.

The cells that express functional luciferase and/or GFP, which may be used alone or in

conjunction with a bioluminescence-generating system, in cell-based assays and screening methods, such as those described herein.

Presently preferred host cells for expressing GFP and luciferase are bacteria, yeasts, fungi, plant cells, insect cells and animal cells.

The luciferases and GFPs or cells that express them also may be used in methods of screening for bacterial contamination and methods of screening for metal contaminants. To screen for bacterial contamination, bacterial cells that express the luciferase and/or GFP are put in autoclaves or in other areas in which testing is contemplated. After treatment or use of the area, the area is tested for the presence of glowing bacteria. Presence of such bacteria is indicative of a failure to eradicate other bacteria. Screening for heavy metals and other environmental contaminants can also be performed with cells that contain the nucleic acids provided herein, if expression is linked to a system that is dependent upon the particular heavy metal or contaminant.

The systems and cells provided herein can be used for high throughout screening protocols, intracellular assays, medical diagnostic assays, environmental testing, such as tracing bacteria in water supplies, in conjunction with enzymes for detecting heavy metals, in spores for testing autoclaves in hospital, foods and industrial autoclaves. Non-pathogenic bacteria containing the systems can be included in feed to animals to detect bacterial contamination in animal products and in meats.

Compositions containing a Renilla or Ptilosarcus GFP are provided. The compositions can take any of a number of forms, depending on the intended method of use therefor. In certain embodiments, for example, the compositions contain a Renilla GFP or GFP peptide, preferably Renilla mulleri GFP or Renilla reniformis GFP peptide, formulated for use in luminescent novelty items, immunoassays, FET [fluorescent energy transfer] assays, FRET [fluorescent resonance energy transfer] assays, HTRF [homogeneous time-resolved fluorescence] assays or used in conjunction with multi-well assay devices containing integrated photodetectors, such as those described herein. In other instances, the GFPs are used in beverages, foods or cosmetics.

Compositions that contain a Renilla mulleri GFP or GFP peptide and at least one component of a bioluminescence-generating system, preferably a luciferase, luciferin or a luciferase and a luciferin, are provided. In preferred embodiments, the luciferase/luciferin bioluminescence-generating system is selected from those isolated from: an insect system, a coelenterate system, a ctenophore system, a bacterial system, a mollusk system, a crustacea system, a fish system, an annelid system, and an earthworm system. Bioluminescence-generating systems include those isolated from Renilla, Aequorea, and Vargula, Gaussia and Pleuromamma.

Combinations containing a first composition containing a Renilla mulleri GFP or Ptilosarcus GFP or mixtures thereof and a second composition containing a bioluminescence- generating system for use with inanimate articles of manufacture to produce novelty items are provided. These novelty items, which are articles of manufacture, are designed for entertainment, recreation and amusement, and include, but are not limited to: toys, particularly squirt guns, toy cigarettes, toy "Halloween" eggs, footbags and board/card games; finger paints and other paints, slimy play material; textiles, particularly clothing, such as shirts, hats and sports gear suits, threads and yarns; bubbles in bubble making toys and other toys that produce bubbles; balloons; figurines; personal items, such as bath powders, body lotions, gels, powders and creams, nail polishes, cosmetics including make-up, toothpastes and other dentifrices, soaps, cosmetics, body paints, and bubble bath, bubbles made from non-detergent sources, particularly proteins such as albumin and other non-toxic proteins; in fishing lures, particularly crosslinked polyacrylamide containing a fluorescent protein and/or components of a bioluminescence generating system, which glow upon contact with water; items such as inks, paper; foods, such as gelatins, icings and frostings; fish food containing luciferins and transgenic fish, particularly transgenic fish that express a luciferase; plant food containing a luciferin or luciferase, preferably a luciferin for use with transgenic plants that express luciferase; and beverages, such as beer, wine, champagne, soft drinks, and ice cubes and ice in other configurations; fountains, including liquid "fireworks" and other such jets or sprays or aerosols of compositions that are solutions, mixtures, suspensions, powders, pastes, particles or other suitable form.

Any article of manufacture that can be combined with a bioluminescence-generating system as provided herein and thereby provide entertainment, recreation and/or amusement, including use of the items for recreation or to attract attention, such as for advertising goods and/or services that are associated with a logo or trademark is contemplated herein. Such uses may be in addition to or in conjunction with or in place of the ordinary or normal use of such items. As a result of the combination, the items glow or produce, such as in the case of squirt guns and fountains, a glowing fluid or spray of liquid or particles.

Methods for diagnosis and visualization of tissues in vivo or in situ using compositions containing a Renilla mulleri GFP and/or a Renilla mulleri luciferase or others of the luciferases and/or GFPs provided herein are provided. For example, the Renilla mulleri GFP protein can be used in conjunction with diagnostic systems that rely on bioluminescence for visualizing tissues in situ. The systems are particularly useful for visualizing and detecting neoplastic tissue and specialty tissue, such as during non-invasive and invasive procedures. The systems include compositions containing conjugates that include a tissue specific, particularly a tumor-specific, targeting agent linked to a targeted agent, a Renilla mulleri GFP, a luciferase or luciferin. The

systems also include a second composition that contains the remaining components of a bioluminescence generating reaction and/or the Renilla mulleri GFP. In some embodiments, all components, except for activators, which are provided in situ or are present in the body or tissue, are included in a single composition.

Methods for diagnosis and visualization of tissues in vivo or in situ using compositions containing a Gaussia luciferase are provided. For example, the Gaussia luciferase or Gaussia luciferase peptide can be used in conjunction with diagnostic systems that rely on bioluminescence for visualizing tissues in situ. The systems are particularly useful for visualizing and detecting neoplastic tissue and specialty tissue, such as during non-invasive and invasive procedures. The systems include compositions containing conjugates that include a tissue specific, particularly a tumor-specific, targeting agent linked to a targeted agent, a Gaussia luciferase, a GFP or luciferin. The systems also include a second composition that contains the remaining components of a bioluminescence generating reaction and/or the Gaussia luciferase. In some embodiments, all components, except for activators, which are provided in situ or are present in the body or tissue, are included in a single composition.

In particular, the diagnostic systems include two compositions. A first composition that contains conjugates that, in preferred embodiments, include antibodies directed against tumor antigens conjugated to a component of the bioluminescence generating reaction, a luciferase or luciferin, preferably a luciferase are provided. In certain embodiments, conjugates containing tumor-specific targeting agents are linked to luciferases or luciferins. In other embodiments, tumor-specific targeting agents are linked to microcarriers that are coupled with, preferably more than one of the bioluminescence generating components, preferably more than one luciferase molecule.

The second composition contains the remaining components of a bioluminescence generating system, typically the luciferin or luciferase substrate. In some embodiments, these components, particularly the luciferin are linked to a protein, such as a serum albumin, or other protein carrier. The carrier and time release formulations, permit systemically administered components to travel to the targeted tissue without interaction with blood cell components, such as hemoglobin that deactivates the luciferin or luciferase.

Methods for diagnosing diseases, particularly infectious diseases, using chip methodology (see, e.g., copending U.S. application Ser. No. 08/990,103) a luciferase/luciferin bioluminescencegenerating system and a Renilla mulleri or Ptilosarcus GFP are provided. In particular, the chip includes an integrated photodetector that detects the photons emitted by the bioluminescencegenerating system, particularly using luciferase encoded by the nucleic acids provided herein and/or Renilla mulleri or Ptilosarcus GFP.

In one embodiment, the chip is made using an integrated circuit with an array, such as an X-Y array, of photodetectors. The surface of circuit is treated to render it inert to conditions of the diagnostic assays for which the chip is intended, and is adapted, such as by derivatization for linking molecules, such as antibodies. A selected antibody or panel of antibodies, such as an antibody specific for a bacterial antigen, is affixed to the surface of the chip above each photodetector. After contacting the chip with a test sample, the chip is contacted with a second antibody linked to a Renilla or Pleuromamm GFP, a chimeric antibody-Renilla GFP fusion protein or an antibody linked to a component of a bioluminescence generating system, such as a luciferase or luciferin, that are specific for the antigen. The remaining components of the bioluminescence generating reaction are added, and, if any of the antibodies linked to a component of a bioluminescence is operatively linked to a component of a bioluminescence generatively linked to a component of a bioluminescence generatively linked to a component of a bioluminescence generatively linked to a component of a bioluminescence generating reaction are added, and, if any of the antibodies linked to a component of a bioluminescence generatively linked to a computer, which is programmed with information identifying the linked antibodies, records the event, and thereby identifies antigens present in the test sample.

Methods for generating chimeric GFP fusion proteins are provided. The methods include linking DNA encoding a gene of interest, or portion thereof, to DNA encoding a GFP coding region in the same translational reading frame. The encoded-protein of interest may be linked in-frame to the amino- or carboxyl-terminus of the GFP. The DNA encoding the chimeric protein is then linked in operable association with a promoter element of a suitable expression vector. Alternatively, the promoter element can be obtained directly from the targeted gene of interest and the promoter-containing fragment linked upstream of the GFP coding sequence to produce chimeric GFP proteins.

Methods for identifying compounds using recombinant cells that express heterologous DNA encoding a GFP under the control of a promoter element of a gene of interest are provided. The recombinant cells can be used to identify novel compounds or ligands that modulate the level of transcription from the promoter of interest by measuring GFP-mediated fluorescence. Recombinant cells expressing the chimeric Renilla or Ptilosarcus GFPs may also be used for monitoring gene expression or protein trafficking, or determining the cellular localization of the target protein by identifying localized regions of GFP-mediated fluorescence within the recombinant cell.

Other assays using the GFPs and/or luciferases are contemplated herein. Any assay or diagnostic method known used by those of skill in the art that employ Aequora GFPs and/or other luciferases are contemplated herein.

Kits containing the GFPs for use in the methods, including those described herein, are provided. In one embodiment, the kits containing an article of manufacture and appropriate reagents for generating bioluminescence are provided. The kits containing such soap compositions, with preferably a moderate Ph [between 5 and 8] and bioluminescence generating reagents, including luciferase and luciferin and the GFP are provided herein. These kits, for example, can be used with a bubble-blowing or producing toy. These kits can also include a reloading or charging cartridge or can be used in connection with a food.

In another embodiment, the kits are used for detecting and visualizing neoplastic tissue and other tissues and include a first composition that contains the GFP and at least one component of a bioluminescence generating system, and a second that contains the activating composition, which contains the remaining components of the bioluminescence generating system and any necessary activating agents.

Thus, these kits will typically include two compositions, a first composition containing the GFP formulated for systemic administration (or in some embodiments local or topical application), and a second composition containing the components or remaining components of a bioluminescence generating system, formulated for systemic, topical or local administration depending upon the application. Instructions for administration will be included.

In other embodiments, the kits are used for detecting and identifying diseases, particularly infectious diseases, using multi-well assay devices and include a multi-well assay device containing a plurality of wells, each having an integrated photodetector, to which an antibody or panel of antibodies specific for one or more infectious agents are attached, and composition containing a secondary antibody, such as an antibody specific for the infectious agent that is linked to a Renilla mulleri or Ptilosarcus GFP protein, a chimeric antibody-Renilla mulleri (or Ptilosarcus) GFP fusion protein or F(Ab).sub.2 antibody fragment-Renilla mulleri GFP fusion protein. A second composition containing a bioluminescence generating system that emits a wavelength of light within the excitation range of the Renilla mulleri GFP, such as species of Renilla or Aequorea, for exciting the Renilla mulleri, which produces green light that is detected by the photodetector of the device to indicate the presence of the agent.

As noted above, fusions of nucleic acid encoding the luciferases and or GFPs provided herein with other luciferases and GFPs are provided. Of particular interest are fusions that encode pairs of luciferases and GFPs, such as a Renilla luciferase and a Renilla GFP (or a homodimer or other multiple of a Renilla GFP). The luciferase and GFP bind and in the presence of a luciferin will produced fluroescence that is red shifted compared to the luciferase in the absence of the GFP.

This fusion or fusions in which the GFP and luciferase are linked via a target, such as a peptide, can be used as a tool to assess anything that interacts with the linker.

Muteins of the GFPs and luciferases are provided. Of particular interest are muteins, such as temperature sensivitive muteins, of the GFP and luciferases that alter their interaction, such as mutations in the Renilla luciferase and Renilla GFP that alters their interaction at a critical temperature.

Antibodies, polyclonal and monoclonal antibodies that specifically bind to any of the proteins encoded by the nucleic acids provided herein are also provided. These antibodies, monoclonal or polyclonal, can be prepared employing standard techniques, known to those of skill in the art. In particular, immunoglobulins or antibodies obtained from the serum of an animal immunized with a substantially pure preparation of a luciferase or GFP provided herein or an or epitopecontaining fragment thereof are provided. Monoclonal antibodies are also provided. The immunoglobulins that are produced have, among other properties, the ability to specifically and preferentially bind to and/or cause the immunoprecipitation of a GFP or luciferase, particularly a Renilla or Ptsilocarpus GFP or a Pleuromamma, Gaussia or Renilla mulleri luciferase, that may be present in a biological sample or a solution derived from such a biological sample.

DESCRIPTION OF THE FIGURES

FIG. 1 depicts the components of the commercially available PET-34 vector (EK is enterokinase).

FIG. 2 shows a portion of the vector with the inserted Gaussia-encoding luciferase.


FIG. 3 displays an alignment of the deduced amino acid sequence of Renilla mulleri green fluorescent protein and the amino acid sequence of isolated Renilla reniformis GFP peptides obtained by proteolytic digestion of purified Renilla reniformis GFP. Positions in the amino acid sequence of direct identity are marked by the solid vertical lines (.vertline.) between the two Renilla species.

FIG. 4 shows the fluorescence emission and excitation spectrum for the Renilla mulleri GFP, with a peak emission at 506 nm.

FIG. 5 shows the fluorescence emission and excitation spectrum for the Ptilosarcus GFP, with a peak emission at 508.

EXHIBIT "B"

.



United States Patent	7,109,315
Bryan, et al.	September 19, 2006

Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items

Abstract

Isolated and purified nucleic acids encoding green fluorescent proteins from Renilla reniformis and the green fluorescent protein encoded thereby are also provided. Mutants of the nucleic acid molecules and the modified encoded proteins are also provided. Compositions and combinations comprising the green fluorescent proteins and/or the luciferase are further provided.

Inventors	: Bryan; Bruce (Beverly Hills, CA), Szent-Gyorgyi; Christopher (Pittsburgh, PA),
	Szczepaniak; William (Pittsburgh, PA)
Assignee:	Bryan; Bruce J. (Beverly Hills, CA)
	Prolone, Ltd. (Pinetop, AR)
Appl. No.	: 09/808,898
Filed:	March 15, 2001
, , , , , , , , , , , , , , , , , , , 	

Related U.S. Patent Documents

Application Number	Filing Date	Patent Number	<u>Issue Date</u>
60189691	Mar., 2000		

Current U.S. Class: Current International Class: Field of Search:

536/23.1; 435/252.3; 435/320.1; 435/325; 435/69.1 C07H 21/04 (20060101) 536/23.1 435/69.1,325,252.3,320.1

References Cited [Referenced By]			
U.S. Patent Documents			
<u>2541851</u>	February 1951	Wright	
<u>3384498</u>	May 1968	Ahrabi	
<u>3511612</u>	May 1970	Kennerly et al.	
<u>3565815</u>	February 1971	Christy	
<u>3584211</u>	June 1971	Rauhut	
<u>3634280</u>	January 1972	Dean et al.	
<u>3649029</u>	March 1972	Worrell	
<u>3661790</u>	May 1972	Dean et al.	
<u>3669891</u>	June 1972	Greenwood et al.	
<u>3727236</u>	April 1973	Lloyd et al.	
<u>3873485</u>	March 1975	Fichera	
<u>4021364</u>	May 1977	Speiser	
<u>4044126</u>	August 1977	Cook et al.	
<u>4175183</u>	November 1979	Ayers	
<u>4177038</u>	December 1979	Biebricher et al.	
<u>4225581</u>	September 1980	Kreuter et al.	
<u>4229790</u>	October 1980	Gilliland et al.	
<u>4269821</u>	May 1981	Kreuter	
<u>4281645</u>	August 1981	Jobsis	
<u>4282287</u>	August 1981	Giese	
<u>4313843</u>	February 1982	Bollyky et al.	
<u>4324683</u>	April 1982	Lim et al.	
<u>4364923</u>	December 1982	Cook et al.	
<u>4414209</u>	November 1983	Cook et al.	
<u>4478817</u>	October 1984	Campbell et al.	
<u>4528180</u>	July 1985	Schaeffer	

<u>4534317</u>	August 1985	Walsh
<u>4542102</u>	September 1985	Dattagupta et al.
<u>4562157</u>	December 1985	Lowe et al.
<u>4563726</u>	January 1986	Newcomb et al.
<u>4581335</u>	April 1986	Baldwin
<u>4676406</u>	June 1987	Frischmann et al.
<u>4681870</u>	July 1987	Balint et al.
<u>4714682</u>	December 1987	Schwartz
<u>4717158</u>	January 1988	Pennisi
<u>4735660</u>	April 1988	Cane
<u>4745051</u>	May 1988	Smith et al.
<u>4762881</u>	August 1988	Kauer
<u>4765510</u>	August 1988	Rende
<u>4767206</u>	August 1988	Schwartz
<u>4774189</u>	September 1988	Schwartz
<u>4777128</u>	October 1988	Lippa
<u>4781647</u>	November 1988	Doane, Jr.
<u>4789633</u>	December 1988	Huang
<u>4853327</u>	August 1989	Dattagupta
<u>4861709</u>	August 1989	Ulitzur et al.
4867908	September 1989	Recktenwald et al.
<u>4870009</u>	September 1989	Evans et al.
<u>4882165</u>	November 1989	Hunt et al.
<u>4891043</u>	January 1990	Zeimer et al.
<u>4908405</u>	March 1990	Bayer et al.
<u>4921757</u>	May 1990	Wheatley et al.
<u>4924358</u>	May 1990	Von Heck
<u>4927923</u>	May 1990	Mathis et al.
<u>4950588</u>	August 1990	Dattagupta
<u>4952496</u>	August 1990	Studier et al.
<u>4963117</u>	October 1990	Gualdoni
<u>4968613</u>	November 1990	Masuda et al.
<u>5004565</u>	April 1991	Schaap

<u>5023181</u>	June 1991	Inouye
<u>5093240</u>	March 1992	Inouye et al.
<u>5096807</u>	March 1992	Leaback
<u>5098828</u>	March 1992	Geiger et al.
<u>5128256</u>	July 1992	Huse et al.
<u>5139937</u>	August 1992	Inouye et al.
<u>5158349</u>	October 1992	Holland et al.
<u>5162227</u>	November 1992	Cormier
<u>5162508</u>	November 1992	Lehn et al.
<u>5169784</u>	December 1992	Summers et al.
<u>5171081</u>	December 1992	Pita et al.
<u>5182202</u>	January 1993	Kajiyama et al.
<u>5189029</u>	February 1993	Boyer et al.
<u>5196318</u>	March 1993	Baldwin et al.
<u>5196524</u>	March 1993	Gustafson et al.
<u>5215899</u>	June 1993	Dattagupta
<u>5219737</u>	June 1993	Kajiyama et al.
<u>5221623</u>	June 1993	Legocki et al.
<u>5222797</u>	June 1993	Holland
<u>5229285</u>	July 1993	Kajiyama et al.
<u>5243041</u>	September 1993	Fernandez-Pol
<u>5246834</u>	September 1993	Tsuji et al.
<u>5266317</u>	November 1993	Tomalski et al.
<u>5268463</u>	December 1993	Jefferson
<u>5277913</u>	January 1994	Thompson et al.
<u>5279943</u>	January 1994	Mathis et al.
<u>5288623</u>	February 1994	Zenno et al.
<u>5292658</u>	March 1994	Cormier et al.
<u>5310421</u>	May 1994	Shapero et al.
<u>5323492</u>	June 1994	DeMars
<u>5330906</u>	July 1994	Kajiyama et al.
<u>5337745</u>	August 1994	Benaron
<u>5352598</u>	October 1994	Kajiyama et al.

TO CORO (
<u>5360726</u>	November 1994	Raikhel
<u>5360728</u>	November 1994	Prasher
<u>5362865</u>	November 1994	Austin
<u>5364797</u>	November 1994	Olson et al.
<u>5366881</u>	November 1994	Singh et al.
<u>5374534</u>	December 1994	Zomer et al.
<u>5383100</u>	January 1995	Kikos
<u>5387526</u>	February 1995	Garner et al.
<u>5405905</u>	April 1995	Darr
<u>5405958</u>	April 1995	VanGemert
<u>5412085</u>	May 1995	Allen et al.
<u>5413098</u>	May 1995	Benaron
<u>5413332</u>	May 1995	Montgomery
<u>5415151</u>	May 1995	Fusi et al.
<u>5418155</u>	May 1995	Cormier et al.
<u>5422075</u>	June 1995	Saito et al.
<u>5422266</u>	June 1995	Cormier et al.
<u>5424216</u>	June 1995	Nagano et al.
<u>5432081</u>	July 1995	Jefferson
<u>5433896</u>	July 1995	Kang et al.
<u>5435937</u>	July 1995	Bell et al.
<u>5439797</u>	August 1995	Tsien et al.
<u>5451347</u>	September 1995	Akhavan-Tafti et al.
<u>5455357</u>	October 1995	Herrmann et al.
<u>5464758</u>	November 1995	Gossen et al.
<u>5484723</u>	January 1996	Zenno et al.
<u>5486455</u>	January 1996	Stults
<u>5491084</u>	February 1996	Chalfie et al.
<u>5496934</u>	March 1996	Shoseyov et al.
<u>5604123</u>	February 1997	Kazami et al.
<u>5605662</u>	February 1997	Heller et al.
<u>5624711</u>	April 1997	Sundberg et al.
<u>5625048</u>	April 1997	Tsien et al.

<u>5632957</u>	May 1997	Heller et al.	
<u>5670623</u>	September 1997	Shoseyov et al.	
<u>5671998</u>	September 1997	Collet	
<u>5719044</u>	February 1998	Shoseyov et al.	
<u>5730321</u>	March 1998	McAllister et al.	
<u>5738984</u>	April 1998	Shoseyov	
<u>5741668</u>	April 1998	Ward et al.	
<u>5776681</u>	July 1998	Virta et al.	
<u>5777079</u>	July 1998	Tsien et al.	
<u>5804387</u>	September 1998	Cormack et al.	
<u>5874304</u>	February 1999	Zolotukhin et al.	
<u>5876995</u>	March 1999	Bryan	
<u>5891646</u>	April 1999	Barak et al.	
<u>5912137</u>	June 1999	Tsien et al.	
<u>6020538</u>	February 2000	Han et al.	
<u>6113886</u>	September 2000	Bryan	
<u>6152358</u>	November 2000	Bryan	
<u>6232107</u>	May 2001	Bryan et al.	
	Foreign Patent Documents		
3935974	May., 1991		DE
0025350	Sep., 1980		EP
0226979	Jul., 1987		EP
0245093	Nov., 1987		EP
0245093	Nov., 1987		EP
0246174	Nov., 1987		EP
0386691	Sep., 1990		EP
0387355	Sep., 1990		EP
0194102	Oct., 1991		EP
0540064	May., 1993		EP
0713089	May., 1996		EP
2292595	Jun., 1976		FR
2288232	Oct., 1995		GB

633177079	Dec., 1988	JP
3030678	Feb., 1991	JP
4258288	Sep., 1992	JP
5064583	Mar., 1993	JP
7222590	Aug., 1995	JP
7241192	Sep., 1995	JP
8603840	Jul., 1986	WO
8703304	Jun., 1987	WO
9001542	Feb., 1990	WO
9201225	Jan., 1992	WO
9204577	Mar., 1992	WO
9215673	Sep., 1992	WO
9313395	Jul., 1993	WO
9418342	Aug., 1994	WO
9425855	Nov., 1994	WO
9507463	Mar., 1995	WO
9518853	Jul., 1995	WO
9521191	Aug., 1995	WO
9525798	Sep., 1995	WO
9607100	Mar., 1996	WO
9607917	Mar., 1996	WO
9623810	Aug., 1996	WO
9627675	Sep., 1996	WO
9711094	Mar., 1997	WO
9726333	Jul., 1997	WO
9728261	Aug., 1997	WO
9729319	Aug., 1997	WO
9741228	Nov., 1997	WO
9802571	Jan., 1998	WO
9814605	Apr., 1998	WO
9826277	Jun., 1998	WO
9949019	Sep., 1999	WO
9966324	Dec., 1999	WO

Other References

Baldwin et al., Active Center Studies on Bacterial Luciferase: Modification of the Enzyme with 2,4-Dinitrofluorobenzene, Biochemistry 20:512-517 (1981). cited by other .

Baldwin et al., Cloning of the luciferase structural genes from Vibro harveyi and expression of bioluminescene in Escherichia coli, Biochemistry 23: 3663-3667 (1984). cited by other .

Belas et al., Bacterial bioluminescene: Isolation and expression of the luciferase genes from Vibrio harveyi, Science 218: 791-793 (1982). cited by other .

Blinks et al., Multiple forms of the calcium-sensitive bioluminescent protein aequorin, Fed. Proc. 1435: 474 (1975). cited by other .

Casper et al. Expression of the green fluorescent protein-encoding gene from a tobacco mosaic virus-based vector Gene 173: 69-73 (1996). cited by other .

Chalfie, Green fluorescent protein, Photochemistry and Photobiology, 62(4):651-656 (1995). cited by other .

Charbonneau et al., "Amino acid sequence of the calcium-dependent photoprotein aequorin," Biochem. 24:6762-6771 (1985). cited by other .

Chemical Abstract #115(5)43510b (citing, Japanese Patent Application No. JP 3-30678 Osaka). cited by other .

Cohn et al., Nucleotide Sequence of the luxA Gene of Vibrio harveyi and the Complete Amino Acid Sequence of the-Subunit of Bacterial Luciferase, J. Biol. Chem., 260(10) : 6139-6146; (1985). cited by other .

Cohn et al. "Cloning of the Vibrio harveyi luciferase genes: use of a synthetic oligonucleotide probe", Proc. Natl. Acad. Sci. U.S.A. 80(1): 102-123 (1983). cited by other .

Database Derwent # 007778737 WPI Acc. No. 89-043849/198906 (citing, Japanese Patent Application No. JP. 63317079, published Dec. 26, 1988). cited by other . Database Derwent #008196500 (citing WO 9001542, Recombinant luciferase, fragments from it, and gene coding for it--the luciferase having increased stability and quantum yield). cited by other .

Database Derwent #010423635 WPI Acc. No. 95-324955/199542 (citing, Japanese Patent Application No. JP 7222590, published Aug. 22, 1995). cited by other .

Database Derwent #008580311 WPI Acc. No. 91-084343/199112 (citing, Japanese Patent Application No. JP 3030678 published Feb. 8, 1991). cited by other .

Database EMBL Nucleotide and Protein Sequences, AC.dbd.AF025844, Co-reporter vector pRL-Null, complete sequence, abstract, (1997). cited by other .

Database Derwent #009227258 WPI Acc. No. 92-354680/199243 (citing, Japanese Patent Application No. JP 4258288, published Sep. 14, 1993). cited by other . de Wet et al., "Cloning and expression of the firefly luciferase gene in mammalian cells," Bioluminescence and Chemlluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds. pp. 368-371, Academic Press (1981). cited by other . de Wet et al., "Cloning firefly luciferase", Meth. Enzymol. 133:3-14 (1986). cited by other .

de Wet et al., "Cloning of firefly luciferase cDNA and the expression of active luciferase in Escherichia coli," Proc. Natl. Acad. Sci. USA 82:7870-7873 (1985). cited by other .

Delagrave et al., Red-shifted excitation mutants of the green fluorescent protein, Bio/Technology 13(2):151-154 (1995). cited by other .

Ehrig et al., Green-fluorescent protein mutants with altered fluorence

excitationspectra, FEBS Letters 367:163-166 (1995). cited by other.

Engebrecht et al., "Techniques for cloning and analyzing bioluminescence genes from marine bacteria," Meth. Enzymol. 133:83-99, 234 (1986). cited by other .

Engebrecht et al., Bacterial bioluminescence: Isolation and genetic analysis of functions from Vibrio fischeri, Cell 32: 773-781 (1983). cited by other .

Engebrecht et al., Identification of genes and gene products necessary for bacterial bioluminescene, Proc. Natl. Acad. Sci. USA 81: 4154-4158 (1984). cited by other .

Gast et al., Separation of a blue fluorescence protein from bacterial luciferase.

Biochem. Biophys. Res. Commun. 80(1): 14-21 (1978). cited by other.

Goto et al., Preliminary report on the pink-colored Cypridina luciferase, a natural model of the luciferin-luciferase complex, in Bioluminescence and

Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 203-207, Academic Press (1981). cited by other .

Hastings et al., The Red Absorbing Flavin Species in the Reaction of Bacterial Luciferase with FMNH.sub.2 and O.sub.2.sup.1, Bioluminescence and Chemiluminescence pp. 403-408 (1981). cited by other .

Hastings et al., Fluorescence Properties of Luciferase Peroxyflavins Prepared with ISO-FMN and 2-THIO FMN.sup.1, Bioluminescence and Chemiluminescence pp. 97-102 (1981). cited by other .

Hastings, Bioluminescence, in Cell Physiol.: Source Book, Sperelakis, ed., pp. 665-681, Academic Press (1995). cited by other .

Hill et al., Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 396-399, Academic Press (1981). cited by other . Hori et al., Structure of native Renilla reniformis luciferin, Proc. Natl. Acad. Sci. USA 74: 4285-4287 (1977). cited by other .

Illarionov et al., Sequence of the cDNA encoding the Ca.sup.2 +-activated photoprotein obelin from the hydroid poly Obelia longissima, Gene 153:273-274 (1995). cited by other .

Inouye et al., "Overexpression and purification of the recombinant ca.sup.2+ --binding protein, apoaequorin," J. Biochem. 105(3):473-477 (1989). cited by other .

Inouye et al., Cloning and sequence analysis of cDNA for the luminescent protein aequorin, Proc. Natl. Acad. Sci. USA 82:3154-3158 (1985). cited by other .

Inouye et al., Squid bioluminescence II. Isolation from Watasenia scintillans and

synthesis of 2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-3,7-dihydroimidazo[1,2-

a]pyrazin-- 3-one, Jap. Soc. Chem. Lett. pp. 141-144 (1975). cited by other .

Inouye et al., Expression of Apoaequorin Complementary DNA in Escherichia coli, Biochemistry 25:8425-8429 (1986). cited by other .

Johnson et al., Introduction to the Cypridina system, Methods in Enzymology.

Bioluminescence and Chemiluminescence. 57:331-349 (1978). cited by other .

Johnson, Luminescence, Narcosis, and Life in the Deep Sea, pp. 50-56, Vantage Press. cited by other.

Johnson et al., "Compartmentalization of algal bioluminescence: autofluorescence of bioluminescent particles in the dinoflagellate Gonyoulax as studied with imageintensified video microscopy and flow cytometry", J. Cell. Biol. 100(5):1435-1446 (1985). cited by other .

Karatani et al., A blue fluorescent protein from a yellow-emitting luminous bacterium, Photochem. Photobiol. 55(2): 293-299 (1992). cited by other .

Kohama et al., Molecular weight of the photoprotein aequorin, Biochemistry 10: 4149-4152 (1971). cited by other .

Kurose et al., Bioluminescence of the Ca.sup.2+-binding photoprotein aequorin after cysteine modification, Proc. Natl. Acad. Sci. USA 86(1): 80-84 (1989). cited by other . Lee et al., "Purification of a Blue-fluorescent Protein from the Bioluminescent Bacterium Photobacterium phosphoreum," Methods Enzymol., (Biolumin.

Chemilumin.), 57:226-234 (1978). cited by other .

Lorenz et al., Isolation and expression of a cDNA encoding Renilla reniformis luciferase, Proc. Natl. Acad. Sci. USA 88: 4438-4442 (1991). cited by other .

Matthews et al., Purification and properties of Renilla reniformis luciferase, Biochemistry, 16: 85-91 (1977). cited by other .

Matz et al., "Fluorescent proteins from nonbioluminescent Anthozoa species", Nature Biotechnol., 17:969-973; (1999). cited by other .

McElroy et al., The colors of bioluminescence: Role of enzyme and substrate structure, in Molecular Architecture in Cell Physiology, pp. 63-80, Hayashi et al., eds., Prentice-Hall, Inc., Englewood Cliffs, NJ (1966). cited by other . Miyamoto et al., Cloning and expression of the genes from the bioluminescent system of marine bacteria, Meth. Enzymol. 133:70-81 (1986). cited by other .

Morise et al., Intermolecular Energy Transfer in the Bioluminescent System of Aequorea Biochemistry 13:2656-2662 (1974). cited by other .

Ormo et al. Crystal Structure of the Aequorea victoria Green Fluorescent Protein Science 273:1392-1395 (1996). cited by other .

Prasher et al., Cloning expression of the cDNA coding for aequorin, a bioluminescent calcium-binding protein, Biochem. Biophys. Res. Commun. 126(3):1259-1268 (1985). cited by other .

Prasher et al., Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 365-367, Academic Press (1981). cited by other .

Prasher et al., Isolation and expression of a cDNA coding for aequorin, the Ca.sup.2+ --activated photoprotein from Aequorea victoria, Meth. Enzymol. 133:288-297 (1986). cited by other .

Prasher et al., Sequence comparisons of complementary DNAs encoding aequorin isotypes, Biochem. 26:1326-1332 (1987). cited by other .

Prasher et al., Primary structure of the Aequorea victoria green-fluorescent protein, Gene 111:229-233 (1992). cited by other .

Prendergast et al., "Chemical and Physical Properties of Aequorin and the Green Fluorescent Protein Isolated from Aequorea forskalea", Biochem., 17: 3448-3453; (1978). cited by other .

Sandalova, Some notions about structure of bacterial luciferase, obtained by analysis of amino acid sequence, and study of monoclonal antibodies binding, In Biological Luminescence, Proceedings of International School, 1st, ed., Jezowska-Trzebiatowska et al., World Science (1990). cited by other .

SeaLite Sciences Technical Report No. 3, "The Recombinant Photoprotein,

AquaLite.TM.", SeaLite Sciences, Inc., pp. 1-6; (1994). cited by other .

Sherf et al., Dual-luciferase reporter assay: an advanced co-reporter technology integrating firefly and Renilla luciferase assays, Promega Notes 57:2-5 (1996). cited by other .

Shimomura et al., Semi-synthetic aequorin. An improved tool for the measurement of calcium ion concentration, Biochem. J. 251(2):405-10 (1988). cited by other .

Shimomura et al. Structure of Light-Emitting Moiety of Aequorin Biochemistry 11:1602-1608 (1972). cited by other .

Shimomura et al., Recombinant aequorin and recombinant semi-synthetic aequorins. Cellular Ca.sup.2+ion indicators, Biochem. J. 270(2): 309-12 (1990). cited by other . Shimomura et al. The Structure of Latia Luciferin Biochemistry 7:1734-1738 (1968). cited by other.

Shimomura, Structure of the Chromophore of Aequorea Green Fluorescent Protein FEBS Letters 104:220-222 (1979). cited by other .

Shimomura et al., Extraction, purification and properties of a aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea, J. Cell. Comp. Physiol. 59: 223-238 (1962). cited by other .

Shimomura et al., Properties and reaction mechanism of the bioluminescence system of the deep-sea shrimp Oplophorus gracilorostris, Biochem 17(6): 994-998 (1978). cited by other .

Shimomura et al., Properties of the bioluminescent protein aequorin, Biochemistry 8: 3991-3997 (1969). cited by other .

Shimomura et al. Reactions Involved in Bioluminescence of Limpet (Latia neritoides) and Luminous Bacteria Proc. Natl. Acad. Sci. U.S.A. 69:2086-2089 (1972). cited by other .

Spurlok et al., A fine structure study of the anthocodium in Renilla mulleri, J. of Cell Biology 64:15-28 (1975). cited by other .

Thompson et al., Cloning and expression of cDNA for the eluciferase from the marine ostracod Vargula hilgendorfi xi, Proc. Natl. Acad. Sci. USA 86: 6567-6571 (1989). cited by other .

Tsien, The Green Fluorescent Protein Annu. Rev. Biochem. 67:509-544 (1998). cited by other .

Tsuji et al., Some properties of luciferase from the bioluminescent crustacean, Cypridina hilgendorfii, Biochem. 13(25):5204-5209 (1974). cited by other .

Tsuji, "Cypridina luciferin and luciferase", Meth. Enzymol. 57:364-372; (1978). cited by other .

Tsuji et al., Site-specific mutagenesis of the calcium-binding photoprotein aequorin, Proc. Natl. Acad. Sci. USA 83:8107-8111 (1986). cited by other .

Wampler et al. Similarities in the Bioluminescence from the Pennatulacea Biochimicia et a Biophysica Acta 314:104-109 (1973). cited by other .

Ward et al., Energy Transfer Via Protein-Protein Interaction in Renilla Bioluminescence, Photochemistry and Photobiology 27:389-396 (1978). cited by other

Ward et al., Sequence and Chemical Structure of the Hexapeptide Chromophore of Aequorea Green-Fluorescent Protein, Photochemistry and Photobiology 49:62S (1989). cited by other .

Ward et al., Extraction of Renilla-type luciferin from the calcium-activated photoproteins aequorin, mnemiopsin, and berovin, Proc. Natl. Acad. Sci. USA 72: 2530-2534 (1975). cited by other .

"AquaLite.RTM.. A calcium-triggered photoprotein," SeaLite Sciences Technical Report No. 3 (1994). cited by other .

Amsterdam, et al. The Aequorea victoria Green Fluorescent Protein Can Be Used as a Reporter in Live Zebrafish Embryos Developmental Biology 171:123-129 (1995). cited by other .

Anctil et al., Mechanism of photoinactivation and re-activatioon in the bioluminescence system of the ctenophore Mnemiopsis, Biochem. J. 22(1): 269-272 (1984). cited by other .

Badminton et al., nucleoplasmin-targeted aequorin provides evidence for a nuclear calcium barrier, Expt. Cell Research 216(1): 236-243 (1995). cited by other .

Baldwin et al., "Applications of the cloned bacterial luciferase genes LUXA and LUXB to the study of transcriptional promoters and terminators," Bioluminescence and Chemiluminescence: Basic Chemistry and Analytical Applications, DeLuca and McElroy, Eds., Academic Press (1981). cited by other .

Becvar et al., A thermodymanic explanation for the kinetic differences observed using different chain length aldehydes in the in vitro bacterial bioluminescent reaction, in Bioluminescence and Chemiluminescence, pp. 147-155, 180-185, Proc. of the IV Int. Bioluminescence and Chemiluminescence Symp., Freiburg, Sep. 1986. cited by other . Button et al., Aequorin-expressing mammalian cell lines used to report

Ca.sup.2+mobilization, Cell Calcium 14(9):663-671 (1993). cited by other . Chalfie et al. Green Fluorescent Protein as a marker for Gene Expression Science 263: 802-805 (1994). cited by other .

Charbonneau et al. Ca.sup.2+-induced Bioluminescence in Renilla reniformis Purification and Characterization of a Calcium-Triggered Luciferin-Binding Protein J. Biol. Chem. 254:769-780 (1979). cited by other .

Cody et al. Chemical Structure of the Hexapeptide Chromophore of the Aequorea Green-Fluorescent Protein Biochemistry 32:1212-1218 (1993). cited by other . Cormack et al. Yeast-enhanced green fluorescent protein (yEGFP): a reporter of gene expression in Candida albicans Microbiology 143:303-311 (1997). cited by other . Cormier et al., Evidence for similar biochemical requirements for bioluminescence among the coelenterates, J. Cell Physiol. 81: 291-298 (1972). cited by other . Cormier "Renilla and Aequorea bioluminescence" pp 225-233 in Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications. DeLuca et al eds, Academic Press 1981. cited by other .

Dabiri et al. Myofibrillogenesis visualized in living embryonic cardiomyocytes Pro. Natl. Acad. Sci. USA 94:9493-9498 (1997). cited by other .

Database Derwent #009443237 WPI Acc. No. 93-136754/199317 (citing Japanese Patent Application No. JP 5064583, published Mar. 19, 1993). cited by other .

Fey et al. Green Fluorescent protein production in the cellular slime molds Polysphondylium pallidum and Dictyostelium discoideum Gene 165:127-130 (1995). cited by other.

Fratamico et al., Construction and characterization of Escherichia coli 0157:H7 strains expressing firefly luciferase and green fluorescent protein and their use in survival studies, J of Food Protection 60(10):1167-1173 (1997). cited by other .

Giuliano et al. Fluorescent-protein biosensors: new tools for drug discovery TiBech 16: 135-140 (1998). cited by other .

Grentzmann et al., A dual-luciferase system for studying recoding signals, RNA 479-486 (1998). cited by other .

Hart et al. "Renilla reniformis bioluminescence: Luciferase-catalyzed production of nonradiating excited states from luciferin analogues and elucidation of the excited state species involved in energy transfer to Renilla green fluorescent protein", (1979) Biochemistry 18:2204-2210 (1979). cited by other .

Heim et al., Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer, Current Biology 6(2):178-182 (1996). cited by other .

Heinlein et al. Interaction of Tobamovirus Movement Proteins with the Plant Cytoskeleton Science 270:1983-1985 (1995). cited by other .

Hori et al., Renilla luciferin as the substrate for calcium induced photoprotein bioluminescence. Assignment of luciferin plutomers in aequorin and mnemiopsin, Biochemistry 14: 2371-2376, (1975). cited by other .

Ikawa et al. A rapid and non-invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP) FEBS Letters 375:125-128 (1995). cited by other .

Inouye et al., Electroporation as a new technique for producing transgenic fish, Cell Differ. Devel. 29:123-128 (1990). cited by other .

Inouye et al., Monitoring gene expression in Chinese hamster ovary cells using secreted apoaequorin, Analyt. Biochem. 201(1): 114-118 (1992). cited by other . Inouye et al., "Imaging of luciferase secretion from transformed Chinese hamster ovary cells," Proc. Natl. Acad. Sci. USA 89:9584-9587 (1992). cited by other . Inouye et al., "Expression of apoaequorin complementary DNA in Escherichia coli,"

Biochem. 25:8425-8429 (1986). cited by other.

Kain et al., Green Fluorescent Protein as a reporter of Gene Expression and Protein Localization BioTechniques 19:650-655 (1995). cited by other .

Karp et al., Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 360-363, Academic Press (1981). cited by other .

Kendall et al., Changes in free calcium in the endoplasmic reticulum of living cells detected using targeted aequorin, Anal. Biochem. 22(1):173-81 (1994). cited by other . Knight et al., Imaging calcium dynamics in living plants using semi-synthetic recombinant aequorins, J. Cell Biol. 121(1):83-90 (1993). cited by other . Knight et al., Transgenic plant aequorin reports the effects of touch and cold-shock and elicitors on cytoplasmic calcium, Nature 352(6335): 524-526 (1991). cited by other .

Leach et al., Commercially available firefly luciferase reagents, in Methods in Enzymology. Bioluminescence and Chemiluminescence Part B 133:51-69, Academic Press (1986). cited by other .

Legocki et al., Bioluminescence in soybean root nodules: Demonstration of a general approach to assay gene expression in vivo by using bacterial luciferase, Proc. Natl. Acad. Sci. USA 81: 9080-9084 (1986). cited by other .

McElroy, et al., The Chemistry and Applications of Firefly Luminescence, Bioluminescence and Chemiluminescence, 179-185, Academic Press, Inc. (1981). cited by other.

Miller et al. An improved GFP cloning cassette designed for prokaryotic transcriptional fusions Gene 191:149-153 (1997). cited by other .

Mitra et al., Fluorescence resonance energy tranfer between blue-emitting and redshifted excitation derivatives of the green fluorescent protein, Gene 73(1):13-17 (1996). cited by other .

Miyawaki et al. Fluorescent indicators for CA.sup.2+based on green fluorescent proteins and calmodulin Nature 388:882-887 (1997). cited by other .

Morin, Energy in a Bioluminescent System, J. Cell Physiol., 77:313-318 (1971). cited by other .

Nakajima-Shimada et al., Monitoring of intracellular calcium in Saccharomyces cerevisiae with an apoaequorin cDNA expression system, Proc. Natl. Acad. Sci. USA 88(15): 6878-6882 (1991). cited by other .

Plautz et al., Green Fluorescent protein and its derivatives as versatile markers for gene expression in living Drosophila melanogaster, plant and mamalian cells Gene 173:83-87 (1996). cited by other .

Rivera et al., AquaLite.RTM. Streptavidin for supersentive TSH assays in microtiter plates and coated tubes, SeaLite Sciences Technical Report No. 6. cited by other . Rizzuto et al., Rapid changes of mitochondrial Ca.sup.2+revealed by specifically targeted recombinant aequorin, Nature 358(6384): 325-327 (1992). cited by other . Romoser et al., Detection in living cells of Ca2+-dependent changes in the fluorescence emission of an indicator composed of two green fluorescent protein variants liked by a calmodulin-binding sequence, J. of Biolog. Chem. 272(20):1327013274 (1997). cited by other.

Rutter et al., Involvement of MAP kinase in insulin signalling revealed by noninvasive imaging of luciferase gene expression in single living cells, Current Biology 5(8): 890-9 (1995). cited by other .

Saran et al., Intracellular free calcium level and its response to cAMP stimulation in developing Dictyostelium cells transformed with jellyfish apoaequorin cDNA, FEBS Lett. 337(1): 43-7 (1994). cited by other .

Sedlak et al., Bioluminescent Technology for Reagents, Diagnostics and Toxicology, Genetic Engineering News, Sep. 15, 1995. cited by other .

Sgoutas et al., AquaLite.RTM. bioluminescence assay of thyrotropin in serum evaluated, Clin. Chem. 41(11):1637-1643 (1995). cited by other .

Sheu et al., Measurement of intracellular calcium using bioluminescent aequorin exposed in human cells, Analyt. Biochem. 209(2): 343-347 (1993). cited by other . Straight et al. GFP tagging of budding yeast chromosomes reveals that protein-protein interations can mediate sister chromatid cohesion Current Biology 12:1599-1608 (1996). cited by other .

Stults et al. Use of Recombinant Biotinylated Apoaequorin in Microtiter and Membrane-Based Assays: Purification of Recombinant Apoaequorin from Escherichia coli Biochemistry 31:1433-1442 (1992). cited by other .

Terry et al. Molecular characterisation of recombinant green fluorescent protein by fluorescence correlation microscopy Biochemical and Biophysical Research Communication 217:21-27 (1995). cited by other .

Thompson et al., Vargula hilgendorfii luciferase: a secreted reporter enzyme for monitoring gene expression in mammalian cells, Gene 96:257-262 (1990). cited by other .

Travis, J. Following the Inner Light, Glow Genes provide revealing pictures of infections Science News 150:220-221 (1996). cited by other .

Xu et al. A bioluminescence resonance energy transfer (BRET) system: Application to interacting circadian clock proteins Proc. Natl. Acad. Sci. USA 96:151-156 (1999). cited by other .

Amato, Race quickens for non-stick blood monitoring technology, Science 258:892-893 (1992). cited by other .

Apt et al., Evolution of phycobiliproteins, J. Mol. Biol. 248: 79-96 (1995). cited by other .

Baird et al., "Biochemistry, mutagenesis, and oligomerization of DsRed, a red fluorescent protein form coral", PNAS, 97(22):11984-11989; (2000). cited by other . Bondar et al., Cadmium-induced luminescence of recombinant photoprotein obelin, Biochim. Biophys. Acta 1231: 29-32 (1995). cited by other .

Campbell et al., Formation of the Ca.sup.2+-activated photoprotein obelin from apoobelin and mRNA inside human neutrophils, Biochem. J. 252(1):143-9 (1988). cited by other .

Cardullo et al. Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer Pro.Natl. Acad. Sci. USA 85:8790-9794 (1988). cited by other .

Crescitelli, Adaptations of visual pigments to the photic environment of the deep sea, J. Exptl. Zool. Supp. 5:66-75 (1991). cited by other .

Database Derwent #008987167 (citing WO 9204577, Chemiluminescence prodn. in liq.-contg. vesssel--by placing reagent envelope in liq. or vessel base). cited by other . Fairchild et al., Oligomeric Structure, Enzyme Kinetics, and Substrate Specificity of the Phycocyanin_Subunit Phycocyanobilin Lyase, The Journal of Biological Chemistry 269(12): 8686-8694 (1994). cited by other .

Frackman et al., "Cloning, Organization, and Expression of the Bioluminescence Genes of Xenorhabdus luminescens," J. Bacteriol., 172(10):5767-5773; (1990). cited by other.

Goldmacher et al., "Photoactivation of Toxin Conjugates", Bioconj. Chem., 3:104-107; (1992). cited by other .

Gautier et al., Alternate determination of ATP and NADH with a single bioluminescence-based fiber-optic sensor, Fifth International Conference on Solid State Sensors and Actuators and Eurosensors III, Montreux, Switzerland, Jun. 25-30, 1989. cited by other .

Gilbert et al., Expression of genes involved in phycocyanin biosynthesis following recoivery of Synechococcus PCC 6301 from nitrogen starvation, and the effect of gabaculine of cpcBa transcript levels, FEMS Microbiol. Lett. 140: 93-98 (1996). cited by other .

Glazer, Phycobilisomes: structure and dynamics, Ann. Rev. Microbiol. 36: 173-98 (1982). cited by other .

Goldstein et al., Characterization of the Cellulose-Binding Domain of the Clostridium cellulovorans Cellulose-Binding Protein A, Journal of Bacteriology 175(18): 5762-5768 (1993). cited by other .

Hart et al., Renilla reniformis Bioluminescence: Luciferase-Catalyzed Production of Nonradiating Excited States from Luciferin Analogues and Elucidation of the Excited State Species Involved in Energy Transfer to Renilla Green Fluorescent Protein, Biochemistry 18(11):2204-2210 (1979). cited by other .

Houmard et al., Genes encoding core components of the phycobilisome in cyanobacterium Calothrix sp. srain PCC 7601: occurrence of a multigene family, J. Bacteriol. 170(12): 5512-5521 (1988). cited by other .

Illarionov et al., "Sequence of the cDNA encoding the Ca.sup.2+-activated photoprotein obelin from the hydroid polyp Obelia longissima", Gene, 153:273-274; (1995). cited by other .

Johnson, F.H., Luminescence, Narcosis, and Life in the Deep Sea, Vantage Press, NY pp. 50-56 (1988). cited by other .

Kronic, The use of phycobiliproteins as flkuorescent labels in immunoassay, J. Immunolog. Meth. 92: 1-13 (1986). cited by other .

Liu et al., A cyanidium caldarium Allophycocyanin_subunit gene, Plant Physiol. 103:293-294. (1993). cited by other .

Lucas et al., Coelenterazine is a superoxide anion-sensitive chemiluminescent probe: its usefulness in the assay of respiratory burst in neutrophils, Analyt. Biochem. 206(2):273-277 (1992). cited by other .

Morin et al., "Energy Transfer in_Bioluminescent System", J. Cell Physiol., 77:313-318; (1971). cited by other .

Muller and Campbell, "The chromophore of pholasin: A highly luminescent protein", J. Biolumin. Chemilum. 5:25-30 (1990). cited by other .

Nicoli et al., Bacterial luciferase: The hydrophobic environment of the reactive sulfhydryl, J. Biol. Chem. 249: 2393-2396 (1974). cited by other .

O'Day et al., Aristostomias scintillans (Malacostiedae): a deep sea fish with visual pigments apparently adapted to its own bioluminescence, Vision Res. 14:545-550 (1974). cited by other .

Peerce et al. Distance between substrate sites on the Na-glucose cotransporter by fluoresence energy transfer Proc. Natl. Acad. Sci. USA 83:8092-8096 (1986). cited by other .

Pilot et al., Cloning and sequencing of the genes encoding the_and_subunits of C-phycocyanin from the cyanobacterium Agmenellum quadruplicatum, Proc. Natl. Acad. Sci. USA 81:6983-6987 (1984). cited by other .

Senter et al., "Novel Photocleavable Protein Crosslinking Reagents and their Use in the Preparation of Antibody-toxin Conjugates", Photochem. & Photobiol., 42(3):231-237; (1985). cited by other .

Shimomura et al., Resistivity to denaturation of the apoprotein of aequorin and reconstitution of the luminescent photoprotein from the partially denatured apoprotein, Biochem J. 199:825-828 (1981). cited by other .

Shimomura et al., Regeneration of the photoprotein aequorin, Nature 256: 236-238 (1975). cited by other .

Shimomura et al., The relative rate of aequorin regeneration from apoaequorin and coelenterazine analogues, Biochem. J. 296(Pt. 3): 549-551 (1993). cited by other . Shimomura, Bioluminescence in the sea: photoprotein systems [Review], Symposia of

the Society for Experimental Biology 39: 351-372 (1985). cited by other .

Shimomura, "Cause of spectral variation in the luminescence of semisynthetic aequorins", Biochem J. 306:537-543 (1995). cited by other .

Shimomura et al., Peroxidized coelenterazine, the active group in the photoprotein aequorin, Proc. Natl. Acad. Sci. USA 75(6): 2611-5 (1978). cited by other .

Smalley et al., "Localization of fluorescent compounds in the firefly light organ", J. Histochem. Cytochem. 28(4):323-329 (1980). cited by other .

Smith et al., Bioluminescent immunoassays using streptavidin and biotin conjugates of recombinant aequorin, reprinted from American Biotechnology Laboratory, Apr. 1995. cited by other .

Stability of AquaLite.RTM.: lyophilized and in solution, SeaLite Sciences Technical Report No. 8 (1994). cited by other .

Stephenson et al. Studies on the Luminescent Response of the Ca.sup.2+-Activated Photoprotein, Obelin Biochimica et Biophysica Acta 678:65-75 (1981). cited by other

Tsuji et al., Mechanism of the enzyme-catalyzed oxidation of Cypridina and firefly luciferins studied by means of .sup.17O.sub.2 and H.sub.2.sup.18O.sup.1, Biochem. Biophys.Res. Commun. 74(2):606-613 (1977). cited by other .

Vysotski et al., Mn.sup.2+-activated luminescence of the photoprotein obelin, Arch. Bioch. Biophys. 316:92-99 (1995). cited by other .

Vysotski et al., Luminescence of Ca.sup.2+-activated photoprotein obelin initiated by NaOCI and MnCl.sub.2, J. Biolumin. Chemilumin. 8:301-305 (1993). cited by other . Wall et al., "The structural basis for red fluorescence in the tetrameric GFP homolog DsRed", Nature Structural Biol., 7(12):1133-1138; (2000). cited by other .

Ward et al. Reversible Denaturation of the Aequorea Green-Fluorescent Protein: Physicial Separation and Characterization of the Renatured Protein Biochemistry 21:4535-4540 (1982). cited by other .

Ward, Properties of the Coelenterate Green-Fluorescent Proteins Bioluminescence and Chemiluminescence 235-242 (1981). cited by other .

Ward, General Aspects of Bioluminescence, in Chemi- and Bioluminescence, Ch. 7, Burr, ed., Marcel Dekker, Inc., New York. cited by other .

Ward et al. Energy Transfer Via Protein-Protein Interation in Renilla Bioluminescence Photochemistry and Photobiology 27:389-396 (1978). cited by other .

Ward, Energy Transfer Processes in Bioluminescence Photochem. Photobiol. Rev. 4:1-57. cited by other .

Ward et al., An energy transfer protein in coelenterate bioluminescence, J. Biol. Chem. 254: 781-788 (1979). cited by other .

Ward et al. In Vitro Energy Transfer in Renilla Bioluminescence The Journal of

Physical Chemistry 8:2289-2291 (1976). cited by other.

Watanabe et al., Bunding of murine monoclonal antibodies to the active and inactive configurations of aequorin, FEBS Lett. 246(1-2): 73-77 (1989). cited by other . Watkins et al., Requirement of the C-terminal proline residue for stability of the Ca(.sup.2+)-activated photoprotein aequorin, Biochem. J. 293(Pt.1): 181-185 (1993). cited by other .

Welches et al., Active center studies on bacterial luciferase: Modification of the enzyme with 2,4-dinitrofluorobenzene, Biochemistry 20: 512-517 (1981). cited by other .

Widder et al., "Far red bioluminescence from two deep-sea fishes", Science 225:512-514 (1984). cited by other .

Wienhausen et al., Luciferases from different species of fireflies are antigenically similar, Photochem. Photobiol. 42: 609-611 (1985). cited by other .

Yarbrough et al., "Refined crystal structure of DsRed, a red fluorescent protein from coral, at 2.0-.ANG. resolution", PNAS, 98(2):462-467; (2001). cited by other .

Yen et al., "Synthesis of water-soluble copolymers containing photocleavable bonds", Makromol. Chem., 190:69-82; (1989). cited by other .

Ziegler et al., Active center studies on bacterial luciferase: Locations of the protease labile regions and the reactive cysteinyl residue in the primary structure of the_subunit, Bioluminescence and Chemiluminescence. Basic Chemistry and Analytical Applications, DeLuca et al., eds., pp. 376-377, Academic Press (1981). cited by other .

Altschul et al., "Basic Local Alignment Search Tool", J. Mol. Biol., 215:403-410; (1990). cited by other .

Anderson, Radiolaria, Springer-Verlag, New York (1983). cited by other .

Aviv et al., Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose, Proc. Natl. Acad. Sci. USA 69(6):1408-1412 (1972). cited by other .

Batra et al., "Insertion of Constant Region Domains of Human IgG, into CD4-PE40 Increases Its Plasma Half-life", Molecular Immunol., 30(4):379-386; (1993). cited by other .

Bayer and Wichek (1980) The Use of Avidin/Biotin Complex as a Tool in Molecular Biology. Meth. Biochem. Anal. 26, 1-45. cited by other .

Berg et al., Long-chain polystyrene-grafted polyethylene film matrix: a new support for solid-phase peptide synthesis, J. Am. Chem. Soc. 111:8026-8027 (1989). cited by other .

Berg et al., Peptide synthesis on polystyrene-grafted polyethylene sheets, Pept., Proc. Eur. Pept. Symp., 20th, Jung et al. (Eds.), pp. 196-198 (1989). cited by other .

Berg et al., Polystyrene-grafted polyethylene: Design of film and felt matrices for solid-phase peptide synthesis, Innovation Perspect. Solid Phase Synth. Collect. Pap., Int. Symp., 1st, Epton (ed.), pp. 453-459 (1990). cited by other .

Biocomputing: Informatics and Genome Projects, Book: Smith, D.W., Ed., Academic Press, New York; (1993). cited by other .

Bodanszky and Bodanszky, The Practice of Peptide Synthesis, Springer-Verlag, New York, (1984). cited by other .

Bunnin et al. The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library, Proc. Natl. Acad. Sci. USA, 91:4708-4712 (1994). cited by other .

Carlsson et al. Protein Thiolation and Reversible Protein-Protein Conjugation Biochem. J. 173: 723-737 (1978). cited by other .

Carrillo et al., "The Multiple Sequence Alignment Problem in Biology", SIAM J. Applied Math, 48(5):1073-1082; (1988). cited by other .

Childress, "Oxygen minimum layer: Vertical distribution and respiration of the mysid gnathophausia ingens", Science 160:1242-1243 (1968). cited by other .

Chirgwin et al., Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease, Biochemistry 18(24):5294-5299 (1979). cited by other.

Computational Molecular Biology, Book: Lesk, A.M., ed., Oxford University Press, New York; (1988). cited by other .

Computer Analysis of Sequence Data, Book: Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey; (1994). cited by other .

Cumber et al., "Structural Features of the Antibody-A Chain Linkage that Influence the Activity and Stability of Ricin A Chain Immunotoxins", 3(5):397-401; (1992). cited by other .

Devereux et al., "A comprehensive set of sequence analysis programs for the VAX", Nucl. Acids Res., 12(1):387-395; (1984). cited by other .

DeWitt et al., Diversomers: an approach to nonpeptide, nonoligomeric chemical diversity, Proc. Natl. Acad. Sci. USA 90: 6909-6913 (1993). cited by other .

DeWitt et al., DIVERSOMER.TM. Technology: solid phase synthesis, automation, and integration for the generation of chemical diversity, Drug Dev Res 33:116-124 (1994). cited by other .

DIALOG Abstract 002042687, citing: JP 7241192. cited by other .

Duzgunes et al., Fusion of phospholipid vesicles induced by divalent cations and protons; modulation by phase trasitions, free fatty acids, monovalent cations, and polyamines, Cell Fusion, Ch. 11 Divalent Cations and Protons, Sowers, A.E. (ed.) pp. 241-267 (1984). cited by other .

Fattom et al., "Comprehensive Immunogenicity of Conjugates Composed of the

Staphylococcus aureus Type 8 Capsular Polysaccharide Bound to Carrier Proteins by Adipic Acid Dihydrazide or N-Succinimidyl-3-(2-Pyridyldithio)propionate", Infection & Immun., 60(2):584-589; (1992). cited by other .

Goodchild, "Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties", Perspectives in Bioconjugate Chemistry, Mears, ed., American Chemical Society, Washington, D.C., Ch 6, pp. 77-99 (1993). cited by other

Gordon et al. Topographical localization of the C-terminal region of the voltagedependent sodium channel from Electrophorus electricus using antibodies raised against a synthetic peptide Proc. Natl. Acad Sci. 84:308-312 (1987). cited by other . Gribskov et al., "Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins", Nucl. Acids Res., 14(16):6745-6762; (1986). cited by other . Guide to Human Genome Computing, Book: Martin J. Bishop, ed., Academic Press, San Diego; (1994). cited by other .

Guyomard et al., Integration and germ line transmission of foreign genes microinjected into fertilized trout eggs, Biochimie 71:857-863 (1989). cited by other . Hazum et al., A photocleavable protecting group for the thiol function of cysteine, Pept., Proc. Eur. Pept. Symp., 16th, Brunfeldt, K (Ed), pp. 105-110 (1981). cited by other .

Hermanson et al., Immobilized Affinity Ligand Techniques, Chaps. 1 and 2, Academic Press, Inc. (1992). cited by other .

Immobilized Biochemicals and Affinity Chromatography, Advances in Experimental Medicine and Biology, vol. 42, ed. R. Dunlap, Plenum Press, N.Y. (1974) Table of Contents. cited by other .

Immobilized Enzyme, Antigens, Antibodies and Peptides, Preparation and Characterization, Marcel Dekker, Inc., N.Y., Howard H. Weetall (ed.) (1975). cited by other.

Jellinek et al., "Potent 2'-Amino-2'-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor", Biochem., 34:11363-11372; (1995). cited by other .

Kennedy and Cabral, Immobilized Enzymes, in Solid Phase Biochemistry, Analytical and Synthetic Aspects, Scouten, Ed., 7:253-391 (1983). cited by other .

Kent et al., Preparation and properties of tert-butyloxcarbonylaminocayl-4-

(oxymethyl) phenylacetamidomethyl-(Kel F-g-styrene) resin, an insoluble,

noncrosslinked support for solid phase peptide synthesis, Israel J. Chem. 17:243-247 (1978). cited by other .

Kozak, Structural Features in Eukaryotic mRNAs that Modulate the Initiation of Translation The Journal of Biological Chemistry 266:19867-19870 (1991). cited by other .

Kroger et al., "A new calcium binding glycoprotein family constitutes a major diatorn cell wall component", EMBO 13:4676-4683 (1996). cited by other .

Kroger et al., "Frustulins: domain consevation in a protein family associated with diatom cell wall", Eur. J. Biochem. 239:259-264 (1996). cited by other .

Lin et al., "Modified RNA sequence pools for in vitro selection", Nucl. Acids Res., 22(24):5229-5234; (1994). cited by other .

Liposome Technology, Targeted Drug Delivery and Biological Interaction, vol. III, G. Gregoriadis (ed.), CRC Press, Inc. (1984) Table of Contents. cited by other .

Mahan et al., "Phase Change Enzyme Immunoassay", Anal. Biochem., 162:163-170; (1987). cited by other .

Mengeling et al., A microplate assay for analysis of solution-phase glycosyltransferase reactions: Determination of kinetic constants, Anal. Biochem. 199:286-292 (1991). cited by other .

Millon et al., "Synthesis of a new reagent, ethyl 4-azidobenzoylaminoacetimidate, and its use for RNA-protein cross-linking within Escherichia coli ribosomal 30-S

subunits", Eur. J. Biochem. 110:485-492 (1980). cited by other .

Molecular Biology of the Gene, 4th Edition, 1987, ed. Watson et al. The Benjamin/Cummings Pub. co. p. 224. cited by other .

Mosbach, AMP and NAD as `general ligands`, Affinity Techniques, Enzyme Purification: Part B. Methods in Enzymology, vol. 34, W. B. Jakoby, et al. (eds.), Acad. Press, N.Y. (1974). cited by other .

Mosbach et al. Immobilization of enzymes to various acrylic copolymers. Methods in Enzymology 44:53-65 (1976). cited by other .

Mosbach et al. Immobilized coenzymes. Methods in Enzymology 44:859-887 (1976). cited by other .

Mosbach, K and Mattiasson, B. Multistep enzyme systems. Methods in Enzymology 44:453-478 (1976). cited by other .

Mosbach, K. Immobilized Enzymes. Methods in Enzymology 44:3-7 (1976). cited by other .

Nakamura et al., DNA Sequence of the Gene for the Outer Membrane Lipoprotein of E. coli: an Extremely AT-Rich Promoter, Cell 18:1109-1117 (1979). cited by other . Needleman et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. MOI. Biol., 48:443-453; (1970). cited by other .

Nogrady, Medicinal Chemistry, A Biochemical Approach, Oxford University Press, New York pp. 388-392. cited by other .

Ozato et al., Production of transgeniuc fish: introduction and expression of chicken-crystalline gene in medaka embryos, Cell Differ. Devel. 19:237-244 (1986). cited by other.

Pagratis et al., "Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor", Nature Biotechnol., 15:68-73; (1997). cited by other . Pearson et al., "Improved tools for biological sequence comparison", Proc. Natl. Acad. Sci. U.S.A., 85:2444-2448; (1988). cited by other .

Peffer et al., "Strand-invasion of duplex DNA by peptide nucleic acid oligomers",

Proc. Natl. Acad. Sci. U.S.A. 90:10648-10652 (1993). cited by other .

Pierce Catalog, pp. T123-T154, (1994). cited by other.

Pierce Catalog & Handbook, pp. O90-O110, T155-T200 (1994). cited by other . Pierce Catalog, ImmunoTechnology Catalog & Handbook (1992-1993). cited by other

Sambrook et al., Molecular Cloning, 2nd ed., Cold Springs Harbor Laboratory press, New York (1989). cited by other .

Sanger et al., DNA sequencing with chain-terminating inhibitors, Proc. Natl. Acad. Sci. USA 74(12):5463-5467 (1977). cited by other .

Schwartz and Dayhoff, eds., Book: #23 "Matrices for Detecting Distant

Relationships", Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358; (1979). cited by other .

Sequence Analysis in Molecular Biology, Book: von Heijne, Academic Press, Inc., (1987). cited by other .

Sequence Analysis Primer, Book: Gribskov M. and Devereux J., eds., Stockton Press, New York; (1991). cited by other .

Smith et al., "Comparison of Biosequences", Adv. Appl. Math., 2:482-489; (1981). cited by other .

Stewart and Young, Laboratory techniques in solid phase peptide synthesis, Solid Phase Peptide Synthesis, 2d Ed., Pierce Chemical Co., pp. 53-73 (1984). cited by other

Studier et al. Use of T7 RNA Polymerase to Direct Expression of Cloned Genes Methods in Enzymology 185: 60-89 (1990). cited by other .

Thorpe et al., "New Coupling Agents for the Synthesis of Immunotoxins Containing a Hindered Disulfide Bond with Improved Stability in Vivo", Cancer Res., 47:5924-5931; (1987). cited by other .

Tomme et al., Cellulose-Binding Domains: Classification and Properties, American Chemical Society pp. 142-163 (1995). cited by other .

Travis, J., X-rays speed healing of rat spinal cords, Science News 150:214, (1996). cited by other .

Urlaub et al., Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions, Somatic Cell and Molecular Genetics 12(6):555-566 (1986). cited by

other.

Walden et al., "Major Histocompatibility Complex-Restricted and Unrestricted Activation of Helper T Cell Lines by Liposome-Bound Antigens", J. Mol. Cell. Immunol., 2:191-197; (1986). cited by other .

Wang et al. Implications for bcd mRNA localization from spatial distribution of exu protein in Drosophila oogenesis Nature 369:400-403 (1994). cited by other .

Wawrzynczak et al., "Molecular and biological properties of an abrin A chain

immunotoxin designed for therapy of human small cell lung cancer", Br. J. Cancer, 66:361-366; (1992). cited by other .

Wellhoner et al., "Uptake and Concentration of Bioactive Macromolecules by K562 Cells via the Transferrin Cycle Utilizing an Acid-labile Transferrin Conjugate", J. Biol. Chem., 266(7):4309-4314; (1991). cited by other .

Wu et al. Resonance Energy Transfer: Methods and Application Analytical Biochemistry 218:1-13 (1994). cited by other.

Primary Examiner: Carlson; Karen Cochrane Assistant Examiner: Liu; Samuel W. Attorney, Agent or Firm: Yosner, Esq.; Alan G. Northrop, Esq.; Lara A. Pletragallo, Bosick & Gordon LLP

Parent Case Text

RELATED APPLICATIONS

Benefit of priority under 35 U.S.C. .sctn.119(e) is claimed to U.S. provisional application Ser. No. 60/189,691, filed Mar. 15, 2000, to Bryan et al., entitled "RENILLA RENIFORMIS FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THE FLUORESCENT PROTEINS AND THE USE THEREOF IN DIAGNOSTICS, HIGH THROUGHPUT SCREENING AND NOVELTY ITEMS" is claimed.

This application is related to allowed U.S. application Ser. No. 09/277,716, filed Mar. 26, 1999, to Bruce Bryan and Christopher Szent-Gyorgyi, entitled "LUCIFERASES, FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THE LUCIFERASES AND FLUORESCENT PROTEINS AND THE USE THEREOF IN DIAGNOSTICS, HIGH THROUGHPUT SCREENING AND NOVELTY ITEMS." This application is related to International PCT application No. WO 99/49019 to Bruce Bryan and Prolume, LTD., entitled "LUCIFERASES, FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THE LUCIFERASES AND

FLUORESCENT PROTEINS AND THE USE THEREOF IN DIAGNOSTICS, HIGH THROUGHPUT SCREENING AND NOVELTY ITEMS."

This application is also related to subject matter in U.S. application Ser. No. 08/757,046, filed Nov. 25, 1996, to Bruce Bryan entitled "BIOLUMINESCENT NOVELTY ITEMS", now U.S. Pat. No. 5,876,995, issued Mar. 2, 1999, and in U.S. application Ser. No. 08/597,274, filed Feb. 6, 1996, to Bruce Bryan, entitled "BIOLUMINESCENT NOVELTY ITEMS". This application is also related to U.S. application Ser. No. 08/908,909, filed Aug. 8, 1997, to Bruce Bryan entitled "DETECTION AND VISUALIZATION OF NEOPLASTIC TISSUE AND OTHER TISSUES". The application is also related to U.S. application Ser. No. 08/990,103, filed Dec. 12, 1997, to Bruce Bryan entitled "APPARATUS AND METHODS FOR DETECTING AND IDENTIFYING INFECTIOUS AGENTS".

Where permitted, the subject matter of each of the above noted applications and patents is herein incorporated by reference in its entirety.

Claims	

What is claimed is:

1. An isolated nucleic acid molecule encoding a Renilla reniformis green fluorescent protein, comprising a nucleotide sequence that encodes the protein of SEQ ID NO. 27 or a green fluorescent protein encoded by a nucleic acid molecule of Renilla reniformis having at least 80% sequence identity thereto.

2. An isolated nucleic acid molecule of claim 1 that encodes a protein having at least 90% sequence identity to the protein of SEQ ID NO. 27.

3. The isolated nucleic acid molecule of claim 1, comprising a nucleotide sequence selected from the group consisting of: (a) the coding portion of the nucleotide sequence set forth in any of SEQ ID NOs. 23-25; (b) a nucleotide sequence that hybridizes under conditions of 0.1.times. standard saline phosphate EDTA buffer, 0.1% SDS at 65.degree. C. to the nucleotide sequence of (a); and (c) a nucleotide sequence comprising degenerate codons of (a) or (b).

4. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid is DNA.

5. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid is RNA.

6. A nucleic acid probe or primer, comprising at least 14 contiguous nucleotides selected from the nucleotide sequence set of claim 1.

7. The probe or primer of claim 6, comprising at least 16 contiguous nucleotides selected from the nucleotide sequence in claim 1.

8. The probe or primer of claim 7, comprising at least 30 contiguous nucleotides.

9. A plasmid, comprising the nucleotide sequence of claim 1.

10. A cell comprising the plasmid of claim 9, wherein the cell is selected from the group consisting of a bacterial cell, a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

11. The plasmid of claim 9 that is an expression vector, further comprising: a promoter element; a cloning site for the introduction of the nucleic acid molecule; and a marker gene; wherein the nucleic acid comprising the cloning site is positioned between nucleic acids encoding the promoter element and the green fluorescent protein and wherein the nucleic acid encoding the green fluorescent protein is operatively linked to the promoter element.

12. The plasmid of claim 11, wherein the marker gene comprises a nucleotide sequence encoding a luciferase.

13. A recombinant host cell, comprising the plasmid of claim 9.

14. The cell of claim 13, wherein the cell is selected from the group consisting of a bacterial cell, a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

15. A reporter gene construct, comprising the nucleic acid molecule of claim 1.

16. A nucleic acid construct, comprising the nucleotide sequence encoding a luciferase and a nucleotide sequence of claim 1 that encodes a Renilla reniformis fluorescent protein (GFP).

17. The nucleic acid construct of claim 16, wherein the luciferase is a Renilla mulleri luciferase, a Gaussia luciferase or a Pleuromamma luciferase.

18. The nucleic acid construct of claim 17, wherein the Gaussia luciferase is a Gaussia princeps

luciferase.

19. The nucleic acid construct of claim 16, wherein the luciferase is encoded by: a nucleotide sequence set forth in SEQ ID NO. 17, SEQ ID NO. 19, or SEQ ID NO. 28; a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO. 18, SEQ ID NO. 20 or SEQ ID NO. 29; and a nucleotide sequence that hybridizes under the condition of claim 3 to the nucleotide sequence set forth in SEQ ID NO. 19, or SEQ ID NO. 28.

20. The nucleic acid construct of claim 16, that is DNA.

21. The nucleic acid construct of claim 16, that is RNA.

22. A plasmid, comprising the nucleic acid construct of claim 16.

23. The plasmid of claim 22, further comprising a nucleotide sequence encoding: a promoter element; and a selectable marker; wherein, the nucleotide sequence encoding the luciferase and Renilla reniformis GFP is operatively linked to the promoter element, whereby the luciferase and Renilla reniformis GFP are expressed.

24. The construct of claim 16, wherein the luciferase and the GFP are encoded by a polycistronic message.

25. The construct of claim 16, wherein the encoded luciferase and Renilla reniformis GFP comprise a fusion protein.

26. The nucleic acid construct of claim 25, wherein the nucleotide sequence that encoding the luciferase and GFP are not contiguous.

27. The nucleic acid construct of claim 26, comprising a nucleotide sequence that encodes a ligand binding domain of a target protein.

28. The construct of claim 16, wherein the luciferase is Renilla reniformis luciferase.

29. A recombinant host cell, comprising the plasmid of claim 22.

Description

FIELD OF INVENTION

Provided herein are isolated and purified nucleic acids and encoded fluorescent proteins from Renilla reniformis and uses thereof.

BACKGROUND OF THE INVENTION

Luminescence is a phenomenon in which energy is specifically channeled to a molecule to produce an excited state. Return to a lower energy state is accompanied by release of a photon (h.gamma.). Luminescence includes fluorescence, phosphorescence, chemiluminescence and bioluminescence. Bioluminescence is the process by which living organisms emit light that is visible to other organisms. Luminescence may be represented as follows: A+B fwdarw.X*+Y X*.fwdarw.X+hv, where X* is an electronically excited molecule and h.gamma. represents light emission upon return of X* to a lower energy state. Where the luminescence is bioluminescence, and creation of the excited state is derived from an enzyme catalyzed reaction. The color of the emitted light in a bioluminescent (or chemiluminescent or other luminescent) reaction is characteristic of the excited molecule, and is independent from its source of excitation and temperature.

An essential condition for bioluminescence is the use of molecular oxygen, either bound or free in the presence of a luciferase. Luciferases, are oxygenases, that act on a substrate, luciferin, in the presence of molecular oxygen and transform the substrate to an excited state. Upon return to a lower energy level, energy is released in the form of light (for reviews see, e.g., McElroy et al. (1966) in Molecular Architecture in Cell Physiology, Hayashi et al., eds., Prentice-Hall, Inc., Englewood Cliffs, N.J., pp. 63-80; Ward et al., Chapter 7 in Chemi-and Bioluminescence, Burr, ed., Marcel Dekker, Inc. NY, pp. 321-358; Hastings, J. W. in (1995) Cell Physiology Source Book, N. Sperelakis (ed.), Academic Press, pp 665-681; Luminescence, Narcosis and Life in the Deep Sea, Johnson, Vantage Press, NY, see, esp. pp. 50-56).

Though rare overall, bioluminescence is more common in marine organisms than in terrestrial organisms. Bioluminescence has developed from as many as thirty evolutionarily distinct origins and, thus, is manifested in a variety of ways so that the biochemical and physiological mechanisms responsible for bioluminescence in different organisms are distinct. Bioluminescent species span many genera and include microscopic organisms, such as bacteria (primarily marine bacteria including Vibrio species), fungi, algae and dinoflagellates, to marine organisms, including arthropods, mollusks, echinoderms, and chordates, and terrestrial organisms including annelid worms and insects.

Assays Employing Bioluminescence

During the past twenty years, high-sensitivity biochemical assays used in research and in medicine have increasingly employed luminescence and fluorescence rather than radioisotopes. This change has been driven partly by the increasing expense of radioisotope disposal and partly by the need to find more rapid and convenient assay methods. More recently, the need to perform biochemical assays in situ in living cells and whole animals has driven researchers toward protein-based luminescence and fluorescence. The uses of firefly luciferase for ATP assays, aequorin and obelin as calcium reporters, Vargula luciferase as a neurophysiological indicator, and the Aequorea green fluorescent protein as a protein tracer and pH indicator show the potential of bioluminescence-based methods in research laboratories.

Bioluminescence is also beginning to directly impact medicine and biotechnology; for example, Aequorea green fluorescent protein (GFP) is employed to mark cells in murine model systems and as a reporter in high throughput drug screening. Renilla luciferase is under development for use in diagnostic platforms.

Bioluminescence Generating Systems

Bioluminescence, as well as other types of chemiluminescence, is used for quantitative determinations of specific substances in biology and medicine. For example, luciferase genes have been cloned and exploited as reporter genes in numerous assays, for many purposes. Since the different luciferase systems have different specific requirements, they may be used to detect and quantify a variety of substances. The majority of commercial bioluminescence applications are based on firefly (Photinus pyralis) luciferase. One of the first and still widely used assays involves the use of firefly luciferase to detect the presence of ATP. It is also used to detect and quantify other substrates or co-factors in the reaction. Any reaction that produces or utilizes NAD(H), NADP(H) or long chain aldehyde, either directly or indirectly, can be coupled to the light-emitting reaction of bacterial luciferase.

Another luciferase system that has been used commercially for analytical purposes is the Aequorin system. The purified jellyfish photoprotein, aequorin, is used to detect and quantify intracellular Ca.sup.2+ and its changes under various experimental conditions. The Aequorin photoprotein is relatively small (.about.20 kDa), nontoxic, and can be injected into cells in quantities adequate to detect calcium over a large concentration range (3.times.10.sup.-7 to 10.sup.-4 M).

Because of their analytical utility, luciferases and substrates have been studied and well-

characterized and are commercially available (e.g., firefly luciferase is available from Sigma, St. Louis, Mo., and Boehringer Mannheim Biochemicals, Indianapolis, Ind.; recombinantly produced firefly luciferase and other reagents based on this gene or for use with this protein are available from Promega Corporation, Madison, Wis.; the aequorin photoprotein luciferase from jellyfish and luciferase from Renilla are commercially available from Sealite Sciences, Bogart, Ga.; coelenterazine, the naturally-occurring substrate for these luciferases, is available from Molecular Probes, Eugene, Oreg.). These luciferases and related reagents are used as reagents for diagnostics, quality control, environmental testing and other such analyses.

Because of the utility of luciferases as reagents in analytical systems and the potential for use in high throughput screening systems, there is a need to identify and isolate a variety of luciferases that have improved or different spectral properties compared to those presently available. For all these reasons, it would be advantageous to have luciferases from a variety of species, such as Gaussia and various Renilla species available.

Fluorescent Proteins

Reporter genes, when co-transfected into recipient cells with a gene of interest, provide a means to detect transfection and other events. Among reporter genes are those that encode fluorescent proteins. The bioluminescence generating systems described herein are among those used as reporter genes. To increase the sensitivity bioluminescence generating systems have been combined with fluorescent compounds and proteins, such as naturally fluorescent phycobiliproteins. Also of interest are the fluorescent proteins that are present in a variety of marine invertebrates, such as the green and blue fluorescent proteins, particularly the green fluorescent protein (GFP) of Aequorea victoria.

The green fluorescent proteins (GFP) constitute a class of chromoproteins found only among certain bioluminescent coelenterates. These accessory proteins are fluorescent and function as the ultimate bioluminescence emitter in these organisms by accepting energy from enzyme-bound, excited-state oxyluciferin (e.g., see Ward et al. (1979) J. Biol. Chem. 254:781-788; Ward et al. (1978) Photochem. Photobiol. 27:389-396; Ward et al. (1982) Biochemistry 21:4535-4540).

The best characterized GFPs are those isolated from the jellyfish species Aequorea, particularly Aequorea victoria (A. victoria) and Aequorea forskalea (Ward et al. (1982) Biochemistry 21:4535-4540; Prendergast et al. (1978) Biochemistry 17:3448-3453). Purified A. victoria GFP is a monomeric protein of about 27 kDa that absorbs blue light with excitation wavelength maximum of 395 nm, with a minor peak at 470 nm, and emits green fluorescence with an emission wavelength of about 510 nm and a minor peak near 540 nm (Ward et al. (1979)

Photochem. Photobiol. Rev 4:1-57). This GFP has certain limitations. The excitation maximum of the wildtype GFP is not within the range of wavelengths of standard fluorescein detection optics.

The detection of green fluorescence does not require any exogenous substrates or co-factors. Instead, the high level of fluorescence results from the intrinsic chromophore of the protein. The chromophore includes modified amino acid residues within the polypeptide chain. For example, the fluorescent chromophore of A. victoria GFP is encoded by the hexapeptide sequence, FSYGVQ, encompassing amino acid residues 64-69. The chromophore is formed by the intramolecular cyclization of the polypeptide backbone at residues Ser65 and Gly67 and the oxidation of the .alpha.-.beta. bond of residue Tyr66 (e.g., see Cody et al. (1993) Biochemistry 32:1212-1218; Shimomura (1978) FEBS Letters 104:220-222; Ward et al. (1989) Photochem. Photobiol. 49:62S). The emission spectrum of the isolated chromophore and the denatured protein at neutral pH do not match the spectrum of the native protein, suggesting that chromophore formation occurs post-translationally (e.g., see Cody et al. (1993) Biochemistry 32:1212-1218).

In addition, the crystal structure of purified A. victoria GFP has been determined (e.g., see Ormo (1996) Science 273:1392-1395). The predominant structural features of the protein are an 11-stranded .beta. barrel that forms a nearly perfect cylinder wrapping around a single central .alpha.-helix, which contains the modified p-hydroxybenzylideneimadaxolidinone chromophore. The chromophore is centrally located within the barrel structure and is completely shielded from exposure to bulk solvent.

DNA encoding an isotype of A. victoria GFP has been isolated and its nucleotide sequence has been determined (e.g., see Prasher (1992) Gene 111:229-233). The A. victoria cDNA contains a 714 nucleotide open reading frame that encodes a 238 amino acid polypeptide of a calculated M.sub.r of 26,888 Da. Recombinantly expressed A. victoria GFPs retain their ability to fluoresce in vivo in a wide variety organisms, including bacteria (e.g., see Chalfie et al. (1994) Science 263:802-805; Miller et al. (1997) Gene 191:149-153), yeast and fungi (Fey et al. (1995) Gene 165:127-130; Straight et al. (1996) Curr. Biol. 6:1599-1608; Cormack et al. (1997) Microbiology 143:303-311), Drosophila (e.g., see Wang et al. (1994) Nature 369:400-403; Plautz (1996) Gene 173:83-87), plants (Heinlein et al. (1995); Casper et al. (1995). Aequorea GFP vectors and isolated Aequorea GFP proteins have been used as markers for measuring gene expression, cell migration and localization, microtubule formation and assembly of functional ion channels (e.g., see Terry et al. (1995) Biochem. Biophys. Res. Commun. 217:21-27; Kain et al. (1995) Biotechniques 19:650-655). The A. victoria GFP, however, is not ideal for use in analytical and diagnostic

United States Patent: 7109315

processes. Consequently GFP mutants have been selected with the hope of identifying mutants that have single excitation spectral peaks shifted to the red.

In fact a stated purpose in constructing such mutants has been to attempt to make the A. victoria GFP more like the GFP from Renilla, but which has properties that make it far more ideal for use as an analytical tool. For many practical applications, the spectrum of Renilla GFP is preferable to that of the Aequorea GFP, because wavelength discrimination between different fluorophores and detection of resonance energy transfer are easier if the component spectra are tall and narrow rather than low and broad (see, U.S. Pat. No. 5,625,048). Furthermore, the longer wavelength excitation peak (475 nm) of Renilla GFP is almost ideal for fluorescein filter sets and is resistant to photobleaching, but has lower amplitude than the shorter wavelength peak at 395 nm, which is more susceptible to photobleaching (Chalfie et al. (1994) Science 263:802-805).

There exists a phylogenetically diverse and largely unexplored repertoire of bioluminescent proteins that are a reservoir for future development. For these reasons, it would be desirable to have a variety of new luciferases and fluorescent proteins, particularly, Renilla reniformis GFP available rather than use muteins of A. victoria GFP. Published International PCT application No. WO 99/49019 (see, also, allowed U.S. application Ser. No. 09/277,716) provides a variety of GFPs including those from Renilla species. It remains desirable to have a variety of GFPs and luciferases available in order to optimize systems for particular applications and to improve upon existing methods. Therefore, it is an object herein to provide isolated nucleic acid molecules encoding Renilla reniformis GFP and the protein encoded thereby. It is also an object herein to provide bioluminescence generating systems that include the luciferases, luciferins, and also include Renilla reniformis GFP.

SUMMARY OF THE INVENTION

"Isolated nucleic acid molecules that encode Renilla reniformis fluorescent proteins are provided. Nucleic acid probes and primers derived therefrom are also provided. Functionally equivalent nucleic acids, such as those that hybridize under conditions of high stringency to the disclosed molecules and those that have high sequence identity, are also contemplated. Nucleic acid molecules and the encoded proteins are set forth in SEQ ID. NOs. 23-27, an exemplary mutein is set forth in SEQ ID. NO. 33. Also contemplated are nucleic acid molecules that encode the protein set forth in SEQ ID. NO. 27."

Host cells, including bacterial, yeast and mammalian host cells, and plasmids for expression of the nucleic acids encoding the Renilla reniformis green fluorescent protein (GFP), are also provided. Combinations of luciferases and the Renilla reniformis GFP are also provided.

The genes can be modified by substitution of codons optimized for expression in selected host cells or hosts, such as humans and other mammals, or can be mutagenized to alter the emission properties. Mutations that alter spectral properties are also contemplated.

Such mutations may be identified by substituting each codon with one encoding another amino acid, such as alanine, and determining the effect on the spectral properties of the resulting protein. Particular regions of interest are those in which corresponding the sites mutated in other GFPs, such Aequora to produce proteins with altered spectral properties are altered.

The Renilla reniformis GFP may be used in combination with nucleic acids encoding luciferases, such as those known to those of skill in the art and those that are described in copending allowed U.S. application Ser. No. 09/277,716 (see, also, Published International PCT application No. WO 99/49019).

Compositions containing the Renilla reniformis GFP or the Renilla reniformis GFP and luciferase combination are provided. The compositions can take any of a number of forms, depending on the intended method of use therefor. In certain embodiments, for example, the compositions contain a Gaussia luciferase, Gaussia luciferase peptide or Gaussia luciferase fusion protein, formulated for use in luminescent novelty items, immunoassays, donors in FET (fluorescent energy transfer) assays, FRET (fluorescent resonance energy transfer) assays, HTRF (homogeneous time-resolved fluorescence) assays or used in conjunction with multi-well assay devices containing integrated photodetectors, such as those described herein.

The bioluminescence-generating system includes, in addition to the luciferase, a Renilla reniformis GFP or mutated form thereof. These compositions can be used in a variety of methods and systems, such as those included in conjunction with diagnostic systems for the in vivo detection of neoplastic tissues and other tissues, such as those methods described herein.

Combinations of the Renilla reniformis GFP with articles of manufacture to produce novelty items are provided. These novelty items are designed for entertainment, recreation and amusement, and include, but are not limited to: toys, particularly squirt guns, toy cigarettes, toy "Halloween" eggs, footbags and board/card games; finger paints and other paints, slimy play material; textiles, particularly clothing, such as shirts, hats and sports gear suits, threads and yarns; bubbles in bubble making toys and other toys that produce bubbles; balloons; figurines; personal items, such as cosmetics, bath powders, body lotions, gels, powders and creams, nail polishes, make-up, toothpastes and other dentifrices, soaps, body paints, and bubble bath; items such as inks, paper; foods, such as gelatins, icings and frostings; fish food containing luciferins and transgenic fish, particularly transgenic fish that express a luciferase; plant food containing a luciferin or luciferase, preferably a luciferin for use with transgenic plants that express luciferase; and beverages, such as beer, wine, champagne, soft drinks, and ice cubes and ice in other configurations; fountains, including liquid "fireworks" and other such jets or sprays or aerosols of compositions that are solutions, mixtures, suspensions, powders, pastes, particles or other suitable form. The combinations optionally include a bioluminescence generating system. The bioluminescence generating systems can be provided as two compositions: a first composition containing a luciferase and a second composition containing one or more additional components of a bioluminescence generating system.

Any article of manufacture that can be combined with a bioluminescence-generating system as provided herein and thereby provide entertainment, recreation and/or amusement, including use of the items for recreation or to attract attention, such as for advertising goods and/or services that are associated with a logo or trademark is contemplated herein. Such uses may be in addition to or in conjunction with or in place of the ordinary or normal use of such items. As a result of the combination, the items glow or produce, such as in the case of squirt guns and fountains, a glowing fluid or spray of liquid or particles. The novelty in the novelty item derives from its bioluminescence.

GFPS

"Isolated nucleic acids that encode GFP from Renilla reniformis are provided herein. Also provided are isolated and purified nucleic acids that encode a component of the bioluminescence generating system and the green fluorescent protein (GFP) (see SEQ ID NOs. 23-27). In particular, nucleic acid molecules that encode Renilla reniformis green fluorescent protein (GFPs) and nucleic acid probes and primers derived therefrom are provided (see SEQ ID NOs. 23-26).

Nucleic acid probes and primers containing 14, 16, 30, 100 or more contiguous nucleotides from any of SEQ ID NOs. 23-26 are provided. Nucleic acid probes can be labeled, if needed, for detection, containing at least about 14, preferably at least about 16, or, if desired, 20 or 30 or more, contiguous nucleotides of the sequence of nucleotides encoding the Renilla reniformis GFP."

Methods using the probes for the isolation and cloning of GFP-encoding DNA in Renilla reniformis are also provided. Vectors containing DNA encoding the Renilla reniformis GFP are provided. In particular, expression vectors that contain DNA encoding a Renilla reniformis or in operational association with a promoter element that allows for the constitutive or inducible

expression of Renilla reniformis are provided.

The vectors are capable of expressing the Renilla reniformis GFP in a wide variety of host cells. Vectors for producing chimeric Renilla reniformis GFP/luciferase fusion proteins and/or polycistronic mRNA containing a promoter element and a multiple cloning site located upstream or downstream of DNA encoding Renilla reniformis GFP are also provided.

Recombinant cells containing heterologous nucleic acid encoding a Renilla reniformis GFP are also provided. Purified Renilla reniformis GFP peptides and compositions containing the Renilla GFPs and GFP peptides alone or in combination with at least one component of a bioluminescence-generating system, such as a Renilla luciferase, are provided. The Renilla GFP and GFP peptide compositions can be used, for example, to provide fluorescent illumination of novelty items or used in methods of detecting and visualizing neoplastic tissue and other tissues, detecting infectious agents using immunoassays, such homogenous immunoassays and in vitro fluorescent-based screening assays using multi-well assay devices, or provided in kits for carrying out any of the above-described methods. In particular, these proteins may be used in FP (fluorescence polarization) assays, FET (fluorescent energy transfer) assays, FRET (fluorescent resonance energy transfer) assays and HTRF (homogeneous time-resolved fluorescence) assays and also in the BRET assays and sensors provided herein.

Non-radioactive energy transfer reactions, such as FET or FRET, FP and HTRF assays, are homogeneous luminescence assays based on energy transfer and are carried out between a donor luminescent label and an acceptor label (see, e.g., Cardullo et al. (1988) Proc. Natl. Acad. Sd. U.S.A. 85:8790-8794; Peerce et al. (1986) Proc. Natl. Acad. Sci. U.S.A. 83:8092-8096; U.S. Pat. No. 4,777,128; U.S. Pat. No. 5,162,508; U.S. Pat. No. 4,927,923; U.S. Pat. No. 5,279,943; and International PCT Application No. WO 92/01 225). Non-radioactive energy transfer reactions using GFPs have been developed (see, International PCT application Nos. WO 98/02571 and WO 97/28261). Non-radioactive energy transfer reactions using GFPs and luciferases, such as a luciferase and its cognate GFP (or multimers thereof), such as in a fusion protein, are contemplated herein.

Nucleic acids that exhibit substantial sequence identity with the nucleic acids provided herein are also contemplated. These are nucleic acids that can be produced by substituting codons that encode conservative amino acids and also nucleic acids that exhibit at least about 80%, preferably 90 or 95% sequence identity. Sequence identity refers to identity as determined using standard programs with default gap penalties and other defaults as provided by the manufacturer thereof.

The nucleic acids provide an opportunity to produce luciferases and GFPs, which have advantageous application in all areas in which luciferase/luciferins and GFPs have application. The nucleic acids can be used to obtain and produce GFPs and GFPs from other, particularly Renilla, species using the probes described herein that correspond to conserved regions. These GFPs provide a means to amplify the output signal of bioluminescence generating systems. Renilla GFP has a single excitation absorbance peak in blue light (and around 498 nm) and a predominantly single emission peak around 510 nm (with a small shoulder near 540 nm). This spectrum provides a means for it to absorb blue light and efficiently convert it to green light. This results in an amplification of the output. When used in conjunction with a bioluminescence generating system that yields blue light, such as Aequorea or Renilla or Vargula (Cypridina), the output signal for any application, including diagnostic applications, is amplified. In addition, this green light can serve as an energy donor in fluorescence-based assays, such as fluorescence polarized assays, FET (fluorescent energy transfer) assays, FRET (fluorescent resonance energy transfer) assays and HTRF (homogeneous time-resolved fluorescence) assays. Particular assays, herein referred to as BRET (bioluminescence resonance energy transfer assays in which energy is transferred from a bioluminescence reaction of a luciferase to a fluorescent protein), arc provided.

Non-radioactive energy transfer reactions, such as FET or FRET, FP and HTRF assays, are homogeneous luminescence assays based on energy transfer that are carried out between a donor luminescent label and an acceptor label (see, e.g., Cardullo et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85:8790-8794; Peerce et al. (1986) Proc. Natl. Acad. Sc. U.S.A. 83:8092-8096; U.S. Pat. No. 4,777,128; U.S. Pat. No. 5,162,508; U.S. Pat. No. 4,927,923; U.S. Pat. No. 5,279,943; and International PCT Application No. WO 92/01225). Non-radioactive energy transfer reactions using GFPs have been developed (see, International PCT application Nos. WO 98/02571 and WO 97/28261).

Mutagenesis of the GFPs is contemplated herein, particularly mutagenesis that results in modified GFPs that have red-shifted excitation and emission spectra. The resulting systems have higher output compared to the unmutagenized forms. These GFPs may be selected by random mutagenesis and selection for GFPs with altered spectra or by selected mutagenesis of the chromophore region of the GFP.

"The DNA may be introduced as a linear DNA molecule (fragment) or may be included in an expression vector for stable or transient expression of the encoding DNA. In certain embodiments, the cells that contain DNA or RNA encoding a Renilla GFP also express the recombinant Renilla GFP or polypeptide. It is preferred that the cells selected to express functional GFPs that retain the ability to fluorescence and that are not toxic to the host cell. In

some embodiments, cells may also include heterologous nucleic acid encoding a component of a bioluminescence-generating system, preferably a photoprotein or luciferase. In preferred embodiments, the nucleic acid encoding the bioluminescence-generating system component is isolated from the species Aequorea, Vargula, Pleuromamma, Ptilosarcus or Renilla. In more preferred embodiments, the bioluminescence-generating system component is a Renilla reniformis luciferase or mullen including the amino acid sequence set forth in SEQ ID NO. 19 or the Pleuromamma luciferase set forth in SEQ ID NO. 28, or the Gaussia luciferase set forth in SEQ ID NO. 19."

The GFPs provided herein may be used in combination with any suitable bioluminescence generating system, but is preferably used in combination with a Renilla or Aequorea, Pleuromamma or Gaussia luciferase.

Purified Renilla GFPs, particularly purified Renilla reniformis GFP peptides are provided. Presently preferred Renilla GFP for use in the compositions herein is Renilla reniformis GFP including the sequence of amino acids set forth above and in the Sequence Listing.

Fusions of the nucleic acid, particularly DNA, encoding Renilla GFP with DNA encoding a luciferase are also provided herein.

The cells that express functional luciferase and/or GFP, which may be used alone or in conjunction with a bioluminescence-generating system, in cell-based assays and screening methods, such as those described herein.

Presently preferred host cells for expressing GFP and luciferase are bacteria, yeasts, fungi, plant cells, insect cells and animal cells.

The luciferases and GFPs or cells that express them also may be used in methods of screening for bacterial contamination and methods of screening for metal contaminants. To screen for bacterial contamination, bacterial cells that express the luciferase and/or GFP are put in autoclaves or in other areas in which testing is contemplated. After treatment or use of the area, the area is tested for the presence of glowing bacteria. Presence of such bacteria is indicative of a failure to eradicate other bacteria. Screening for heavy metals and other environmental contaminants can also be performed with cells that contain the nucleic dependent upon the particular heavy metal or contaminant.

The systems and cells provided herein can be used for high throughout screening protocols, intracellular assays, medical diagnostic assays, environmental testing, such as tracing bacteria in

water supplies, in conjunction with enzymes for detecting heavy metals, in spores for testing autoclaves in hospital, foods and industrial autoclaves. Non-pathogenic bacteria containing the systems can be included in feed to animals to detect bacterial contamination in animal products and in meats.

Compositions containing a Renilla GFP are provided. The compositions can take any of a number of forms, depending on the intended method of use therefor. In certain embodiments, for example, the compositions contain a Renilla GFP or GFP peptide, preferably Renilla mulleri GFP or Renilla reniformis GFP peptide, formulated for use in luminescent novelty items, immunoassays, FET (fluorescent energy transfer) assays, FRET (fluorescent resonance energy transfer) assays, HTRF (homogeneous time-resolved fluorescence) assays or used in conjunction with multi-well assay devices containing integrated photodetectors, such as those described herein. In other instances, the GFPs are used in beverages, foods or cosmetics.

Compositions that contain a Renilla reniformis GFP or GFP peptide and at least one component of a bioluminescence-generating system, preferably a luciferase, luciferin or a luciferase and a luciferin, are provided. In preferred embodiments, the luciferase/luciferin bioluminescencegenerating system is selected from those isolated from: an insect system, a coelenterate system, a ctenophore system, a bacterial system, a mollusk system, a crustacea system, a fish system, an annelid system, and an earthworm system. Bioluminescence-generating systems include those isolated from Renilla, Aequorea, and Vargula, Gaussia and Pleuromamma.

Combinations containing a first composition containing a Renilla reniformis GEP or Ptilosarcus GFP or mixtures thereof and a second composition containing a bioluminescence-generating system for use with inanimate articles of manufacture to produce novelty items are provided. These novelty items, which are articles of manufacture, are designed for entertainment, recreation and amusement, and include, but are not limited to: toys, particularly squirt guns, toy cigarettes, toy "Halloween" eggs, footbags and board/card games; finger paints and other paints, slimy play material; textiles, particularly clothing, such as shirts, hats and sports gear suits, threads and yarns; bubbles in bubble making toys and other toys that produce bubbles; balloons; figurines; personal items, such as bath powders, body lotions, gels, powders and creams, nail polishes, cosmetics including make-up, toothpastes and other dentifrices, soaps, cosmetics, body paints, and bubble bath, bubbles made from non-detergent sources, particularly proteins such as albumin and other non-toxic proteins; in fishing lures and glowing transgenic worms, particularly crosslinked polyacrylamide containing a fluorescent protein and/or components of a bioluminescence generating system, which glow upon contact with water; items such as inks, paper; foods, such as gelatins, icings and frostings; fish food containing luciferins and transgenic animals, such as transgenic fish, worms, monkeys, rodents, ungulates, ovine, ruminants and

United States Patent: 7109315

others, that express a luciferase and/or Renilla reniformis GFP; transgenic worms that express Renilla reniformis GFP and are used as lures; plant food containing a luciferin or luciferase, preferably a luciferin for use with transgenic plants that express luciferase and Renilla reniformis GFP, transgenic plants that express Renilla reniformis GFP, particularly ornamental plants, such as orchids, roses, and other plants with decorative flowers; transgenic plants and animals in which the Renilla reniformis GFP is a marker for tracking introduction of other genes; and beverages, such as beer, wine, champagne, soft drinks, milk and ice cubes and ice in other configurations containing Renilla reniformis GFP; fountains, including liquid "fireworks" and other such jets or sprays or aerosols of compositions that are solutions, mixtures, suspensions, powders, pastes, particles or other suitable forms.

Any article of manufacture that can be combined with a bioluminescence-generating system and Renilla reniformis GFP or with just a Renilla reniformis GFP, as provided herein, that thereby provides entertainment, recreation and/or amusement, including use of the items for recreation or to attract attention, such as for advertising goods and/or services that are associated with a logo or trademark is contemplated herein. Such uses may be in addition to or in conjunction with or in place of the ordinary or normal use of such items. As a result of the combination, the items glow or produce, such as in the case of squirt guns and fountains, a glowing fluid or spray of liquid or particles.

Methods for diagnosis and visualization of tissues in vivo or in situ using compositions containing a Renilla reniformis GFP and/or a Renilla reniformis or mulleri luciferase or others of the luciferases and/or GFPs provided herein are provided. For example, the Renilla reniformis GFP protein can be used in conjunction with diagnostic systems that rely on bioluminescence for visualizing tissues in situ. The systems are particularly useful for visualizing and detecting neoplastic tissue and specialty tissue, such as during non-invasive and invasive procedures. The systems include compositions containing conjugates that include a tissue specific, particularly a tumor-specific, targeting agent linked to a targeted agent, a Renilla reniformis GFP, a luciferase or luciferin. The systems also include a second composition that contains the remaining components of a bioluminescence generating reaction and/or the Renilla reniformis GFP. In some embodiments, all components, except for activators, which are provided in situ or are present in the body or tissue, are included in a single composition.

Methods for diagnosis and visualization of tissues in vivo or in situ using compositions containing a Gaussia luciferase are provided. For example, the Gaussia luciferase or Gaussia luciferase peptide can be used in conjunction with diagnostic systems that rely on bioluminescence for visualizing tissues in situ. The systems are particularly useful for visualizing and detecting neoplastic tissue and specialty tissue, such as during non-invasive and invasive procedures. The systems include compositions containing conjugates that include a tissue specific, particularly a tumor-specific, targeting agent linked to a targeted agent, a Gaussia luciferase, a GFP or luciferin. The systems also include a second composition that contains the remaining components of a bioluminescence generating reaction and/or the Gaussia luciferase. In some embodiments, all components, except for activators, which are provided in situ or are present in the body or tissue, are included in a single composition.

In particular, the diagnostic systems include two compositions. A first composition that contains conjugates that, in preferred embodiments, include antibodies directed against tumor antigens conjugated to a component of the bioluminescence generating reaction, a luciferase or luciferin, preferably a luciferase are provided. In certain embodiments, conjugates containing tumor-specific targeting agents are linked to luciferases or luciferins. In other embodiments, tumor-specific targeting agents are linked to microcarriers that are coupled with, preferably more than one of the bioluminescence generating components, preferably more than one luciferase molecule.

The second composition contains the remaining components of a bioluminescence generating system, typically the luciferin or luciferase substrate. In some embodiments, these components, particularly the luciferin are linked to a protein, such as a serum albumin, or other protein carrier. The carrier and time release formulations permit systemically administered components to travel to the targeted tissue without interaction with blood cell components, such as hemoglobin that deactivates the luciferin or luciferase.

Methods for diagnosing diseases, particularly infectious diseases, using chip methodology (see, e.g., copending U.S. application Ser. No. 08/990,103) a luciferase/luciferin bioluminescence-generating system and a Renilla reniformis GFP are provided. In particular, the chip includes an integrated photodetector that detects the photons emitted by the bioluminescence-generating system, particularly using luciferase encoded by the nucleic acids provided herein and/or Renilla reniformis GFP.

In one embodiment, the chip is made using an integrated circuit with an array, such as an X-Y array, of photodetectors. The surface of circuit is treated to render it inert to conditions of the diagnostic assays for which the chip is intended, and is adapted, such as by derivatization for linking molecules, such as antibodies. A selected antibody or panel of antibodies, such as an antibody specific for a bacterial antigen, is affixed to the surface of the chip above each photodetector. After contacting the chip with a test sample, the chip is contacted with a second antibody linked to a Renilla GFP, a chimeric antibody-Renilla GFP fusion protein or an antibody linked to a component of a bioluminescence generating system, such as a luciferase or luciferin,

that are specific for the antigen. The remaining components of the bioluminescence generating reaction are added, and, if any of the antibodies linked to a component of a bioluminescence generating system are present on the chip, light will be generated and detected by the adjacent photodetector. The photodetector is operatively linked to a computer, which is programmed with information identifying the linked antibodies, records the event, and thereby identifies antigens present in the test sample.

Methods for generating chimeric GFP fusion proteins are provided. The methods include linking DNA encoding a gene of interest, or portion thereof, to DNA encoding a GFP coding region in the same translational reading frame. The encoded-protein of interest may be linked in-frame to the amino- or carboxyl-terminus of the GFP. The DNA encoding the chimeric protein is then linked in operable association with a promoter element of a suitable expression vector. Alternatively, the promoter element can be obtained directly from the targeted gene of interest and the promoter-containing fragment linked upstream of the GFP coding sequence to produce chimeric GFP proteins or to produce polycistronic mRNAs that encode the Renilla reniformis GFP and a luciferase, preferably a Renilla luciferase, more preferably Renilla reniformis luciferase.

Methods for identifying compounds using recombinant cells that express heterologous DNA encoding a Renilla reniformis GFP under the control of a promoter element of a gene of interest are provided. The recombinant cells can be used to identify compounds or ligands that modulate the level of transcription from the promoter of interest by measuring Renilla reniformis GFP-mediated fluorescence. Recombinant cells expressing the chimeric Renilla reniformis GFP or polycistronic mRNA encoding Renilla reniformis and a lucifierase, may also be used for monitoring gene expression or protein trafficking, or determining the cellular localization of the target protein by identifying localized regions of GFP-mediated fluorescence within the recombinant cell.

Other assays using the GFPs and/or luciferases are contemplated herein. Any assay or diagnostic method known used by those of skill in the art that employ Aequora GFPs and/or other luciferases are contemplated herein.

Kits containing the GFPs for use in the methods, including those described herein, are provided. In one embodiment, the kits containing an article of manufacture and appropriate reagents for generating bioluminescence are provided. The kits containing such soap compositions, with preferably a moderate pH (between 5 and 8) and bioluminescence generating reagents, including luciferase and luciferin and the GFP are provided herein. These kits, for example, can be used with a bubble-blowing or producing toy. These kits can also include a reloading or charging cartridge or can be used in connection with a food.

In another embodiment, the kits are used for detecting and visualizing neoplastic tissue and other tissues and include a first composition that contains the GFP and at least one component of a bioluminescence generating system, and a second that contains the activating composition, which contains the remaining components of the bioluminescence generating system and any necessary activating agents.

Thus, these kits will typically include two compositions, a first composition containing the GFP formulated for systemic administration (or in some embodiments local or topical application), and a second composition containing the components or remaining components of a bioluminescence generating system, formulated for systemic, topical or local administration depending upon the application. Instructions for administration will be included.

In other embodiments, the kits are used for detecting and identifying diseases, particularly infectious diseases, using multi-well assay devices and include a multi-well assay device containing a plurality of wells, each having an integrated photodetector, to which an antibody or panel of antibodies specific for one or more infectious agents are attached, and composition containing a secondary antibody, such as an antibody specific for the infectious agent that is linked to a Renilla reniformis GFP protein, a chimeric antibody-Renilla reniformis GFP fusion protein or F(Ab).sub.2 antibody fragment-Renilla reniformis GFP fusion protein. A second composition contains a bioluminescence generating system that emits a wavelength of light within the excitation range of the Renilla mulleri GFP, such as species of Renilla or Aequorea, for exciting the Renilla reniformis, which produces light that is detected by the photodetector of the device to indicate the presence of the agent.

As noted above, fusions of nucleic acid encoding the luciferases and or GFPs provided herein with other luciferases and GFPs are provided. Of particular interest are fusions that encode pairs of luciferases and GFPs, such as a Renilla luciferase and a Renilla GFP (or a homodimer or other multiple of a Renilla GFP). The luciferase and GFP bind and in the presence of a luciferin will produced fluorescence that is red shifted compared to the luciferase in the absence of the GFP. This fusion or fusions in which the GFP and luciferase are linked via a target, such as a peptide, can be used as a tool to assess anything that interacts with the linker.

Muteins of the GFPs and luciferases are provided. Of particular interest are muteins, such as temperature sensitive muteins, of the GFP and luciferases that alter their interaction, such as mutations in the Renilla luciferase and Renilla GFP that alters their interaction at a critical temperature.

Antibodies, polyclonal and monoclonal antibodies that specifically bind to any of the proteins encoded by the nucleic acids provided herein are also provided. These antibodies, monoclonal or polyclonal, can be prepared employing standard techniques, known to those of skill in the art. In particular, immunoglobulins or antibodies obtained from the serum of an animal immunized with a substantially pure preparation of a luciferase or GFP provided herein or an or epitopecontaining fragment thereof are provided. Monoclonal antibodies are also provided. The immunoglobulins that are produced have, among other properties, the ability to specifically and preferentially bind to and/or cause the immunoprecipitation of a GFP or luciferase, particularly a Renilla or Ptilosarcus GFP or a Pleuromamma, Gaussia or Renilla mulleri luciferase, that may be present in a biological sample or a solution derived from such a biological sample.

DESCRIPTION OF THE FIGURES

FIG. 1 depicts phylogenetic relationships among the anthozoan GFPs.

FIGS. 2A-D illustrate the underlying principle of Bioluminescent Resonance Energy Transfer (BRET) and its use as sensor: A) in isolation, a luciferase, preferably an anthozoan luciferase, emits blue light from the coelenterazine-derived chromophore; B) in isolation, a GFP, preferably an anthozoan GFP that binds to the luciferase, that is excited with blue-green light emits green light from its integral peptide based fluorophore; C) when the luciferase and GFP associate as a complex in vivo or in vitro, the luciferase non-radiatively transfers its reaction energy to the GFP flurophore, which then emits the green light; D) any molecular interaction that disrupts the luciferase-GEP complex can be quantitatively monitored by observing the spectral shift from green to blue light.

FIG. 3 illustrates exemplary BRET sensor architecture.

"FIG. 4 depicts the substitution of altered fluorophores into the background of Ptilosarcus, Renilla mulleri and Renilla reniformis GFPs (the underlined regions correspond to amino acids 56-75 of SEQ ID NO. 27 Renilla reniformis GFP; amino acids 59-78 of SEQ ID NO. 16 Renilla mulleri GFP; and amino acids 59-78 of SEQ ID NO. 32 for Ptilosarcus GFP)."

FIG. 5 depicts the three anthozoan fluorescent proteins for which a crystal structure exists; another is available commercially from Clontech as dsRed (from Discosoma striata; also known as drFP583, as in this alignment); a dark gray background depicts amino acid conservation, and a light gray background depicts shared physicochemical properties.

FIG. 6 compares the sequences of a variety of GFPs, identifying sites for mutation to reduce multimerization; abbreviations are as follows: Amemonia majona is amFP486; Zoanthus sp. zFP506 and zFP538; Discosoma sp. "red" is drFP583; Clavularia sp. is cFP484; and the GFP from the anthozoal A. sulcata is designated FP595.

DETAILED DESCRIPTION OF THE INVENTION

A. Definitions

B. Fluorescent Proteins 1. Green and blue fluorescent proteins 2. Renilla reniformis GFP

C. Bioluminescence Generating Systems and Components 1. General description a. Luciferases b. Luciferins c. Activators d. Reactions 2. The Renilla system 3. Ctenophore systems 4. The aequorin system a. Aequorin and related photoproteins b. Luciferin 5. Crustacean, particularly Cyrpidina systems a. Vargula luciferase (1) Purification from Cypridina (2) Preparation by Recombinant Methods b. Vargula luciferin c. Reaction 6. Insect bioluminescent systems including fireflies, click beetles, and other insect system a. Luciferase b. Luciferin c. Reaction 7. Other systems a. Bacterial systems (1) Luciferases (2) Luciferins (3) Reactions b. Dinoflagellate bioluminescence generating systems

D. Isolation and Identification of Nucleic Acids Encoding Luciferases and GFPs 1. Isolation of specimens of the genus Renilla 2. Preparation of Renilla cDNA expression libraries a. RNA isolation and cDNA synthesis b. Construction of cDNA expression libraries 3. Cloning of Renilla reniformis Green Fluorescent Protein 4. Isolation and identification of DNA encoding Renilla mulleri GFP 5. Isolation and identification of DNA encoding Renilla mulleri luciferase

E. Recombinant Expression of Proteins 1. DNA encoding Renilla proteins 2. DNA constructs for recombinant production of Renilla reniformis and other proteins 3. Host organisms for recombinant production of Renilla proteins 4. Methods for recombinant production of Renilla proteins 5. Recombinant cells expressing heterologous nucleic acid encoding luciferases and GFPs

F. Compositions and Conjugates 1. Renilla GFP compositions 2. Renilla luciferase compositions 3. Conjugates a. Linkers b. Targeting Agents c. Anti-tumor Antigen Antibodies d. Preparation of the conjugates 4. Formulation of the compositions for use in the diagnostic systems a. The first composition: formulation of the conjugates b. The second composition c. Practice of the reactions in combination with targeting agents

G. Combinations

H. Exemplary uses of Renilla reniformis GFPs and encoding nucleic acid molecules 1. Methods for diagnosis of neoplasms and other tissues 2. Methods of diagnosing diseases 3. Methods for generating Renilla mulleri luciferase, Pleuromamma luciferase and Gaussia luciferase fusion proteins with Renilla reniformis GFP 4. Cell-based assays for identifying compounds

I. Kits

J. Muteins 1. Mutation of GFP surfaces to disrupt multimerization 2. Use of advantageous GFP surfaces with substituted fluorophores

K. Transgenic Plants and Animals

L. Bioluminescence Resonance Energy Transfer (BRET) System 1. Design of sensors based on BRET 2. BRET Sensor Architectures 3. Advantages of BRET sensors A. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, applications and publications of referred to throughout the disclosure are incorporated by reference in their entirety.

As used herein, chemiluminescence refers to a chemical reaction in which energy is specifically channeled to a molecule causing it to become electronically excited and subsequently to release a photon thereby emitting visible light. Temperature does not contribute to this channeled energy. Thus, chemiluminescence involves the direct conversion of chemical energy to light energy.

"As used herein, luminescence refers to the detectable electromagnetic (EM) radiation, generally, ultraviolet (UV), infrared (IR) or visible EM radiation that is produced when the excited product of an exergic chemical process reverts to its ground state with the emission of light. Chemiluminescence is luminescence that results from a chemical reaction. Bioluminescence is chemiluminescence that results from a chemical reaction using biological molecules (or synthetic versions or analogs thereof) as substrates and/or enzymes.

As used herein, bioluminescence, which is a type of chemiluminescence, refers to the emission of light by biological molecules, particularly proteins. The essential condition for bioluminescence is molecular oxygen, either bound or free in the presence of an oxygenase, a luciferase, which acts on a substrate, a luciferin. Bioluminescence is generated by an enzyme or other protein

(luciferase) that is an oxygenase that acts on a substrate luciferin (a bioluminescence substrate) in the presence of molecular oxygen and transforms the substrate to an excited state, which upon return to a lower energy level releases the energy in the form of light.

As used herein, the substrates and enzymes for producing bioluminescence are generically referred to as luciferin and luciferase, respectively. When reference is made to a particular species thereof, for clarity, each generic term is used with the name of the organism from which it derives, for example, bacterial luciferin or firefly luciferase.

As used herein, luciferase refers to oxygenases that catalyze a light emitting reaction. For instance, bacterial luciferases catalyze the oxidation of flavin mononucleotide (FMN) and aliphatic aldehydes, which reaction produces light. Another class of luciferases, found among marine arthropods, catalyzes the oxidation of Cypridina (Vargula) luciferin, and another class of luciferases catalyzes the oxidation of Coleoptera luciferin.

Thus, luciferase refers to an enzyme or photoprotein that catalyzes a bioluminescent reaction (a reaction that produces bioluminescence). The luciferases, such as firefly and Gaussia and Renilla luciferases, that are enzymes which act catalytically and are unchanged during the bioluminescence generating reaction. The luciferase photoproteins, such as the aequorin photoprotein to which luciferin is non-covalently bound, are changed, such as by release of the luciferin, during bioluminescence generating reaction. The luciferase is a protein that occurs naturally in an organism or a variant or mutant thereof, such as a variant produced by mutagenesis that has one or more properties, such as thermal stability, that differ from the naturally-occurring protein. Luciferases and modified mutant or variant forms thereof are well known. For purposes herein, reference to luciferase refers to either the photoproteins or luciferases.

Thus, reference, for example, to "Gaussia luciferase" means an enzyme isolated from member of the genus Gaussia or an equivalent molecule obtained from any other source, such as from another related copepod, or that has been prepared synthetically. It is intended to encompass Gaussia luciferases with conservative amino acid substitutions that do not substantially alter activity. Suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p. 224).

. .

"Renilla GFP" refers to GFPs from the genus Renilla and to mutants or variants thereof. It is intended to encompass Renilla GFPs with conservative amino acid substitutions that do not substantially alter activity and physical properties, such as the emission spectra and ability to shift the spectral output of bioluminescence generating systems.

Such substitutions are preferably made in accordance with those set forth in TABLE 1 as follows:

TABLE-US-00001 TABLE 1 Original residue Conservative substitution Ala (A) Gly; Ser Arg (R) Lys Asn (N) Gln; His Cys (C) Ser Gln (Q) Asn Glu (E) Asp Gly (G) Ala; Pro His (H) Asn; Gln Ile (I) Leu; Val Leu (L) Ile; Val Lys (K) Arg; Gln; Glu Met (M) Leu; Tyr; Ile Phe (F) Met; Leu; Tyr Ser (S) Thr Thr (T) Ser Trp (W) Tyr Tyr (Y) Trp; Phe Val (V) Ile; Leu

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

The luciferases and luciferin and activators thereof are referred to as bioluminescence generating reagents or components. Typically, a subset of these reagents will be provided or combined with an article of manufacture. Bioluminescence will be produced upon contacting the combination with the remaining reagents. Thus, as used herein, the component luciferases, luciferins, and other factors, such as O.sub.2, Mg.sup.2+, Ca.sup.2+ are also referred to as bioluminescence generating reagents (or agents or components).

"As used herein, a Renilla reniformis green fluorescent protein (GEP) refers to a fluorescent protein that is encoded by a sequence of nucleotides that encodes the protein of SEQ ID NO. 27 or to a green fluorescent protein from Renilla reniformis having at least 80%, 90% or 95% or greater sequence identity thereto; or that is encoded by a sequence of nucleotides that hybridizes under high stringency along its full length to the coding portion of the sequence of nucleotides set forth in any of SEQ ID NOs. 23-25. A Renilla reniformis GEP is protein that is fluorescent and is produced in a Renilla reniformis."

As used herein, bioluminescence substrate refers to the compound that is oxidized in the presence of a luciferase, and any necessary activators, and generates light. These substrates are referred to as luciferins herein, are substrates that undergo oxidation in a bioluminescence reaction. These bioluminescence substrates include any luciferin or analog thereof or any synthetic compound with which a luciferase interacts to generate light. Preferred substrates are those that are oxidized in the presence of a luciferase or protein in a light-generating reaction. Bioluminescence substrates, thus, include those compounds that those of skill in the art recognize as luciferins.